bendamustine hydrochloride profile

Bendamustine hydrochloride is an alkylating agent used in the treatment of chronic lymphocytic leukemia (CLL) and other hematologic malignancies. It is a nitrogen mustard derivative that acts by binding to DNA and inhibiting cell replication. Bendamustine hydrochloride is synthesized through a multi-step process that involves the reaction of an aromatic amine with a chloroethylating agent. The compound is then reacted with hydrochloric acid to form the hydrochloride salt. Bendamustine hydrochloride has shown promising results in clinical trials for the treatment of CLL, Waldenstrom macroglobulinemia, and non-Hodgkin lymphoma. It is also being investigated for other types of cancer, such as multiple myeloma and breast cancer. The compound is well tolerated, but it can cause side effects such as nausea, vomiting, fatigue, and bone marrow suppression.'

ID Source	ID
PubMed CID	77082
CHEMBL ID	1201734
SCHEMBL ID	18843
MeSH ID	M0307744

Synonym
bendamustine hydrochloride injection
unii-981y8sx18m
981y8sx18m ,
gamma(1-methyl-5-bis(beta-chloraethyl)aminobenzimidazoyl-2)buttersaeurehydrochlorid
bendamustine hydrochloride [usan:jan]
ribomustine
zimet 33/93
bendit
imet 3393
bendamustin hydrochloride
1h-benzimidazole-2-butanoic acid, 5-(bis(2-chloroethyl)amino)-1-methyl-, monohydrochloride
2-benzimidazolinebutryric acid, 1-methyl-5-bis(2-chloroethyl)amino-, hydrochloride
cytostasan
ccris 1864
2-benzimidazolebutyric acid, 5-(bis(2-chloroethyl)amino)-1-methyl-, monohydrochloride
nsc 138783
gamma(1-methyl-5-bis(beta-chloraethyl)aminobenzimidazoyl-2)buttersaeurehydrochlorid [german]
ribomustin (tn)
D07085
bendamustine hydrochloride (jan/usan)
3543-75-7
nsc138783
2-benzimidazolebutyric acid, monohydrochloride
2-benzimidazolinebutryric acid, hydrochloride
cytostosan
wln: t56 bn dnj b1 c3vq gn2g2g &gh
nsc-138783
treanda
bendamustine hydrochloride ,
sdx-105
ribomustin
symbenda
syb l-0501
benda
inno-p08001
treakisym
levact
innomustine
CHEMBL1201734
bendamustine hcl
vivimusta
sybl-0501
FT-0650624
FT-0696296
4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid hydrochloride
BCP9000390
97832-05-8
AKOS015951203
4-(5-(bis(2-chloroethyl)amino)-1-methyl-1h-benzo[d]imidazol-2-yl)butanoic acid hydrochloride
bendeka
BCPP000348
LP00623
bendamustine hydrochloride [usan]
bendamustine hydrochloride [mart.]
bendamustine hydrochloride [who-dd]
bendamustine hydrochloride [jan]
bendamustine hydrochloride [usp-rs]
bendamustine hydrochloride [orange book]
bendamustine hydrochloride [mi]
4-[5-[bis(2-chloroethyl)amino]-1-methyl-1h-benzimidazole-2-yl]butanoic acid monohydrochloride
bendamustine hydrochloride [usp monograph]
S1212
1h-benzimidazole-2-butanoicacid, 5-[bis(2-chloroethyl)amino]-1-methyl-, hydrochloride (1:?)
CCG-221927
HY-B0077
CS-1771
bendamustine (hydrochloride)
smr004234484
MLS006010156
B4033
1h-benzimidazole-2-butanoic acid, 5-[bis(2-chloroethyl)amino]-1-methyl-, hydrochloride (1:1)
AM20090666
5-[bis(2-chloroethyl)amino]-1-methylbenzimidazole-2-butyric acid hydrochloride
SCHEMBL18843
NCGC00261308-01
tox21_500623
ZHSKUOZOLHMKEA-UHFFFAOYSA-N
5-[bis(2-chloroethyl)amino]-1-methyl-1h-benzimidazole-2-butanoic acid hydrochloride
4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid;hydrochloride
hydrochloride, bendamustine
DTXSID40188912 ,
ep-3101
sdx-105 (cytostasane) hcl
AC-1619
mfcd01658758
bendamustine hcl (sdx-105, cytostasane)
3543-75-7 (hcl)
4-(5-(bis(2-chloroethyl)amino)-1-methyl-1h-benzo-[d]imidazol-2-yl)butanoic acid hydrochloride
SW219266-1
fmoc-(s)-3-amino-3-(3-trifluoromethyl-phenyl)-propionicacid
4-(5-(bis(2-chloroethyl)amino)-1-methylbenzimidazol-2-yl)butanoic acid hcl
AS-15856
BCP02107
SB17462
Q27272066
5-[bis(2-chloroethyl)-amino]-1-methyl-1h-benzimidazole-2-butanoic acid hydrochloride;ribomustin hcl
treanda hcl
BP-25399
4-(5-(bis(2-chloroethyl)amino)-1-methyl-1h-benzo[d]imidazol-2-yl)butanoicacidhydrochloride
BB164239
4-{5-[bis(2-chloroethyl)amino]-1-methyl-1h-1,3-benzodiazol-2-yl}butanoic acid hydrochloride
EN300-18586056
4-(5-(bis(2-chloroethyl)amino)-1-methyl-1h-benzimidazole-2-yl)butanoic acid monohydrochloride
belrapzo
bendamustine hydrochloride (mart.)
4-(5-(bis(2-chloroethyl)amino)-1-methyl-1h-benzoimidazol-2-yl)butanoic acid monohydrochloride
bendamustine hydrochloride (usp monograph)
bendamustine hydrochloride (usp-rs)
dtxcid00111403
cytostasan hydrochloride
Z2235802251

Excerpt	Reference	Relevance
"Bendamustine hydrochloride (BH) is a key therapeutic agent for mantle cell lymphoma (MCL), while the mechanism underlying BH-resistance has not been verified."	( Establishment and Characteristics of a Novel Mantle Cell Lymphoma-derived Cell Line and a Bendamustine-resistant Subline. Chinen, Y; Fujibayashi, Y; Horiike, S; Kobayashi, T; Kuroda, J; Maegawa, S; Matsumura-Kimoto, Y; Mizuno, Y; Mizutani, S; Nagoshi, H; Shimura, Y; Takimoto-Shimomura, T; Taniwaki, M; Tsukamoto, T, )	1.57
"Bendamustine hydrochloride is an alkylating agent that was developed for the treatment of various human cancers. "	( An efficient and facile synthesis of deuterium-labeled anticancer agent bendamustine hydrochloride. Liu, B; Qin, H; Zhang, Y, 2018)	2.16
"Bendamustine hydrochloride is an alkylating antitumor agent with a good efficacy in the treatment of chronic lymphocytic leukemia (CLL) and B-cell non-Hodgkin's lymphoma (B-NHL). "	( Determination and characterization of two degradant impurities in bendamustine hydrochloride drug product. Chen, W; Ding, L; Li, X; Liao, M; Xu, X; Zhang, F; Zhang, L; Zou, L, )	1.81
"Bendamustine hydrochloride is a novel cytotoxic agent that possesses alkylator and purine-like structural groups, which may confer a unique mechanism of action."	( Bendamustine: a novel cytotoxic agent for hematologic malignancies. Blumel, S; Dang, NH; Goodrich, A; Martin, C, 2008)	1.07
"Bendamustine hydrochloride is a multifunctional, alkylating agent with a purine-like ring system that exhibits activity in multiple cancer models, including CLL and MCL, but whose mechanism is only partially described."	( Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling. Campo, E; Colomer, D; López-Guerra, M; Milpied, P; Montserrat, E; Pérez-Galán, P; Roué, G; Villamor, N, 2008)	1.07
"Bendamustine hydrochloride is a novel alkylating agent. "	( Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study. Bartlett, NL; Chen, L; Cheson, BD; Czuczman, MS; Ganjoo, K; Joyce, R; Kahl, BS; Leonard, JP; Robinson, KS; van der Jagt, RH; Williams, ME, 2010)	1.8
"Bendamustine hydrochloride is a bifunctional alkylating agent that is not cross-resistant to other DNA-interacting substances including anthracyclines and oxazaphosphorines."	( Bendamustine hydrochloride in patients with refractory soft tissue sarcoma: a noncomparative multicenter phase 2 study of the German sarcoma group (AIO-001). Grünwald, V; Hartmann, JT; Horger, M; Huober, J; Käfer, G; Kanz, L; Mayer, F; Meisinger, I; Pintoffl, J; Schleicher, J, 2007)	2.5
"Bendamustine hydrochloride is an alkylating agent with novel mechanisms of action. "	( Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. Bessudo, A; Camacho, ES; Chen, L; Cheson, BD; Cohen, P; Fayad, LE; Forero-Torres, A; Friedberg, JW; La Casce, AS; Oliver, JW; Robinson, KS; van der Jagt, RH; Williams, ME, 2008)	1.79

Excerpt	Reference	Relevance
" Considerable toxic side effects led to a dose reduction of cytostasan and adriamycin in 31 female patients without clinical efficiency loss."	( [Therapeutic results and toxic side effects of the combination cytostasan, adriamycin and vincristine as second-line therapy of metastatic breast cancer]. Brockmann, B; Geschke, E; Kirchhof, I; Schmidt, UM, 1989)	0.28
" CCNU in liposomes of different size and composition showed in lower doses a diminished therapeutic effectiveness in the P388 or L 1210 leukaemia and the B 16 melanoma, while in higher doses toxic deaths occurring with the free drug could be prevented totally by using liposomes."	( Antineoplastic activity and toxicity of some alkylating cytostatics (cyclophosphamide, CCNU, cytostasan) encapsulated in liposomes in different murine tumour models. Arndt, D; Fichtner, I; Reszka, R, )	0.13
" First-line use of bendamustine is a safe option for CLL-patients requiring treatment, because bendamustine-owing to its unique pharmacodynamics-(1) is highly effective, (2) reasonably safe, and (3) does hardly produce cross-resistance against other anti-neoplastic drugs effective in this indication."	( Phase-I/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pre-treated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapy. Arnaudov, G; Lissitchkov, T; Merkle, Kh; Peytchev, D, 2006)	0.33
" However, numerous adverse effects limited their use."	( Optimization of the N-lost drugs melphalan and bendamustine: synthesis and cytotoxicity of a new set of dendrimer-drug conjugates as tumor therapeutic agents. Gust, R; Scheffler, H; Scutaru, AM; Wenzel, M; Wolber, G, 2010)	0.36
" In conclusion, the new BeEAM regimen is safe and effective for heavily pretreated lymphoma patients."	( BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Caballero, MD; Capria, S; Cuberli, F; Falcioni, S; Ferrara, F; Galieni, P; Gaudio, F; Gherlinzoni, F; Giardini, C; Gobbi, M; Isidori, A; Malerba, L; Meloni, G; Ocio, EM; Rocchi, M; Santoro, A; Sarina, B; Specchia, G; Stefani, PM; Visani, G, 2011)	0.37
"Bendamustine is a safe and useful addition to the drug arsenal against lymphoproliferative disorders."	( Preliminary experience with the use of bendamustine: a peculiar skin rash as the commonest side effect. Ganesan, P; Malipatil, B; Sagar, TG; Sundersingh, S, 2011)	0.37
" No life-threatening or unexpected adverse events occurred."	( Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma. Amore, A; Angrilli, F; Arcamone, M; Califano, C; Corazzelli, G; Cox, MC; D'Arco, A; De Filippi, R; Falorio, S; Ferrara, F; Guarini, A; Iannitto, E; Musto, P; Pinto, A; Stelitano, C; Storti, S, 2013)	0.39
" Also, bendamustine can be regarded as a safe and effective alternative for patients with relapse after autologous transplantation and as an interesting cytoreductive strategy before allogeneic transplantation."	( Safety and efficacy of single-agent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory hodgkin's lymphoma: experience with 27 patients. Argnani, L; Broccoli, A; Cascavilla, N; Corradini, P; Hohaus, S; Merli, F; Motta, G; Tani, M; Vitolo, U; Viviani, S; Zinzani, PL, 2015)	0.42
" The treatment was well tolerated, with rather infrequent adverse events and transient and manageable toxicities."	( Safety and efficacy of single-agent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory hodgkin's lymphoma: experience with 27 patients. Argnani, L; Broccoli, A; Cascavilla, N; Corradini, P; Hohaus, S; Merli, F; Motta, G; Tani, M; Vitolo, U; Viviani, S; Zinzani, PL, 2015)	0.42
" Main non-hematologic adverse events were nausea (69 %), fatigue (56 %), decreased appetite (42 %), constipation (38 %), diarrhea (36 %), vomiting (36 %), and decreased weight (31 %)."	( Phase II study of bendamustine combined with rituximab in relapsed/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings. Czuczman, MS; Goy, A; Graf, DA; Lamonica, D; Munteanu, MC; van der Jagt, RH, 2015)	0.42
" The good tolerability and feasibility of bendamustine with and without rituximab, in particular for the elderly population with CLL argues for it being a safe outpatient treatment."	( Bendamustin-Rituximab Combination Is a Safe and Effective, Ambulatory Treatment for Elderly Patients with Chronic Lymphocytic Leukemia: Retrospective Real-world Analysis by Age from a German Registry and Review of the Literature. Günther, G; Kersting, M; Kleeberg, UR; Linde, H; Tessen, HW, 2016)	0.43
" All patients experienced at least one adverse event during induction, most commonly infusion-related reactions (58%), the majority of which were grade 1/2."	( Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma. Díaz, MG; Dreyling, M; Dyer, MJ; Grigg, A; Knapp, A; Lei, G; Marlton, P; Rule, S; Wassner-Fritsch, E, 2017)	0.46
"Adverse events (AEs) captured from 12 quarterly postmarketing periodic adverse drug experience reports spanning 2008-2015 were included and summarized."	( Long-term safety experience with bendamustine for injection in a real-world setting. Barr, PM; James, L; Kahl, B; Martin, P; Pathak, A, 2017)	0.46
"Adverse events that resulted in label updates included Stevens-Johnson syndrome, toxic epidermal necrolysis, extravasation, secondary neoplasm, and drug reactions with eosinophilia and systemic symptoms."	( Long-term safety experience with bendamustine for injection in a real-world setting. Barr, PM; James, L; Kahl, B; Martin, P; Pathak, A, 2017)	0.46
" Rapid BDM infusions were safe and tolerable for cancer patients in this study."	( Safety and Pharmacokinetics of Bendamustine Rapid-Infusion Formulation. Anthony, SP; Chanas, B; Cheung, EM; Edenfield, WJ; Hepner, A; Mattar, B; Mutch, PJ; Smith, M, 2017)	0.46
" A less toxic regimen might improve the outcome of patients with lymphoma after transplantation."	( High-dose Bendamustine-EAM followed by autologous stem cell rescue results in long-term remission rates in lymphoma patients, without renal toxicity. Boehm, A; Keil, F; Koller, E; Menschel, E; Moestl, M; Noesslinger, T; Panny, M; Simanek, R, 2018)	0.48
" Outcomes were number of responders to treatment, remission rate of treatment responders, overall probability of 5-year remission, and the occurrence of adverse events."	( Corticosteroids in chronic inflammatory demyelinating polyneuropathy : A retrospective, multicentre study, comparing efficacy and safety of daily prednisolone, pulsed dexamethasone, and pulsed intravenous methylprednisolone. Basta, I; Doneddu, PE; Eftimov, F; Gallia, F; Nikolic, A; Nobile-Orazio, E; Peric, S; van Lieverloo, GGA; van Schaik, IN; Verhamme, C; Wieske, L, 2018)	0.48
" Adverse events leading to a change in treatment occurred in ten patients (8%)."	( Corticosteroids in chronic inflammatory demyelinating polyneuropathy : A retrospective, multicentre study, comparing efficacy and safety of daily prednisolone, pulsed dexamethasone, and pulsed intravenous methylprednisolone. Basta, I; Doneddu, PE; Eftimov, F; Gallia, F; Nikolic, A; Nobile-Orazio, E; Peric, S; van Lieverloo, GGA; van Schaik, IN; Verhamme, C; Wieske, L, 2018)	0.48
" Grade ≥3 adverse events occurred in 80."	( Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study. Aktan, M; Bosch, F; Dartigeas, C; Ferra Coll, CM; Foà, R; Gresko, E; Kisro, J; Leblond, V; Merot, JL; Montillo, M; Raposo, J; Robson, S; Stilgenbauer, S, 2018)	0.48
" Obinutuzumab exposure was not associated with occurrence or severity of adverse events, but higher exposure appeared to be associated with greater efficacy, particularly longer progression-free survival."	( Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab-refractory follicular lymphoma patients in the GADOLIN phase III study. Brewster, M; Buchheit, V; Fingerle-Rowson, G; Frey, N; Gibiansky, E; Gibiansky, L; Jamois, C, 2019)	0.51
" The selected obinutuzumab dosing regimen offers clinical benefit in a majority of rituximab-refractory FL patients treated with bendamustine, irrespective of variability in exposure, whilst minimising adverse events."	( Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab-refractory follicular lymphoma patients in the GADOLIN phase III study. Brewster, M; Buchheit, V; Fingerle-Rowson, G; Frey, N; Gibiansky, E; Gibiansky, L; Jamois, C, 2019)	0.51
" Among the adverse events associated with the earlier termination of bendamustine treatment, infections were the most common (20."	( Safety and Efficacy of Bendamustine Monotherapy in the First-Line Treatment of Patients with Chronic Lymphocytic Leukemia: Polish Lymphoma Research Group Real-Life Analysis. Bramowicz-Jarosz, B; Długosz-Danecka, M; Graboś-Michalak, J; Hus, I; Kopacz, A; Krochmalczyk, D; Malenda, A; Piotrowska, M; Potoczek, S; Raźny, M; Seweryn, M; Soroka-Wojtaszko, M; Szymczyk, A; Wąsik-Szczepanek, E; Wichary, R; Wołowiec, D; Zawirska, D, 2019)	0.51
" Treatment-related adverse event was observed in 95."	( Efficacy and safety of ofatumumab and bendamustine followed by ofatumumab maintenance in patients with relapsed indolent non-Hodgkin lymphoma after prior rituximab. Boyd, TE; Cannan, M; Fellague-Chebra, R; Feng, X; Kingsley, E; Lyons, RM; Moezi, M; Richards, D; Sharman, J; Shtivelband, M, 2021)	0.62
"Limited published real-world data describe adverse events (AEs) among patients treated for mantle-cell lymphoma (MCL)."	( Adverse Events and Economic Burden Among Patients Receiving Systemic Treatment for Mantle Cell Lymphoma: A Real-World Retrospective Cohort Study. Byfield, SD; Kabadi, SM; LE, L; Olufade, T, 2021)	0.62
" At the final analysis, no new safety signals were observed [Grade ≥ 3 adverse events (AEs): 1L 82·7%, R/R 84·5%; serious AEs: 1L 58·1%, R/R 62·5%]."	( Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study. Bosch, F; Böttcher, S; Foà, R; Ilhan, O; Kisro, J; Leblond, V; Mahé, B; Mikuskova, E; Osmanov, D; Perretti, T; Reda, G; Robinson, S; Stilgenbauer, S; Tausch, E; Trask, P; Turgut, M; Van Hoef, M; Wójtowicz, M, 2021)	0.62
"Most data on overall survival (OS) and adverse events (AEs) in patients with mantle cell lymphoma (MCL) are from controlled trials; therefore, in this population-based study, we retrospectively assessed treatment patterns, OS, and AEs in MCL patients initiating systemic treatment during 2013-2015 using the United States Medicare claims database."	( Real-world evidence on survival, adverse events, and health care burden in Medicare patients with mantle cell lymphoma. Davis, K; Du, XL; Goyal, RK; Jain, P; Kabadi, SM; Kaye, JA; Le, H; Nagar, SP; Wang, M, 2021)	0.62
"Ibrutinib has superior progression-free survival compared with bendamustine plus rituximab (BR) in older CLL patients, however, differences in treatment duration, six monthly BR cycles versus continuous ibrutinib, complicate adverse event (AE) comparisons."	( Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202. Abramson, JS; Bartlett, NL; Booth, AM; Brander, DM; Brown, JR; Byrd, JC; Coutre, S; Ding, W; Erba, H; Kuzma, CS; Larson, RA; Little, RF; Litzow, M; Mandrekar, SJ; Nattam, S; Owen, C; Ruppert, AS; Smith, SE; Stone, RM; Woyach, JA, 2021)	0.62
" Grade 5 (fatal) adverse events (AEs) were reported in 5 patients."	( Safety and efficacy of atezolizumab with obinutuzumab and bendamustine in previously untreated follicular lymphoma. Burke, JM; Diefenbach, C; Ferrari, S; Gilbertson, M; Khan, C; Nielsen, TG; Raval, A; Sellam, G; Sharman, JP; Shivhare, M; Tani, M; Ujjani, C; Vitolo, U; Younes, A; Yuen, S, 2022)	0.72
" We observed significant differences, however, in the frequency and severity of adverse events."	( Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas. Ballard, HJ; Barta, SK; Chen, AI; Chong, EA; Garfall, A; Gerson, JN; Ghilardi, G; Gier, S; Hodges Dwinal, A; Jäger, U; Landsburg, JD; Maziarz, RT; Myers, J; Napier, E; Nasta, SD; Pajarillo, R; Porter, DL; Ruella, M; Schachter, L; Schuster, SJ; Svoboda, J; Victoriano, D; Weber, E; Williamson, S; Wohlfarth, P; Yelton, R, 2022)	0.72
" The most common adverse effects were febrile neutropenia (98%), mucositis (72%) and colitis (60%)."	( Single-center retrospective study assessing the efficacy and safety of BeEAM (bendamustine, etoposide, cytarabine, melphalan) as conditioning regimen for autologous hematopoietic stem cell transplantation. Boudreault, JS; Feng, X; Plante, MÉ, )	0.13
" Although this treatment is effective, it comes at the cost of severe long-term adverse events, such as reduced fertility and an increased risk of secondary cancers."	( Nivolumab plus Brentuximab vedotin +/- bendamustine combination therapy: a safe and effective treatment in pediatric recurrent and refractory classical Hodgkin lymphoma. Beishuizen, A; Boes, M; Diez, C; Greve, P; Hagleitner, M; Loeffen, J; Meyer-Wentrup, F; Peperzak, V; Veening, M, 2023)	0.91
" Only one adverse event of CTCAE grade 3 or higher due to nivolumab + BV was identified."	( Nivolumab plus Brentuximab vedotin +/- bendamustine combination therapy: a safe and effective treatment in pediatric recurrent and refractory classical Hodgkin lymphoma. Beishuizen, A; Boes, M; Diez, C; Greve, P; Hagleitner, M; Loeffen, J; Meyer-Wentrup, F; Peperzak, V; Veening, M, 2023)	0.91

Excerpt	Reference	Relevance
"The pharmacokinetic profiles of bendamustine and active metabolites were defined in patients with rituximab-refractory, relapsed indolent B-cell non-Hodgkin's lymphoma, and supported understanding of exposure-response relationships for efficacy and safety."	( Bendamustine pharmacokinetic profile and exposure-response relationships in patients with indolent non-Hodgkin's lymphoma. D'Andrea, D; Darwish, M; Kahl, B; Melhem, M; Owen, JS; Passarell, JA, 2010)	0.36
" Pharmacokinetic models were developed, with covariate assessment."	( Bendamustine pharmacokinetic profile and exposure-response relationships in patients with indolent non-Hodgkin's lymphoma. D'Andrea, D; Darwish, M; Kahl, B; Melhem, M; Owen, JS; Passarell, JA, 2010)	0.36
" Bendamustine was rapidly eliminated, with a mean elimination half-life (t(1/2) ) of 29 min."	( Phase I and pharmacokinetic study of bendamustine hydrochloride in relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Ando, K; Kasai, M; Matsumoto, Y; Ogawa, Y; Ogura, M; Ohmachi, K; Shimizu, D; Taniwaki, M; Tobinai, K; Uchida, T; Watanabe, T; Yokoyama, H, 2010)	0.63
" Secondary endpoints were adverse events (AE), the overall response rate (ORR), and pharmacokinetic parameters."	( Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Ando, K; Matsumoto, Y; Ogura, M; Ohmachi, K; Taniwaki, M; Tobinai, K; Uchida, T; Watanabe, T, 2011)	0.64
"The authors present the chemical structure, mechanism of action, pharmacokinetic properties and clinical application of bendamustine in hematological malignancies."	( Pharmacokinetic evaluation and therapeutic activity of bendamustine in B-cell lymphoid malignancies. Korycka-Wołowiec, A; Robak, T, 2012)	0.38
" Bendamustine clearance from plasma was rapid, with a half-life of ~40 minutes."	( Pharmacokinetics and excretion of 14C-bendamustine in patients with relapsed or refractory malignancy. Beijnen, JH; Bond, M; D'Andrea, D; Darwish, M; Dubbelman, AC; Hellriegel, E; Robertson, P; Rosing, H; Schellens, JH, 2013)	0.39
" This validated method was successfully applied to a pharmacokinetic study enrolling 10 Chinese patients with indolent B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia administered a single intravenous infusion of 100 mg m(2) bendamustine hydrochloride."	( Simultaneous determination of bendamustine and its active metabolite, gamma-hydroxy-bendamustine in human plasma and urine using HPLC-fluorescence detector: application to a pharmacokinetic study in Chinese cancer patients. Cheng, H; Cheng, Z; Xie, F; Yu, P, 2014)	0.58
"The pharmacokinetic (PK) profile of bendamustine has been characterized in adults with indolent non-Hodgkin lymphoma (NHL), but remains to be elucidated in pediatric patients with hematologic malignancies."	( Population pharmacokinetics and pharmacokinetics/pharmacodynamics of bendamustine in pediatric patients with relapsed/refractory acute leukemia. Bond, M; Darwish, M; Grasela, T; Hellriegel, E; Megason, G; Phillips, L; Robertson, P, 2014)	0.4
" Model-predicted mean Cmax and area under the curve values from time 0-24 h were 6806 ng/mL and 8240 ng*h/mL, respectively."	( Population pharmacokinetics and pharmacokinetics/pharmacodynamics of bendamustine in pediatric patients with relapsed/refractory acute leukemia. Bond, M; Darwish, M; Grasela, T; Hellriegel, E; Megason, G; Phillips, L; Robertson, P, 2014)	0.4
" Despite the extensive experience with bendamustine, its pharmacokinetic profile has only recently been described."	( Pharmacokinetic and pharmacodynamic profile of bendamustine and its metabolites. Bond, M; Chovan, JP; Darwish, M; Hellriegel, E; Robertson, P, 2015)	0.42
"A literature search and data on file (including a human mass balance study, pharmacokinetic population analyses in adult and pediatric patients, and modeling analyses) were evaluated for inclusion."	( Pharmacokinetic and pharmacodynamic profile of bendamustine and its metabolites. Bond, M; Chovan, JP; Darwish, M; Hellriegel, E; Robertson, P, 2015)	0.42
" Serial pharmacokinetic samples were collected and were analysed for the circulatory levels of bendamustine and its M3 metabolite."	( Infusion Rate Dependent Pharmacokinetics of Bendamustine with Altered Formation of γ-hydroxybendamustine (M3) Metabolite Following 30- and 60-min Infusion of Bendamustine in Rats. Bhamdipati, RK; Devaraj, VC; Mullangi, R; Richter, W; Srinivas, NR; Suresh, PS, 2016)	0.43
" No clinically relevant differences in other evaluated pharmacokinetic parameters were found."	( Safety and Pharmacokinetics of Bendamustine Rapid-Infusion Formulation. Anthony, SP; Chanas, B; Cheung, EM; Edenfield, WJ; Hepner, A; Mattar, B; Mutch, PJ; Smith, M, 2017)	0.46
" Here, we describe the pharmacokinetic (PK) observations, along with modeling to further explore the interaction between ibrutinib and rituximab."	( Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial. Avigdor, A; Bartlett, N; Cramer, P; de Jong, J; De Nicolao, G; Demirkan, F; Dilhuydy, MS; Fraser, G; Ganguly, S; Goy, A; Howes, A; Lavezzi, SM; Loscertales, J; Mahler, M; Neyens, M; Poggesi, I; Rule, S; Salman, M; Samoilova, O, 2019)	0.51
"Using a previously described population pharmacokinetic (PK) model of obinutuzumab in patients with non-Hodgkin lymphoma and CLL, we conducted an exposure-response analysis using data from 6 clinical trials in patients with CD20+ B-cell malignancies (CLL11, GADOLIN, GATHER, GAUDI, GAUGUIN and GAUSS) to describe the PK properties of obinutuzumab, identify covariates influencing exposure, and explore how exposure affects safety, efficacy and pharmacodynamics."	( Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab-refractory follicular lymphoma patients in the GADOLIN phase III study. Brewster, M; Buchheit, V; Fingerle-Rowson, G; Frey, N; Gibiansky, E; Gibiansky, L; Jamois, C, 2019)	0.51

Excerpt	Reference	Relevance
"Because of its efficacy and low toxicity, bendamustine in combination with rituximab may be an alternative treatment for aggressive lymphomas in old patients not eligible for R-CHOP."	( Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas. Al-Batran, SE; Atmaca, A; Fauth, F; Jäger, E; Neumann, A; Pauligk, C; Weidmann, E, 2011)	0.37
" The present dose-escalation study evaluated the safety, efficacy, and pharmacokinetics of bendamustine hydrochloride in combination with rituximab in patients with relapsed/refractory, CD20-positive, aggressive B-NHL."	( Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Ando, K; Matsumoto, Y; Ogura, M; Ohmachi, K; Taniwaki, M; Tobinai, K; Uchida, T; Watanabe, T, 2011)	0.86
"The objective of this trial was to evaluate safety and efficacy of bendamustine combined with rituximab (BR) in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL)."	( Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. Bahlo, J; Böttcher, S; Bühler, A; Busch, R; Cramer, P; Döhner, H; Eckart, MJ; Eichhorst, BF; Elter, T; Fischer, K; Goede, V; Hallek, M; Kiehl, M; Kneba, M; Kranz, G; Schweighofer, CD; Staib, P; Stilgenbauer, S; Wendtner, CM; Winkler, D, 2011)	0.37
" Bendamustine was administered at a dose of 70 mg/m(2) on days 1 and 2 combined with rituximab 375 mg/m(2) on day 0 of the first course and 500 mg/m(2) on day 1 during subsequent courses for up to six courses."	( Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. Bahlo, J; Böttcher, S; Bühler, A; Busch, R; Cramer, P; Döhner, H; Eckart, MJ; Eichhorst, BF; Elter, T; Fischer, K; Goede, V; Hallek, M; Kiehl, M; Kneba, M; Kranz, G; Schweighofer, CD; Staib, P; Stilgenbauer, S; Wendtner, CM; Winkler, D, 2011)	0.37
" Its favorable toxicity profile in-vivo favors its combination with other cytotoxic drugs."	( The cytotoxic effects of bendamustine in combination with cytarabine in mantle cell lymphoma cell lines. Albiero, E; Bernardi, M; Castegnaro, S; Chieregato, K; Madeo, D; Rodeghiero, F; Visco, C; Zanon, C, 2012)	0.38
" Bendamustine was administered at a dose of 90 mg/m(2) on days 1 and 2 combined with 375 mg/m(2) rituximab on day 0 of the first course and 500 mg/m(2) on day 1 during subsequent courses for up to six courses."	( Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. Bahlo, J; Böttcher, S; Bühler, A; Busch, R; Cramer, P; Döhner, H; Eichhorst, BF; Fink, AM; Fischer, K; Goede, V; Hallek, M; Isfort, S; Kneba, M; Kreuzer, KA; Pflüger, KH; Ritgen, M; Schott, S; Schubert, J; Staib, P; Stilgenbauer, S; von Tresckow, J; Wendtner, CM; Winkler, D, 2012)	0.38
"We conducted a phase II, noncomparative, open-label, multicenter GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) study (CLL0809) to assess the efficacy and safety of bendamustine in combination with ofatumumab (BendOfa) in relapsed/refractory chronic lymphocytic leukemia (CLL)."	( Bendamustine in combination with ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial. Angelucci, E; Cascavilla, N; Chiarenza, A; Cortelezzi, A; Cuneo, A; Fabris, S; Foà, R; Giannarelli, D; Gobbi, M; Gritti, G; Guarini, A; Laurenti, L; Liberati, AM; Marasca, R; Mauro, FR; Morabito, F; Neri, A; Orsucci, L; Piciocchi, A; Reda, G; Rossi, D; Sciumè, M; Storti, S; Vignetti, M; Vincenti, D; Zaja, F, 2014)	0.4
" This analysis investigated the potential for drug-drug interactions between the drugs in patients with indolent non-Hodgkin lymphoma or mantle cell lymphoma."	( An evaluation of the potential for drug-drug interactions between bendamustine and rituximab in indolent non-Hodgkin lymphoma and mantle cell lymphoma. Bond, M; Burke, JM; Darwish, M; Hellriegel, E; Ludwig, E; Munteanu, MC; Phillips, L; Robertson, P, 2014)	0.4
" This study evaluated the safety, pharmacokinetics, and efficacy of otlertuzumab administered in combination with rituximab and bendamustine to patients with relapsed, indolent B-cell non-Hodgkin Lymphoma (NHL)."	( Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients. Bellam, N; Eisenfeld, AJ; Feldman, T; Gopal, AK; Goy, A; Green, DJ; Griffin, M; Mato, AR; Stromatt, SC; Tarantolo, SR, 2014)	0.4
"Otlertuzumab in combination with rituximab and bendamustine was well tolerated and induced responses in the majority of patients with relapsed indolent B-NHL."	( Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients. Bellam, N; Eisenfeld, AJ; Feldman, T; Gopal, AK; Goy, A; Green, DJ; Griffin, M; Mato, AR; Stromatt, SC; Tarantolo, SR, 2014)	0.4
" In the present protocol, bortezomib was combined with bendamustine and prednisone, in order to assess the efficacy and safety of this combination therapy in patients with newly diagnosed/untreated MM."	( Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with newly diagnosed/untreated multiple myeloma. Andrea, M; Becker, C; Behre, G; Bourgeois, M; Edelmann, T; Gutsche, K; Hammerschmidt, D; Hennig, E; Heyn, S; Hoffmann, FA; Holzvogt, B; Kaiser, T; Krahl, R; Kreibich, U; Lindner, T; Niederwieser, D; Plötze, M; Pönisch, W; Reifenrath, K; Remane, Y; Schliwa, T; Schwarz, M; Schwarzer, A; Vucinic, V; Winkelmann, C; Zehrfeld, T, 2014)	0.4
" Bendamustine was administered with a cumulative dose of up to 200 mg/m(2)."	( Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide. Aitchison, R; Blesing, N; Lau, IJ; Peniket, A; Rabin, N; Ramasamy, K; Roberts, P; Smith, D; Yong, K, 2015)	0.42
"BENDA used either alone or in combination with RIT strongly induced apoptosis as well as enhanced expression of selected apoptotic proteins, especially those involved in the intrinsic apoptotic pathway: P53, PUMA and BAX, which cause mitochondrial transmembrane potential changes leading to activation of caspase-9 and -3."	( Cytotoxic and apoptosis-inducing effects of bendamustine used alone and in combination with rituximab on chronic lymphocytic leukemia cells in vitro. Blonski, JZ; Cebula-Obrzut, B; Korycka-Wolowiec, A; Robak, T; Smolewski, P; Wolowiec, D; Ziolkowska, E, 2014)	0.4
"Between Sept 19, 2012, and Jan 21, 2014, 578 eligible patients were randomly assigned to ibrutinib or placebo in combination with bendamustine plus rituximab (289 in each group)."	( Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Avigdor, A; Balasubramanian, S; Bartlett, NL; Chanan-Khan, A; Cramer, P; Demirkan, F; Dilhuydy, MS; Fraser, G; Goy, A; Grosicki, S; Hallek, M; Howes, A; Janssens, A; Karlsson, C; Loscertales, J; Mahler, M; Mato, A; Mayer, J; Panagiotidis, P; Pavlovsky, MA; Phelps, C; Pristupa, A; Pylypenko, H; Rule, S; Salman, M; Samoilova, O; Silva, RS; Sun, S; Villa, D, 2016)	0.43
"This phase Ib, dose-escalation study investigated the maximum tolerated dose (MTD), recommended phase II dose (RP2D), safety, pharmacokinetics (PK) and preliminary efficacy of the pan-class I phosphoinositide 3-kinase (PI3K) and mechanistic target of rapamycin (mTOR) inhibitor voxtalisib [30 or 50 mg twice daily (BID)], in combination with rituximab (voxtalisib+rituximab) or rituximab plus bendamustine (voxtalisib+rituximab+bendamustine), in relapsed or refractory indolent B-cell non-Hodgkin lymphoma (NHL), mantle cell lymphoma and chronic lymphocytic leukaemia (CLL)."	( Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies. Awan, FT; Costa, LJ; Gao, L; Gore, L; Lager, J; Sharma, J, 2016)	0.43
"Bendamustine in combination with rituximab (BR) has been associated with high response rates and acceptable toxicity in older patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL)."	( A phase II trial of bendamustine in combination with rituximab in older patients with previously untreated diffuse large B-cell lymphoma. Asch, AS; Deal, AM; Foster, MC; Grover, NS; Ivanova, A; Muss, HB; Olajide, O; Park, SI; Richards, KL; Shea, TC; Sobol, AL; Wall, JG, 2016)	0.43
" We aim to investigate the safety and efficacy of the Akt inhibitor MK-2206 in combination with bendamustine and rituximab (BR) in relapsed and/or refractory CLL in a phase I/II study."	( Akt inhibitor MK-2206 in combination with bendamustine and rituximab in relapsed or refractory chronic lymphocytic leukemia: Results from the N1087 alliance study. Bowen, D; Boysen, J; Call, T; Conte, M; Ding, W; Erlichman, C; Habermann, TM; Hanson, C; Jelinek, D; Kay, NE; LaPlant, B; Larsen, JT; Leis, JF; Lesnick, C; Nikcevich, D; Pettinger, A; Reeder, C; Secreto, C; Shanafelt, TD; Tschumper, R, 2017)	0.46
"To evaluate the cost-effectiveness of obinutuzumab in combination with bendamustine followed by obinituzumab maintenance (Obin-Benda) compared to bendamustine alone (Benda) in patients with refractory follicular lymphoma (FL) in a Norwegian setting."	( Cost-Effectiveness of Obinutuzumab in Combination with Bendamustine Followed by Obinutuzumab Maintenance versus Bendamustine Alone in Treatment of Patients with Rituximab-Refractory Follicular Lymphoma in Norway. Haukaas, FS; Krivasi, T; Ohna, A, 2018)	0.48
" The results of the analysis indicate that obinutuzumab in combination with bendamustine followed by obinutuzumab maintenance may be cost-effective compared to bendamustine alone in Norway."	( Cost-Effectiveness of Obinutuzumab in Combination with Bendamustine Followed by Obinutuzumab Maintenance versus Bendamustine Alone in Treatment of Patients with Rituximab-Refractory Follicular Lymphoma in Norway. Haukaas, FS; Krivasi, T; Ohna, A, 2018)	0.48
" Newly diagnosed patients are treated with rituximab in combination with anthracycline-containing chemotherapy, but a significant number of patients relapse after initial treatment."	( Polatuzumab vedotin to treat relapsed or refractory diffuse large B-cell lymphoma, in combination with bendamustine plus rituximab. Amaya, ML; Jimeno, A; Kamdar, M, 2020)	0.56
" However, the efficacy and underlying toxicity of these hybrids in combination with other agents remain unclear."	( Novel SAHA‑bendamustine hybrid NL‑101 in combination with daunorubicin synergistically suppresses acute myeloid leukemia. Guo, W; Huang, J; Huang, S; Huang, X; Jin, J; Li, F; Li, X; Ling, Q; Pan, J; Ye, W, 2020)	0.56
" In a monocentric cohort of 68 SMLZ patients, we showed that rituximab in monotherapy or in combination with bendamustine, compared with rituximab associated with the polychemotherapy cycle cyclophosphamide, hydroxydaunorubicin, vincristine and prednisolone (CHOP), resulted in a higher 5-year progression-free survival (91."	( Rituximab Monotherapy or in Combination with Bendamustine Is Not Inferior to Rituximab-CHOP Regimen in the Treatment of Patients with Splenic Marginal Zone Lymphoma in the Real Life. Cabras, MG; Caocci, G; Dessì, D; La Nasa, G; Mantovani, D; Moi, G; Mulas, O, 2021)	0.62
"The protocol followed a 3+3 design of carfilzomib dose escalation combined with standard doses of bendamustine and rituximab."	( Carfilzomib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma: A Phase I Trial. Ai, WZ; Andreadis, CB; Aoun, C; Castillo, M; Cavallone, E; Crawford, E; Fakhri, B; Kambhampati, S; Kaplan, LD; Le, D; Martinelli, M; Padilla, M; Reiner, J; Sudhindra, A; Ta, T; Tuscano, JM; Wieduwilt, MJ, 2021)	0.62
"Carfilzomib in combination with bendamustine and rituximab is a safe and well-tolerated treatment for patients with relapsed/refractory non-Hodgkin lymphoma."	( Carfilzomib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma: A Phase I Trial. Ai, WZ; Andreadis, CB; Aoun, C; Castillo, M; Cavallone, E; Crawford, E; Fakhri, B; Kambhampati, S; Kaplan, LD; Le, D; Martinelli, M; Padilla, M; Reiner, J; Sudhindra, A; Ta, T; Tuscano, JM; Wieduwilt, MJ, 2021)	0.62
" Brentuximab vedotin (BV) in combination with bendamustine may represent a suitable salvage therapy; data on 32 patients aged less than 25 years were retrospectively analyzed."	( Brentuximab vedotin in combination with bendamustine in pediatric patients or young adults with relapsed or refractory Hodgkin lymphoma. Buffardi, S; De Vito, R; Del Bufalo, F; Di Matteo, A; Di Ruscio, V; Locatelli, F; Mariggiò, E; Paganelli, V; Pagliara, D; Parasole, R; Petruzziello, F; Stocchi, F; Strocchio, L; Vinti, L, 2022)	0.72
" The monitoring of serum IgG during chemotherapy may help to predict the development of infection in blood cancer patients undergoing chemotherapy with bendamustine in combination with rituximab."	( Serum immunoglobulin G as a discriminator of infection in follicular lymphoma patients undergoing chemotherapy with bendamustine in combination with rituximab. Choi, I; Hirata, A; Hirata, K; Miyashita, K; Nakashima, E; Narazaki, T; Ohno, H; Suehiro, Y; Tachikawa, Y; Taguchi, K; Tanaka, T; Utsunomiya, H, 2022)	0.72
" Ofatumumab PK concentration profiles and parameters were similar, alone or in combination with bendamustine."	( Phase 1 Study Evaluating Pharmacokinetics and Tolerability of Ofatumumab Combined With Bendamustine in Patients With Indolent B-Cell Non-Hodgkin's Lymphoma. Chandler, JC; Davis, J; Forero-Torres, A; Hoever, P; Iyer, SP; Izquierdo, M; Kanate, AS; Madan, S; Quinlan, M, 2022)	0.72
"Venetoclax in combination with obinutuzumab has significantly improved efficacy versus immunochemotherapy (progression-free survival) in patients with chronic lymphocytic leukaemia who have not received prior treatment."	( Cost-utility analysis of venetoclax in combination with obinutuzumab as first-line treatment of chronic lymphocytic leukaemia in Spain. De la Serna-Torroba, J; Escudero-Vilaplana, V; Hernández-Rivas, JÁ; Moreno-Martínez, E; Sánchez-Cuervo, M; Sánchez-Hernández, R, 2022)	0.72
"Venetoclax in combination with obinutuzumab was shown to be a dominant alternative compared to the rest of the treatment alternatives, with a lower cost per patient (€-67,869 compared to chlorambucil in combination with obinutuzumab, €-375,952 compared to ibrutinib, €-61,996 compared to fludarabine in combination with cyclophosphamide and rituximab, and €- 77,398 compared to bendamustine in combination with rituximab)."	( Cost-utility analysis of venetoclax in combination with obinutuzumab as first-line treatment of chronic lymphocytic leukaemia in Spain. De la Serna-Torroba, J; Escudero-Vilaplana, V; Hernández-Rivas, JÁ; Moreno-Martínez, E; Sánchez-Cuervo, M; Sánchez-Hernández, R, 2022)	0.72
"Venetoclax in combination with obinutuzumab is an efficient and dominant alternative for treating previously untreated patients with chronic lymphocytic leukaemia compared to the available alternatives and from the perspective of the Spanish National Health System."	( Cost-utility analysis of venetoclax in combination with obinutuzumab as first-line treatment of chronic lymphocytic leukaemia in Spain. De la Serna-Torroba, J; Escudero-Vilaplana, V; Hernández-Rivas, JÁ; Moreno-Martínez, E; Sánchez-Cuervo, M; Sánchez-Hernández, R, 2022)	0.72
" CY/BEN treated mice when combined with cyclosporine A (CSA) (10mg/kg daily from days +5 to +18 and thrice weekly thereafter), had improved outcomes over CY/CY +CSA treated mice."	( Partially replacing cyclophosphamide with bendamustine in combination with cyclosporine A improves survival and reduces xenogeneic graft-versus-host-disease. Cracchiolo, MJ; Davini, DW; Gilman, KE; Katsanis, E; Matiatos, AP; Simpson, RJ, 2022)	0.72
"Together, we illustrate that the use of CY/BEN is safe and shows similar control of xGvHD to CY/CY, but when combined with CSA, survival with CY/BEN is significantly prolonged compared to CY/CY."	( Partially replacing cyclophosphamide with bendamustine in combination with cyclosporine A improves survival and reduces xenogeneic graft-versus-host-disease. Cracchiolo, MJ; Davini, DW; Gilman, KE; Katsanis, E; Matiatos, AP; Simpson, RJ, 2022)	0.72

Excerpt	Reference	Relevance
" administration of 1, the bioavailability of the drug was found to be increased in the leukemia-bearing animals."	( Influence of leukemia P388 on plasma concentration-time profiles of bendamustine in B6D2F1 mice. Amlacher, R; Hoffmann, H; Preiss, R; Weber, H, 1992)	0.28
" The absorption of the drug from the gastrointestinal tract is incomplete resulting in an absolute bioavailability of about 40%."	( [Pharmacokinetics of bendamustin (Cytostasan) in B6D2F1-mice]. Amlacher, R; Hoffmann, H; Preiss, R; Weber, H, 1991)	0.28
" It has good oral bioavailability but has been studied almost exclusively in the intravenous formulation."	( Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma. Dennie, TW; Kolesar, JM, 2009)	0.35

Excerpt	Relevance	Reference
"Although bendamustine has been used for more than 30 years in the treatment of lymphoma, little is known about the optimal dosing schedule in relapsed or refractory B-cell chronic lymphocytic leukemia (CLL)."	( Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group. Bergmann, MA; Boening, L; Emmerich, B; Goebeler, ME; Hallek, MJ; Herold, M; Ruelfs, C; Wilhelm, M, 2005)	0.33
" Optimal bendamustine dosing for CLL patients had not been finally established and a phase I/II study was conducted to determine the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of bendamustine."	( Phase-I/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pre-treated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapy. Arnaudov, G; Lissitchkov, T; Merkle, Kh; Peytchev, D, 2006)	0.33
" dosing of 3 mg/kg."	( Metabolic profile of [(14)C]bendamustine in rat urine and bile: preliminary structural identification of metabolites. Chovan, JP; Li, F; Ring, SC; Yu, E, 2007)	0.34
"The BSA-based dosing regimen for bendamustine achieved the targeted exposure and was associated with a high incidence of therapeutic response."	( Bendamustine pharmacokinetic profile and exposure-response relationships in patients with indolent non-Hodgkin's lymphoma. D'Andrea, D; Darwish, M; Kahl, B; Melhem, M; Owen, JS; Passarell, JA, 2010)	0.36
" Bendamustine dosage was 80-150 mg on day 1+2 of a monthly cycle."	( Bendamustine in patients with relapsed or refractory multiple myeloma. Bölke, E; Bruns, I; Czibere, A; Fenk, R; Haas, R; Kobbe, G; Michael, M; Neumann, F; Safaian, NN; Zohren, F, 2010)	0.36
"The pharmacology, efficacy, safety, and dosage and administration of bendamustine and its use in indolent non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL) are reviewed."	( Bendamustine for the treatment of indolent non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Czuczman, MS; Elefante, A, 2010)	0.36
" The dosage and administration differ for the treatment of NHL and CLL."	( Bendamustine for the treatment of indolent non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Czuczman, MS; Elefante, A, 2010)	0.36
" Additionally, phase I and pharmacokinetic studies are limited, although increased understanding of the clinical pharmacology of bendamustine led to development of dosing recommendations by international experts based on the available data."	( Bendamustine: rescue of an effective antineoplastic agent from the mid-twentieth century. Leoni, LM, 2011)	0.37
" When dosed based upon BSA, it appeared that age, body weight, race, mild renal (n = 3) or hepatic (n = 2) dysfunction, cancer type, and cytochrome P450 1A2 inhibitors (n = 17) or inducers (n = 3) did not affect systemic exposure, which was comparable between pediatric and adult patients."	( Population pharmacokinetics and pharmacokinetics/pharmacodynamics of bendamustine in pediatric patients with relapsed/refractory acute leukemia. Bond, M; Darwish, M; Grasela, T; Hellriegel, E; Megason, G; Phillips, L; Robertson, P, 2014)	0.4
"Altogether, the findings support dosing based on body surface area for most patient populations."	( Pharmacokinetic and pharmacodynamic profile of bendamustine and its metabolites. Bond, M; Chovan, JP; Darwish, M; Hellriegel, E; Robertson, P, 2015)	0.42
" Thus, the strategy of host-guest inclusion was very effective and could be successfully used in the development of suitable pharmaceutical dosage form with enhanced therapeutic activity."	( Inclusion complexes of bendamustine with β-CD, HP-β-CD and Epi-β-CD: in-vitro and in-vivo evaluation. Gidwani, B; Vyas, A, 2015)	0.42
" Dosage varied from 60 to 300 mg/m(2) (median 120 mg/m(2)) and was administered intravenously on day 1 and 2 of a 28-day cycle."	( Bendamustine in heavily pre-treated patients with relapsed or refractory multiple myeloma. Hänel, M; Schmeel, FC; Schmeel, LC; Schmidt-Wolf, IG; Stöhr, E, 2015)	0.42
" In 2014, this panel met again to update these recommendations since the clarification of issues including optimal dosing and management of bendamustine-related toxicities."	( Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel - an update. Brugger, W; Cheson, BD; Damaj, G; Dreyling, M; Kahl, B; Kimby, E; Ogura, M; Weidmann, E; Wendtner, CM; Zinzani, PL, 2016)	0.43
" Obinutuzumab plus bendamustine dosing was obinutuzumab 1000 mg (days 1, 8, and 15, cycle 1; day 1, cycles 2-6) plus bendamustine 90 mg/m(2) per day (days 1 and 2, cycles 1-6), and bendamustine monotherapy dosing was 120 mg/m(2) per day (days 1 and 2, all cycles)."	( Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Bouabdallah, K; Cheson, BD; Chua, N; Delwail, V; Dimier, N; Dueck, G; Fingerle-Rowson, G; Fowler, N; Gribben, J; Lennard, A; Lugtenburg, PJ; Mayer, J; Press, O; Salles, G; Sehn, LH; Trněný, M; Wassner-Fritsch, E, 2016)	0.43
" Since bendamustine showed genotoxic effects in all tested concentrations, two of them corresponding to the peak plasma concentrations observed in cancer patients treated with bendamustine, data provided in the current research work may be useful to identify the most appropriate dosage regimen to achieve the efficacy and safety of this anticancer medication."	( Assessment of bendamustine-induced genotoxicity in eukaryotic cells. Castro-Prado, MAA; Franco, CCDS; Mathias, PCF; Morais, JF; Pereira, TS; Sant'anna, JR; Yajima, JPRS, 2019)	0.51
" The selected obinutuzumab dosing regimen offers clinical benefit in a majority of rituximab-refractory FL patients treated with bendamustine, irrespective of variability in exposure, whilst minimising adverse events."	( Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab-refractory follicular lymphoma patients in the GADOLIN phase III study. Brewster, M; Buchheit, V; Fingerle-Rowson, G; Frey, N; Gibiansky, E; Gibiansky, L; Jamois, C, 2019)	0.51
" In summary, BR was well tolerated even in patients ≥80 years, with similar efficacy and safety as in less old patients, provided that carefully adapted dosing was applied."	( Risk-adapted bendamustine + rituximab is a tolerable treatment alternative for elderly patients with chronic lymphocytic leukaemia: a regional real-world report on 141 consecutive Swedish patients. Asklid, A; Hansson, L; Johansson, H; Lundin, J; Mansouri, L; Mattsson, A; Österborg, A; Rosenquist, R; Sylvan, SE; Wiggh, J; Winqvist, M, 2020)	0.56
"Same-day G-CSF compared with next-day G-CSF was the most common G-CSF dosing method utilized in primary and secondary prophylaxis (94% and 100%), respectively."	( Outcomes of primary and secondary prophylaxis of chemotherapy-induced and febrile neutropenia in bendamustine plus rituximab regimens in patients with lymphoma and chronic lymphocytic leukemia: real-world, single-center experience. Abraham, I; Bartels, T; Kumar, A; McBride, A; Moore, L; Persky, DO, 2021)	0.62
" One strategy to reduce relapse rates being explored by others is a dosage reduction of PT-CY."	( Feasibility and Efficacy of Partially Replacing Post-Transplantation Cyclophosphamide with Bendamustine in Pediatric and Young Adult Patients Undergoing Haploidentical Bone Marrow Transplantation. Husnain, M; Katsanis, E; Khurana, S; Kovacs, K; Roe, DJ; Simpson, RJ; Stea, B; Truscott, L, 2022)	0.72

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
estrogen-related nuclear receptor alpha	Homo sapiens (human)	Potency	33.4915	0.0015	30.6073	15,848.9004	AID1224819; AID1224820
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Assay ID	Title	Year	Journal	Article
AID1347410	qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library	2019	Cellular signalling, 08, Volume: 60	A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347405	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347057	CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347151	Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347059	CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347058	CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).	2014	Journal of biomolecular screening, Jul, Volume: 19, Issue:6	A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	12 (1.15)	18.7374
1990's	11 (1.06)	18.2507
2000's	118 (11.34)	29.6817
2010's	608 (58.41)	24.3611
2020's	292 (28.05)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	246 (23.10%)	5.53%
Reviews	151 (14.18%)	6.00%
Case Studies	173 (16.24%)	4.05%
Observational	18 (1.69%)	0.25%
Other	477 (44.79%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (340)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Phase I Study of FT576 as Monotherapy and in Combination With Daratumumab in Subjects With Relapsed/Refractory Multiple Myeloma [NCT05182073]	Phase 1	168 participants (Anticipated)	Interventional	2021-11-24	Recruiting
Study of Bendamustine Hydrochloride Injection in Previously Untreated Chronic Lymphocytic Leukemia Patients [NCT01109264]	Phase 2	147 participants (Actual)	Interventional	2010-03-31	Completed
Isatuximab and Bendamustine in Systemic Light Chain Amyloidosis [NCT04943302]	Phase 2	0 participants (Actual)	Interventional	2022-09-30	Withdrawn(stopped due to PI left institution. Study not moving forward in her absence.)
A Phase III, Open-Label, Multicenter Randomized Study Evaluating Glofitamab as a Single Agent Versus Investigator's Choice in Patients With Relapsed/Refractory Mantle Cell Lymphoma [NCT06084936]	Phase 3	182 participants (Anticipated)	Interventional	2023-10-22	Recruiting
A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL) [NCT01886872]	Phase 3	547 participants (Actual)	Interventional	2013-12-09	Active, not recruiting
The Efficacy of Bendamustine, Gemcytabine, Dexamethasone (BGD) Salvage Chemotherapy With Autologous Stem Cell Transplantation (ASCT) Consolidation in Advanced Classical Hodgkin Lymphoma Patients Not Responding to ABVD Therapy- Multicentre Phase II Clinica [NCT03615664]	Phase 2	115 participants (Actual)	Interventional	2017-11-06	Active, not recruiting
Phase 1b Study Evaluating the Safety and Efficacy of Autologous CD30.CAR-T in Combination With PD-1 Checkpoint Inhibitor (Nivolumab) in Relapsed or Refractory Classical Hodgkin Lymphoma Patients After Failure of Frontline Therapy (ACTION) [NCT05352828]	Phase 1	15 participants (Actual)	Interventional	2022-07-25	Active, not recruiting
A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 [NCT02954406]	Phase 1	43 participants (Actual)	Interventional	2017-03-05	Terminated(stopped due to Business decision, insufficient enrollment, no safety or efficacy concerns.)
Bendamustine + Obinutuzumab Induction Chemoimmunotherapy With Risk-adapted Obinutuzumab Maintenance Therapy in Previously Untreated Mantle Cell Lymphoma [NCT03311126]	Phase 2	21 participants (Actual)	Interventional	2017-10-19	Active, not recruiting
Study Phase II Non-randomized Prospective Open to Assess the Combination of Rituximab, Bendamustine (RB) for Patients With Follicular Lymphoma Refractory or Relapsed After Treatment With R-chemotherapy in First Line. [NCT01127841]	Phase 2	60 participants (Anticipated)	Interventional	2009-07-31	Active, not recruiting
PHASE 1B/PHASE 3 MULTICENTER STUDY OF AVELUMAB (MSB0010718C) IN COMBINATION REGIMENS THAT INCLUDE AN IMMUNE AGONIST, EPIGENETIC MODULATOR, CD20 ANTAGONIST AND/OR CONVENTIONAL CHEMOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHO [NCT02951156]	Phase 3	29 participants (Actual)	Interventional	2016-12-16	Terminated(stopped due to Study was terminated due to closure of study arms following futility analysis and difficulty in enrolling participants due to evolving treatment landscape)
A Randomised, Open Label, Multi-centre, Phase III Study to Investigate the Efficacy of Bendamustine Compared to Treatment of Physician's Choice in the Treatment of Subjects With Indolent Non-Hodgkin's Lymphoma (NHL) Refractory to Rituximab [NCT01289223]	Phase 3	88 participants (Actual)	Interventional	2011-02-28	Terminated(stopped due to Ongoing challenges to successfully recruit the required number of subjects)
A Phase III, Randomised, Open-label,, Multi-Center Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1 Monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL) [NCT06170489]	Phase 3	185 participants (Anticipated)	Interventional	2023-12-22	Not yet recruiting
A Phase 3, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib Versus Chemoimmunotherapy for Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Without TP53 Aberrations [NCT05624554]	Phase 3	300 participants (Anticipated)	Interventional	2023-03-16	Recruiting
A Phase I/II b (Randomized Controlled) Study of Atezolizumab Combined to BEGEV Regimen as First Salvage Treatment in Patients With Relapsed or Refractory Hodgkin's Lymphoma Candidate to Autologous Stem-Cell Transplantation [NCT05300282]	Phase 1/Phase 2	140 participants (Anticipated)	Interventional	2022-08-03	Recruiting
Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma - a Nordic Lymphoma Group Trial [NCT00963534]	Phase 1/Phase 2	51 participants (Actual)	Interventional	2009-09-30	Completed
A Randomized, Multicenter, Open-Label, Phase 3 Study of Acalabrutinib (ACP-196) Versus Investigator's Choice of Either Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Subjects With R/R Chronic Lymphocytic Leukemia [NCT02970318]	Phase 3	310 participants (Actual)	Interventional	2017-02-02	Active, not recruiting
Phase I Dose-Escalation Study of CPI-613, in Combination With Bendamustine, in Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Classic Hodgkin Lymphoma [NCT02168140]	Phase 1	16 participants (Actual)	Interventional	2014-09-30	Completed
An Open-label Phase I/II Trial of Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Systemic Light-Chain Amyloidosis [NCT05451771]	Phase 1/Phase 2	53 participants (Anticipated)	Interventional	2022-10-26	Recruiting
A Single Center Phase Ib Study of Carfilzomib, Bendamustine, and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma [NCT02095834]	Phase 1	18 participants (Actual)	Interventional	2014-04-24	Completed
Phase 1 Study of the Administration of T Lymphocytes Expressing the Kappa Chimeric Antigen Receptor (CAR) and CD28 Endodomain for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. [NCT04223765]	Phase 1	20 participants (Anticipated)	Interventional	2020-11-12	Recruiting
Phase II Study of Simvastatin, Zoledronic Acid, Bortezomib, Bendamustine and Methylprednisolone for Relapsed/Refractory Myeloma [NCT01332617]	Phase 2	0 participants (Actual)	Interventional	2011-04-30	Withdrawn(stopped due to Investigators no longer interested in activating study)
Observational Program for Evaluation of Ribomustin Use in the First Line Therapy of Chronic Lymphocytic Leukemia [NCT02110394]		190 participants (Actual)	Observational	2012-06-30	Completed
[NCT01376401]	Phase 2	60 participants (Anticipated)	Interventional	2011-07-31	Completed
A Multi-Center, Open-Label, Single-Arm Phase II Trial of Bendamustine, Rituximab and the Second Generation BTK Inhibitor Acalabrutinib in Previously Untreated Waldenstrom's Macroglobulinemia [NCT04624906]	Phase 2	59 participants (Anticipated)	Interventional	2021-03-02	Recruiting
Clinical Research of Gene Therapy for Refractory B-Cell Non-Hodgkin Lymphoma Using Autologous T Cells Expressing a Chimeric Antigen Receptor Specific to the CD19 Antigen [NCT02134262]	Phase 1/Phase 2	18 participants (Anticipated)	Interventional	2014-05-31	Recruiting
[NCT02162888]	Phase 1	81 participants (Actual)	Interventional	2013-11-30	Completed
Bendamustine Plus Bortezomib Plus Dexamethasone in the Treatment of Stage II/III Relapsed or Refractory Multiple Myeloma [NCT01168804]	Phase 2	79 participants (Actual)	Interventional	2010-06-30	Completed
Phase I/II Study With Bendamustine and Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Non-hodgkin's Lymphoma (NHL) Not Eligible for High Dose Chemotherapy and Autologous/Allogeneic Stem Cell Transplantation [NCT01170052]	Phase 1/Phase 2	20 participants (Anticipated)	Interventional	2010-05-31	Withdrawn(stopped due to insufficient enrollment)
Bendamustine, Cytarabine, Etoposide and Melphalan as Conditioning for Autologous Stem Cell Transplant in Patients With Aggressive Non Hodgkin's Lymphoma. [NCT01296256]	Phase 2	60 participants (Actual)	Interventional	2011-05-31	Completed
A Phase I/II Trial to Evaluate the Safety, Feasibility and Efficacy of the Addition of Temsirolimus to a Regimen of Bendamustine and Rituximab for the Treatment of Patients With Follicular Lymphoma or Mantle Cell Lymphoma in First to Third Relapse [NCT01078142]	Phase 1/Phase 2	39 participants (Actual)	Interventional	2010-02-02	Completed
Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma - a Single Center Phase II Trial [NCT05868395]	Phase 2	16 participants (Anticipated)	Interventional	2023-05-24	Not yet recruiting
A Phase 1b, Open-Label, Multicenter Study of FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma [NCT05934097]	Phase 1	0 participants (Actual)	Interventional	2022-12-31	Withdrawn(stopped due to This study was withdrawn (Sponsor decision).)
Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lymphoma [NCT05025423]	Phase 2	40 participants (Anticipated)	Interventional	2022-06-21	Recruiting
A Phase 3 Multicenter, Randomized, Prospective, Open-label Trial of Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab Plus Venetoclax (RVe) Versus Obinutuzumab (GA101) Plus Venetoclax (GVe) Versus Obinutuzumab Plus Ibrutinib Plus Venetoclax (GIVe) in [NCT02950051]	Phase 3	926 participants (Actual)	Interventional	2016-12-13	Active, not recruiting
A Phase I/II Clinical Trial to Evaluate the Safety and Efficacy of Nivolumab and Bendamustine Combination (NB) in Patients With Relapsed or Refractory Hodgkin's Lymphoma [NCT03343652]	Phase 1/Phase 2	30 participants (Actual)	Interventional	2017-05-27	Completed
Phase I Dose-Escalation Study of CPI-613, in Combination With Bendamustine and Rituximab, in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma [NCT02168907]	Phase 1	1 participants (Actual)	Interventional	2014-12-31	Terminated(stopped due to Slow Accruals)
Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant [NCT01437709]	Phase 2	30 participants (Actual)	Interventional	2011-09-30	Completed
A Phase I Safety and Feasibility Study of Cellular Immunotherapy for Extensive Stage Small Cell Neuroendocrine Prostate Cancer Using Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptor [NCT06094842]	Phase 1	20 participants (Anticipated)	Interventional	2024-03-01	Not yet recruiting
A Multicenter, Phase 1/2 Study of Selinexor in Combination With Backbone Treatments or Novel Therapies in Patients With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL) [NCT04607772]	Phase 1/Phase 2	350 participants (Anticipated)	Interventional	2020-11-18	Suspended(stopped due to Sponsor decision)
A Study of Thalidomide, Bendamustine and Dexamethasone (BTD) Versus Bortezomib, Bendamustine and Dexamethasone (BBD) in Patients With Renal Failure Defined as a GFR Below 30 Mls/Min [NCT02424851]	Phase 2	31 participants (Actual)	Interventional	2014-11-30	Completed
Phase I Study of Escalating-Doses of Bendamustine for Patients With Previously Treated Multiple Myeloma [NCT02315157]	Phase 1	0 participants (Actual)	Interventional		Withdrawn(stopped due to Withdrawn by PI)
A Prospective, Multicenter, Phase-II Trial Evaluating Efficacy and Safety of Bendamustine + GA101 (BG) in Patients With Relapsed CLL Followed by Maintenance Therapy With GA101 for Responding Patients [NCT02320383]	Phase 2	27 participants (Actual)	Interventional	2014-11-30	Active, not recruiting
Fase II Study With Bortezomib, Rituximab and Bendamustin-BRB- for Non-Hodgkin Lymphoplasmocytic Lymphoma/Waldenstrom Macroglobulinemia's Patients at First Relapse [NCT02371148]	Phase 2	38 participants (Actual)	Interventional	2014-06-30	Completed
Bendamustine, Prednisone and Velcade® for First-line Treatment of Patients With Symptomatic Multiple Myeloma Not Eligible for High-dose Chemotherapy Followed by Autologous Stem Cell Transplantation (BPV). [NCT02237261]	Phase 2	46 participants (Actual)	Interventional	2014-11-30	Completed
A Multicenter, Open-label, Phase I Study of SyB C-0501(Oral Bendamustine) in Patients With Advanced Solid Tumors: [NCT03604679]	Phase 1	18 participants (Actual)	Interventional	2018-05-24	Completed
A Prospective, Open-label, Multicenter Phase-II Trial to Evaluate the Efficacy and Safety of a Sequential Regimen of Bendamustine Followed by GA101 and ABT-199 Followed by ABT-199 and GA101 Maintenance in CLL Patients [NCT02401503]	Phase 2	66 participants (Actual)	Interventional	2015-05-06	Active, not recruiting
A Multi-Center, Open Label Phase 1/2 Study of CYT-0851 in Patients With Relapsed/Refractory B-Cell Malignancies and Advanced Solid Tumors [NCT03997968]	Phase 1/Phase 2	170 participants (Anticipated)	Interventional	2019-10-09	Active, not recruiting
A Phase I/Ib Study of Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide and/or Bendamustine [NCT02996773]	Phase 1	50 participants (Actual)	Interventional	2016-11-29	Active, not recruiting
A Phase 2 Clinical Trial to Evaluate the Efficacy of Zanubrutinib Followed Zanubrutinib Plus FCR (Fludarabine Cyclophosphamide and Rituximab) / BR(Bendamustine and Rituximab) in Newly Diagnosed Symptomatic CLL/SLL (STOP Trial) [NCT05287984]	Phase 2	63 participants (Anticipated)	Interventional	2022-03-22	Not yet recruiting
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) an dCD30-expressing Peripheral T-cell Lymphoma (PTCL) in Older Patients or Patients With Significant Comorbidities Ineligible for Standard Chemotherapy [NCT01716806]	Phase 2	131 participants (Actual)	Interventional	2012-10-31	Completed
Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab and Lenalidomide in Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) [NCT01754857]	Phase 2	36 participants (Actual)	Interventional	2013-11-12	Completed
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination With Bendamustine and Rituximab (BR) in Subjects With Newly Diagnosed Mantle Cell Lymphoma [NCT01776840]	Phase 3	523 participants (Actual)	Interventional	2013-05-16	Active, not recruiting
A Phase II Study of Rituximab/Bendamustine Followed by Rituximab/Cytarabine for Untreated Mantle Cell Lymphoma [NCT01661881]	Phase 2	23 participants (Actual)	Interventional	2012-08-16	Active, not recruiting
A Study to Infuse ROR1-Specific Autologous T Cells for Patients With Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) [NCT02194374]	Phase 1	0 participants (Actual)	Interventional	2015-01-31	Withdrawn(stopped due to Study closed with no enrollment due to unavailability of reagent.)
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102) [NCT03039114]	Phase 1	26 participants (Actual)	Interventional	2017-02-15	Completed
Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) Added to Fludarabine, Bendamustine and Rituximab and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies [NCT01664910]	Phase 1/Phase 2	27 participants (Actual)	Interventional	2012-10-29	Completed
A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma [NCT06136351]	Phase 2	23 participants (Anticipated)	Interventional	2023-11-15	Recruiting
Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy (REFRACT): A Randomised Phase II Trial of Investigator Choice Standard Therapy Versus Sequential Novel Therapy Experimental Arms [NCT05848765]	Phase 2	284 participants (Anticipated)	Interventional	2023-09-04	Recruiting
Intergroup Randomized Phase 2 Four Arm Study In Patients ≥ 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB → R); Arm B = Rituximab + Bendamustine + Bortezomib Follo [NCT01415752]	Phase 2	373 participants (Actual)	Interventional	2012-08-09	Active, not recruiting
Observational Program for Evaluation of Ribomustin and Rituximab Combined Therapy With Following Rituximab Maintenance of Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma [NCT02072967]		97 participants (Actual)	Observational	2012-05-31	Completed
Phase 2 Study Evaluating the Safety and Efficacy of Pembrolizumab (KEytruda) in Combination With Bendamustine (TREanda) in Relapsed/Refractory Hodgkin Lymphoma [NCT04510636]	Phase 2	37 participants (Anticipated)	Interventional	2021-12-20	Recruiting
A Phase I/II Trial of Rituximab, Bendamustine, and Obatoclax in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma [NCT01238146]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2010-10-31	Withdrawn(stopped due to No patients accrued.)
Prospective, Open-label, Multicenter Phase-II Trial to Evaluate Efficacy and Safety of a Sequential Regimen of Bendamustine Followed by GA101 (Obinutuzumab) and CAL-101 (Idelalisib) Followed by CAL-101 and GA101 Maintenance in CLL Patients [NCT02445131]	Phase 2	48 participants (Actual)	Interventional	2015-05-28	Completed
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody®-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) [NCT04663347]	Phase 1/Phase 2	662 participants (Anticipated)	Interventional	2020-11-03	Recruiting
PHASE II CLINICAL PROTOCOL FOR THE TREATMENT OF PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA WITH A COMBINATION OF BENDAMUSTINE AND OFATUMUMAB [NCT01125787]	Phase 2	1 participants (Actual)	Interventional	2010-05-31	Terminated(stopped due to Low enrollment)
Randomized Phase 3 Study Evaluating the Efficacy and the Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patient With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma [NCT03593018]	Phase 3	86 participants (Actual)	Interventional	2018-11-09	Active, not recruiting
Phase I/II Trial of Dexamethasone, Ofatumumab and Bendamustine [Treanda] (DOT) as First-line Treatment of Mantle-cell Lymphoma (MCL) in the Elderly [NCT01221103]	Phase 1/Phase 2	50 participants (Anticipated)	Interventional	2010-04-30	Recruiting
A Retrospective Multicenter Trial on Efficacy and Toxicity of Bendamustine Alone or Associated With Rituximab, as Salvage Therapy in Patients With Chronic Lymphoproliferative Disorders [NCT01224769]		109 participants (Actual)	Observational	2005-09-30	Completed
PHASE II CLINICAL PROTOCOL FOR THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA WITH A COMBINATION OF BENDAMUSTINE AND OFATUMUMAB [NCT01131247]	Phase 2	37 participants (Anticipated)	Interventional		Withdrawn(stopped due to PI left institution)
Phase I Trial With Cohort Expansion of Pentostatin, Bendamustine and Ofatumumab (PBO) for the Treatment of Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma [NCT01352312]	Phase 1	10 participants (Actual)	Interventional	2011-05-25	Terminated(stopped due to Insufficient accrual over 12 mo period)
BRIEF: Bendamustine and Rituximab In Elderly Follicular: A Multicentric Phase II Study Evaluating the Benefit of a Short Induction Treatment by Bendamustine and Rituximab Followed by Maintenance Therapy With Rituximab In Elderly (≥ 60 Years Old) Patients [NCT01313611]	Phase 2	62 participants (Actual)	Interventional	2011-02-28	Terminated(stopped due to Treament with rituximab during maintenance phase was stoped, according to DSMC recommendations, since 3 cases of deaths occured.)
A Phase I Study of Bendamustine and Bevacizumab for Patients With Advanced Cancers [NCT01152203]	Phase 1	59 participants (Actual)	Interventional	2010-06-30	Completed
A Phase 1/2 Study of Lenalidomide in Combination With Bendamustine (LEBEN) in Relapsed and Primary Refractory Hodgkin Lymphoma [NCT01412307]	Phase 1/Phase 2	36 participants (Anticipated)	Interventional	2011-07-31	Active, not recruiting
A Phase II, Multicenter, Prospective, Non-randomised, Open-label, Clinical Trial to Evaluate Effectiveness and Safety of BeEAC Conditioning Regimen in Malignant Lymphoma Subjects With Indications to Autologous Hematopoietic Stem-cell Transplantation [NCT03315520]	Phase 2	100 participants (Anticipated)	Interventional	2016-01-22	Recruiting
A Phase II Study of Bendamustine HCL in Relapsed and Primary Refractory Hodgkin Lymphoma. [NCT00705250]	Phase 2	36 participants (Actual)	Interventional	2008-06-30	Completed
A Prospective, Open-label, Multicenter Phase-II Trial to Evaluate the Efficacy and Safety of a Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL ( [NCT04515238]	Phase 2	42 participants (Actual)	Interventional	2020-10-01	Active, not recruiting
An Open-Label, Multi-Centre, Randomised, Phase Ib Study to Investigate the Safety and Efficacy of RO5072759 Given in Combination With CHOP, FC or Bendamustine Chemotherapy in Patients With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma [NCT00825149]	Phase 1	137 participants (Actual)	Interventional	2009-02-28	Completed
"A PHASE 3 OPEN-LABEL RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF RITUXIMAB PLUS LENALIDOMIDE (CC-5013) VERSUS RITUXIMAB PLUS CHEMOTHERAPY FOLLOWED BY RITUXIMAB IN SUBJECTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA The RELEVANCE Trial (Ritu [NCT01650701]	Phase 3	1,030 participants (Actual)	Interventional	2012-02-29	Active, not recruiting
A Phase II Trial of Bendamustine in Combination With Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma [NCT01234467]	Phase 2	23 participants (Actual)	Interventional	2011-03-31	Completed
Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy With Maintenance Lenalidomide and Rituximab in Relapsed/Refractory CLL/SLL [NCT00974233]	Phase 2	34 participants (Actual)	Interventional	2009-10-31	Completed
A Phase 3, Randomized, Double-blind Study of Duvelisib Administered in Combination With Rituximab and Bendamustine vs Placebo Administered in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma [NCT02576275]	Phase 3	0 participants (Actual)	Interventional	2015-12-31	Withdrawn(stopped due to The scope of the program has been reduced to focus resources on studies which can potentially enable the registration of duvelisib.)
Phase II Clinical Study on SyB L-0501 in Patients With Indolent B-cell Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma (Multicenter, Open-label Study) [NCT00612183]	Phase 2	56 participants (Anticipated)	Interventional	2007-12-31	Completed
A Phase 3b Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy [NCT03406156]	Phase 3	120 participants (Actual)	Interventional	2018-08-10	Completed
A Phase 1-2 Study of a Novel Conditioning Regimen of Bendamustine and Melphalan Followed by Autologous Stem Cell Transplant for Patients With Multiple Myeloma [NCT00916058]	Phase 1/Phase 2	57 participants (Actual)	Interventional	2009-04-23	Completed
An Open-Label Study to Evaluate Bendamustine Hydrochloride in the Treatment of Chinese Patients With Indolent Non-Hodgkin Lymphoma (NHL) Refractory to Rituximab Treatment [NCT01596621]	Phase 3	102 participants (Actual)	Interventional	2012-08-06	Completed
The CAD5 Study::Therapy for Chronic Cold Agglutinin Disease: A Prospective, Non-randomized International Multicenter Trial on the Safety and Efficacy of Bendamustine and Rituximab Combination Therapy [NCT02689986]	Phase 2	43 participants (Actual)	Interventional	2013-01-31	Completed
Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma. A Randomized, Open Label, Phase III Study by Fondazione Italiana Linfomi. [NCT05058404]	Phase 3	602 participants (Anticipated)	Interventional	2021-12-01	Recruiting
Post-Transplant Bendamustine (PT-BEN) for GVHD Prophylaxis [NCT04022239]	Phase 1/Phase 2	40 participants (Anticipated)	Interventional	2020-03-13	Recruiting
Phase I Study of Bendamustine With Concurrent Whole Brain Radiation Therapy in Patients With Brain Metastases From Solid Tumors [NCT00879073]	Phase 1	12 participants (Actual)	Interventional	2009-04-30	Terminated(stopped due to Principal Investigator is leaving Moffitt)
Phase I Study to Evaluate Cellular Immunotherapy Using Memory-Enriched T Cells Lentivirally Transduced to Express a CD19-Specific, Hinge-Optimized, CD28-Costimulatory Chimeric Receptor and a Truncated EGFR Following Lymphodepleting Chemotherapy in Adult P [NCT02153580]	Phase 1	37 participants (Actual)	Interventional	2014-09-24	Active, not recruiting
A Phase II Evaluation of Bendamustine, Obinutuzumab and Venetoclax in Patients With Untreated Mantle Cell Lymphoma [NCT03872180]	Phase 2	23 participants (Actual)	Interventional	2019-04-11	Active, not recruiting
A Phase I/II Study of Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma [NCT03739619]	Phase 1/Phase 2	54 participants (Anticipated)	Interventional	2018-11-26	Active, not recruiting
A Phase II Study With Bendamustine Plus Brentuximab Vedotin in Hodgkin's Lymphoma and CD30+ Peripheral T-cell Lymphoma in First Salvage Setting: the BBV Regimen. [NCT02499627]	Phase 2	43 participants (Actual)	Interventional	2015-12-23	Terminated(stopped due to expected accrual not reached)
A Phase 1/2 Clinical Trial to Assess Safety and Efficacy of a New Treatment for Hodgkin Lymphoma's Disease Combining Adcetris® and Levact® in Old Patients [NCT02467946]	Phase 1/Phase 2	60 participants (Actual)	Interventional	2016-01-14	Completed
Phase I/II Study of the Combination of Bendamustine, Rituximab and MK-2206 in the Treatment of Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma [NCT01369849]	Phase 1/Phase 2	15 participants (Actual)	Interventional	2011-09-30	Completed
Adjustment of Chemotherapy Duration in Follicular Lymphoma Patients According to Peripheral Blood or Bone Marrow Minimal Residual Disease Status [NCT04934930]	Phase 2	40 participants (Anticipated)	Interventional	2020-01-29	Recruiting
A Phase I Study of Melphalan, Bendamustine, and Carfilzomib for Autologous Hematopoietic Stem Cell Transplantation in Patients With Multiple Myeloma [NCT02148913]	Phase 1	18 participants (Actual)	Interventional	2014-06-30	Completed
A Phase II Study of Bendamustine Plus Rituximab (BR) in Patients With Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL) [NCT02433795]	Phase 2	27 participants (Actual)	Interventional	2015-05-31	Completed
A Phase II Trial of Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-cell Lymphoma: BENCART Trial [NCT02424045]	Phase 2	30 participants (Actual)	Interventional	2015-05-31	Completed
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 X Anti-CD3 Bispecific Antibody Versus Investigator's Choice in Previously Untreated Participants With Follicular Lymphoma (OLYMPIA-1) [NCT06091254]	Phase 3	478 participants (Anticipated)	Interventional	2023-12-12	Recruiting
A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas [NCT02130869]	Phase 1	8 participants (Actual)	Interventional	2014-10-10	Completed
A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) Plus Rituximab Versus Bendamustine Plus Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation [NCT04002297]	Phase 3	500 participants (Anticipated)	Interventional	2019-08-21	Recruiting
A Phase Ib Dose Escalation Trial of Carfilzomib in Combination With Bendamustine and Rituximab In Patients With Relapsed or Refractory Non-Hodgkin Lymphoma [NCT02187133]	Phase 1	10 participants (Actual)	Interventional	2015-05-05	Completed
A Phase I Trial of Bendamustine Plus Alemtuzumab for the Treatment of Fludarabine Refractory Chronic Lymphocytic Leukemia [NCT00947388]	Phase 1	9 participants (Actual)	Interventional	2008-11-30	Terminated(stopped due to No more eligible patients)
A Phase 1, Open-Label, Single Center Study of KYV-101, an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis [NCT06138132]	Phase 1	12 participants (Anticipated)	Interventional	2023-12-31	Not yet recruiting
Phase II Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Relapsed/Refractory CD30+ Peripheral T Cell Lymphoma [NCT04083495]	Phase 2	20 participants (Anticipated)	Interventional	2019-09-17	Recruiting
A Phase 1/2, Open-label, Multi-center Study to Assess the Safety and Tolerability of Durvalumab (Anti-PDL1 Antibody) as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocitic Leukemia [NCT02733042]	Phase 1/Phase 2	106 participants (Actual)	Interventional	2016-05-11	Completed
A Multicentric, Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion (SDI) in Patients With Previously Untreated Advanced Follicular Lymphoma [NCT03817853]	Phase 4	114 participants (Actual)	Interventional	2019-02-26	Completed
Frontline Treatment With Bendamustine in Combination With Rituximab in Adults Age 65 or Older With Chronic Lymphocytic Leukemia: A Phase II Study [NCT00758693]	Phase 2	0 participants (Actual)	Interventional	2008-10-31	Withdrawn(stopped due to Funding was withdrawn due to insufficient accrual)
An Open-Label Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma [NCT00920855]	Phase 1/Phase 2	40 participants (Actual)	Interventional	2009-06-30	Completed
A Phase II Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Bendamustine and Rituximab (BR) for Patients With Relapsed/Refractory Aggressive B Cell Lymphomas [NCT02747732]	Phase 2	72 participants (Anticipated)	Interventional	2016-12-31	Recruiting
An Open-Label Study of Bendamustine Hydrochloride in Combination With Rituximab in the Treatment of Patients With Relapsed/Refractory Mantle Cell Lymphoma [NCT00891839]	Phase 2	45 participants (Actual)	Interventional	2009-06-30	Completed
Rituximab, Bendamustine and Lenalidomide in Patients With Aggressive B-cell Lymphoma Not Eligible for High Dose Chemotherapy or Anthracycline-Based Therapy. A Phase I/II Trial. [NCT00987493]	Phase 1/Phase 2	49 participants (Actual)	Interventional	2009-09-30	Completed
Phase 2 Study of Cytarabine in Association With Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma [NCT02758925]	Phase 2	78 participants (Anticipated)	Interventional	2016-06-30	Not yet recruiting
A Phase 2/3 Multicenter, Open-label, Randomized, Active-Control Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (waveLINE-003) [NCT05139017]	Phase 2/Phase 3	420 participants (Anticipated)	Interventional	2022-01-14	Recruiting
Multicentric, Non-Randomized Phase 2 Trial of Bendamustine And Rituximab for Patients With Previously Untreated Extranodal Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma [NCT01015248]	Phase 2	60 participants (Actual)	Interventional	2009-05-31	Completed
Prospective Randomised Multicenter Study for Therapy Optimization (First Line) of Advanced Progredient, Low Malignant Non-Hodgkin Lymphomas and Mantle Cell Lymphomas [NCT00991211]	Phase 3	549 participants (Actual)	Interventional	2004-01-31	Completed
IIT2017-03-Merin-HaploBFR: Bendamustine, Fludarabine, And Rituximab Conditioning For Haploidentical Stem Cell Transplantation With CD56-Enriched Donor Cell Infusion For Relapsed/Refractory Lymphoma, Multiple Myeloma, and CLL [NCT03524235]	Phase 1	30 participants (Anticipated)	Interventional	2018-07-18	Active, not recruiting
Phase I Study of Bendamustine and Fractionated Stereotactic Radiotherapy of Patients With 1- 4 Brain Metastases From Solid Malignancies [NCT00837928]	Phase 1	18 participants (Actual)	Interventional	2009-02-19	Completed
A Multicentre Phase I-II Study to Investigate the Combination of Bendamustine With Weekly Paclitaxel as First or Second Line Therapy in Patients With Metastatic Breast Cancer [NCT00661739]	Phase 1	38 participants (Actual)	Interventional	2005-07-31	Completed
Phase III Trial of Combined Immunochemotherapy With Fludarabine, Cyclophosphamide and Rituximab (FCR) Versus Bendamustine and Rituximab (BR) in Patients With Previously Untreated Chronic Lymphocytic Leukaemia [NCT00769522]	Phase 3	564 participants (Actual)	Interventional	2008-10-02	Completed
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With [NCT04236141]	Phase 3	42 participants (Actual)	Interventional	2020-07-10	Terminated(stopped due to Sponsor's decision, no safety concerns)
Open Label Phase II Trial of Bendamustine Hydrochloride (HCL) in Women With Advanced Ovarian Cancer [NCT00867503]	Phase 2	10 participants (Actual)	Interventional	2009-02-28	Completed
A Multicenter Phase I Clinical Trial to Assess the Safety of Two Consecutive Days of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's Lymphoma [NCT00794638]	Phase 1	9 participants (Actual)	Interventional	2008-11-30	Completed
First-line Treatment of Mantle Cell Lymphoma of Old Patients . Evaluate the Efficacy, Toxicity, and Molecular Prognostic Factors of Velcade®) in Association With Chemotherapy and Immunotherapy With Rituximab [NCT00740415]	Phase 2	39 participants (Actual)	Interventional	2007-06-30	Completed
Prospective, Open-label, Multicentre Phase-II Trial to Evaluate Efficacy and Safety of a Sequential Regimen of Bendamustine Followed by Ofatumumab and Ibrutinib Followed by Ibrutinib and Ofatumumab Maintenance in CLL Patients [NCT02689141]	Phase 2	66 participants (Actual)	Interventional	2016-02-04	Completed
A Randomized Phase II Trial of Ofatumumab and Bendamustine vs. Ofatumumab, Bortezomib (NSC # 681239) and Bendamustine in Patients With Untreated Follicular Lymphoma [NCT01286272]	Phase 2	135 participants (Actual)	Interventional	2011-04-08	Active, not recruiting
Multicenter Phase II Study of Bendamustine Plus Subcutaneous Rituximab in Patients With Diffuse Large B-cell Lymphoma (DLBCL) Type Monomorphic Post-transplant Lymphoproliferative Disorder [NCT02753062]	Phase 2	22 participants (Anticipated)	Interventional	2015-08-31	Recruiting
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma [NCT00831597]	Phase 2	61 participants (Actual)	Interventional	2008-11-30	Completed
S0902, Phase II Study of Bendamustine Plus Rituximab for the Treatment of Refractory B-Cell Chronic Lymphocytic Leukemia [NCT00939328]	Phase 2	0 participants (Actual)	Interventional	2009-09-30	Withdrawn(stopped due to question was no longer committee priority)
A Phase 1 Study Evaluating the Safety of ABT-263 in Combination With Either Fludarabine/Cyclophosphamide/Rituximab (FCR) or Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia [NCT00868413]	Phase 1	32 participants (Actual)	Interventional	2009-11-30	Completed
Pilot Study of Bortezomib, Bendamustine and Rituximab for Patients With Relapsed or Refractory, Indolent or Mantle Cell Non-Hodgkin's Lymphoma [NCT00547534]	Phase 2	31 participants (Actual)	Interventional	2007-10-31	Completed
Fludarabine, Bendamustine, and Rituximab (FBR) Non-Myeloablative Allogeneic Conditioning for Patients With Lymphoid Malignancies [NCT00880815]	Phase 1	60 participants (Actual)	Interventional	2009-02-17	Completed
Addition of Inotuzumab Ozogamicin Pre- and Post-Allogeneic Transplantation [NCT03856216]	Phase 2	44 participants (Anticipated)	Interventional	2019-10-28	Recruiting
"Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma. A Phase II Multicenter Study BENTLY" [NCT00959686]	Phase 2	45 participants (Anticipated)	Interventional	2009-09-30	Completed
Bendamustine Versus Fludarabine as 2nd-line Treatment in Chronic Lymphocytic Leukemia, Stage BINET B+C / RAI II-IV [NCT01423032]	Phase 2/Phase 3	96 participants (Actual)	Interventional	2001-09-30	Completed
A Phase II Study of Bendamustine, Velcade and Dexamethasone (BVD) in the Treatment of Elderly Patients (>= 65 Years) With Multiple Myeloma in 1st Relapse or Refractory to 1st Line Therapy [NCT01045681]	Phase 2	75 participants (Actual)	Interventional	2010-03-03	Completed
A Phase II Multicenter Open Label Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB) in Patients Newly Diagnosed. [NCT04138875]	Phase 2	0 participants (Actual)	Interventional	2022-01-31	Withdrawn(stopped due to Lack of funding)
Immunochemotherapy With Rituximab-Bendamustine-Cytarabine for Patients With Mantle Cell Lymphoma Not Eligible for Intensive Regimens or Autologous Transplantation. [NCT00992134]	Phase 2	41 participants (Actual)	Interventional	2009-06-30	Completed
Open-Label Study to Investigate the Pharmacokinetics of Bendamustine Hydrochloride Following Intravenous Infusion of [14C] Bendamustine Hydrochloride in Patients With Relapsed or Refractory Malignancy [NCT00863850]	Phase 1	6 participants (Actual)	Interventional	2009-05-31	Completed
Phase I Clinical Trial of Bendamustine, Lenalidomide and Rituximab in B-Cell Lymphoid Malignancies [NCT00864942]	Phase 1	28 participants (Actual)	Interventional	2009-02-28	Completed
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma [NCT01042704]	Phase 1	29 participants (Actual)	Interventional	2008-02-29	Completed
A Phase 3, Randomized, Open-Label, Controlled, Multicenter Study of Zandelisib (ME- 401) in Combination With Rituximab Versus Standard Immunochemotherapy in Patients With Relapsed Indolent Non Hodgkin's Lymphoma (iNHL) - The COASTAL Study [NCT04745832]	Phase 3	82 participants (Actual)	Interventional	2021-08-13	Terminated(stopped due to Discontinuation of zandelisib program)
Pilot Study of CPI-613, in Combination With Bendamustine, in Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma [NCT04217317]	Phase 2	12 participants (Anticipated)	Interventional	2020-09-16	Recruiting
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination With Acalabrutinib (ACP-196) in Subjects With Previously Untreated Mantle Cell Lymphoma [NCT02972840]	Phase 3	635 participants (Actual)	Interventional	2017-04-05	Active, not recruiting
Adequacy of Peripheral Blood Stem Cell Mobilization in Patients With Relapsed Lymphoma Treated With Bendamustine: A Pilot Project and a Proof of Concept Study [NCT01022021]	Early Phase 1	17 participants (Actual)	Interventional	2010-01-31	Completed
Phase II Study With Bendamustine, Gemcitabine and Vinorelbine (BeGEV) as Induction Therapy in Relapsed/Refractory Hodgkin's Lymphoma Patients Before High Dose Chemotherapy With Autologous Hematopoietic Stem Cells Transplant [NCT01884441]	Phase 2	59 participants (Anticipated)	Interventional	2011-07-31	Recruiting
A Phase I Trial of Bendamustine in Combination With Clofarabine and Etoposide in Pediatric Patients With Relapsed or Refractory Hematologic Malignancies [NCT01900509]	Phase 1	16 participants (Actual)	Interventional	2013-08-31	Completed
A Phase I/II Trial of Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed or Refractory Multiple Myeloma: Hoosier Cancer Research Network MM08-141 [NCT01177683]	Phase 1/Phase 2	32 participants (Actual)	Interventional	2010-07-31	Terminated(stopped due to Lack of accrual)
A Multicenter, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Bendamustine Hydrochloride Injection in Subjects With Rituximab-resistant Indolent B-Cell Non-Hodgkin's Lymphomas [NCT04569838]	Phase 2	91 participants (Actual)	Interventional	2012-05-31	Completed
Rituximab Plus Bendamustine as Front Line Treatment in Frail Elderly (>70 Years) Patients With Diffuse Large B-cell Non-Hodgkin's Lymphoma: a Phase II Multicenter Study of the Fondazione Italiana Linfomi (FIL) [NCT01990144]	Phase 2	49 participants (Anticipated)	Interventional	2011-11-30	Recruiting
Phase I/II Study of Carfilzomib in Combination With Bendamustine and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma [NCT02002598]	Phase 1/Phase 2	20 participants (Actual)	Interventional	2013-11-30	Completed
A Phase I/Ib Study Evaluating the Efficacy and Safety of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Combination With TGR-1202, a Novel PI3k Delta Inhibitor; and Ibrutinib or Bendamustine, in Patients With B-cell Malignancies. [NCT02006485]	Phase 1	160 participants (Actual)	Interventional	2013-12-13	Completed
A Phase 1b/2 Open Label Study to Evaluate the Safety and Efficacy of TRU-016 in Combination With Bendamustine vs. Bendamustine Alone in Patients With Relapsed Chronic Lymphocytic Leukemia [NCT01188681]	Phase 1/Phase 2	79 participants (Actual)	Interventional	2010-09-30	Completed
Phase I Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma [NCT03295240]	Early Phase 1	10 participants (Actual)	Interventional	2017-09-20	Active, not recruiting
A Multicenter Phase II Study Evaluating BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Prior to Autologous Stem Cell Transplant for First and Second Chemosensitive Relapses in Patients With Follicular Lymphoma [NCT02008006]	Phase 2	21 participants (Actual)	Interventional	2014-07-09	Terminated(stopped due to Insufficient recruitment and unavailability of the treatment)
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF INOTUZUMAB OZOGAMICIN ADMINISTERED IN COMBINATION WITH RITUXIMAB COMPARED TO DEFINED INVESTIGATOR'S CHOICE THERAPY IN SUBJECTS WITH RELAPSED OR REFRACTORY CD22-POSITIVE AGGRESSIVE NON-HODGKIN LYMPHOMA WHO ARE NO [NCT01232556]	Phase 3	338 participants (Actual)	Interventional	2011-04-04	Terminated(stopped due to The study was terminated prematurely on May 16, 2013, for futility. No new or unexpected safety issues were identified.)
A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma [NCT05023980]	Phase 3	250 participants (Anticipated)	Interventional	2021-09-23	Recruiting
A Phase 3 Randomized Clinical Study of MK-4280A (Coformulated Favezelimab [MK-4280] Plus Pembrolizumab [MK-3475]) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (KEYFORM-008) [NCT05508867]	Phase 3	360 participants (Anticipated)	Interventional	2022-10-18	Recruiting
Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma [NCT03269669]	Phase 2	95 participants (Anticipated)	Interventional	2018-01-23	Recruiting
An Open-Label Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia [NCT01088984]	Phase 1/Phase 2	43 participants (Actual)	Interventional	2010-08-31	Completed
A Phase I Study to Investigate the Safety and Clinical Activity of Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 mAb in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma, Mantle Cell [NCT01088048]	Phase 1	241 participants (Actual)	Interventional	2010-03-25	Completed
Phase II Trial of Bendamustine in Adult Patients With Acute Lymphoblastic Leukemia/Lymphoma [NCT01649622]	Phase 2	0 participants (Actual)	Interventional	2012-12-31	Withdrawn
"Subcutaneous Rituximab and Intravenous Bendamustine in Very Elderly Patients or Elderly Medically Non Fit Patients (Slow Go) With Aggressive CD20-positive B-cell" [NCT01686321]	Phase 2	68 participants (Actual)	Interventional	2012-07-04	Completed
A Multicenter, Phase III, Open-Label, Randomized Study in Previously Untreated Patients With Advanced Indolent Non-Hodgkin's Lymphoma Evaluating the Benefit of GA101 (RO5072759) Plus Chemotherapy Compared With Rituximab Plus Chemotherapy Followed by GA101 [NCT01332968]	Phase 3	1,401 participants (Actual)	Interventional	2011-07-06	Completed
A Phase 1b/2a Study of ABT-888 in Combination With Bendamustine +/- Rituximab in Lymphoma, Multiple Myeloma and Solid Tumors [NCT01326702]	Phase 1/Phase 2	43 participants (Actual)	Interventional	2011-07-31	Completed
Phase 1 Trial of Dasatinib and Bendamustine in Chronic Lymphocytic Leukemia [NCT00872976]	Phase 1	0 participants (Actual)	Interventional	2009-05-31	Withdrawn(stopped due to Business Objectives Changed)
Treatment With Lenalidomide, Bendamustine and Prednisone (RBP) in Patients With Relapsed or Refractory Multiple Myeloma After Autologous Stem Cell Transplantation or Conventional Chemotherapy OSHO #077 [NCT01002703]	Phase 1/Phase 2	50 participants (Anticipated)	Interventional	2009-09-30	Recruiting
Phase II Study of Brentuximab Vedotin in Combination With Bendamustine and Rituximab, in Patients With CD30 Positive, Relapsed or Refractory B Cell Non-Hodgkin Lymphoma (NHL) [NCT02623920]	Phase 2	0 participants (Actual)	Interventional	2015-12-16	Withdrawn(stopped due to Pharmaceutical company supplying the drug withdraw financial support. PI has decided to close study prior to enrollment of any patients.)
Phase I/IIa Study of the Novel Combination of Bendamustine With Irinotecan Followed by Etoposide/Carboplatin in Chemonaive Patients With Extensive Stage Small Cell Lung Cancer [NCT00856830]	Phase 1/Phase 2	30 participants (Actual)	Interventional	2009-04-30	Completed
Bendamustine Combined With Alemtuzumab in Pretreated Chronic Lymphocytic Leukemia (CLL) - A Phase I/II Trial With Concomitant Evaluation of Safety and Efficacy [NCT00951457]	Phase 1/Phase 2	20 participants (Actual)	Interventional	2009-03-31	Completed
An Open-Label, Multicenter, Randomized, Phase III Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+RO5072759 (GA101) in Patients With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma [NCT01059630]	Phase 3	413 participants (Actual)	Interventional	2010-04-30	Completed
An Open-Label Study to Evaluate the Efficacy and Safety of Treatment With Bendamustine in Combination With Ofatumumab in Previously Untreated Patients With Indolent B-Cell Non-Hodgkin's Lymphoma (NHL) [NCT01108341]	Phase 2	50 participants (Actual)	Interventional	2010-05-31	Completed
A Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) [NCT01073163]	Phase 3	54 participants (Actual)	Interventional	2010-02-28	Completed
A Phase II Study of Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular Lymphoma [NCT00901927]	Phase 2	14 participants (Actual)	Interventional	2009-05-31	Terminated(stopped due to Study was closed early due to toxicity)
Nonmyeloablative Stem Cell Transplantation With or Without Lenalidomide for Chronic Lymphocytic Leukemia (RV-CLL-PI-0294) [NCT00899431]	Phase 2	39 participants (Actual)	Interventional	2009-05-06	Terminated(stopped due to Terminated per PI's request at the time of continuing review)
An Open-Label, Randomized, Parallel-Group Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHO [NCT00877006]	Phase 3	447 participants (Actual)	Interventional	2009-04-30	Completed
Phase II Study for Safety and Efficacy of BEB (Bendamustine, Etoposide, Busulfan) Conditioning Regimen for ASCT in Non-Hodgkin's Lymphoma [NCT02836639]	Phase 2	20 participants (Anticipated)	Interventional	2016-02-29	Recruiting
Bendamustine and Rituximab for the Treatment of Splenic Marginal Zone Lymphoma. The International Extranodal Lymphoma Study Group (IELSG) 36 Phase II Prospective Study [NCT02853370]	Phase 2	78 participants (Actual)	Interventional	2012-07-31	Completed
Lenalidomide in Combination With Bendamustine and Rituximab for Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma(CLL/SLL): a Phase I Study [NCT01400685]	Phase 1	34 participants (Anticipated)	Interventional	2012-12-31	Completed
A Phase II, Multicenter, Randomized, Controlled, Open-Label Study of Bendamustine + Rituximab With or Without Navitoclax in Patients With Relapsed Diffuse Large B-Cell Lymphoma [NCT01423539]	Phase 2	0 participants (Actual)	Interventional	2011-10-31	Withdrawn(stopped due to The NAVIGATE study has been terminated due to non-safety related reasons.)
A Pilot/Feasibility Phase I Study of Bendamustine, Rituximab and Lenalidomide in Patients With Refractory/Relapsed Indolent NHL [NCT01429025]	Phase 1	26 participants (Actual)	Interventional	2012-05-31	Completed
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkin's Lymphoma [NCT02793583]	Phase 2/Phase 3	710 participants (Actual)	Interventional	2016-05-25	Terminated(stopped due to Strategic/Business Decision)
Randomized Open Label of Ofatumumab and Bendamustine Combination Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma Unresponsive to Rituximab or a Rituximab-Containing Regimen During or Within Six Months of Treatment [NCT01077518]	Phase 3	346 participants (Actual)	Interventional	2010-08-26	Terminated(stopped due to The study was terminated early as it did not meet the Primary efficacy objective after primary analysis.)
Dose-escalation Study of Graft-versus-host Disease Prophylaxis With High-dose Post-transplantation Bendamustine in Patients With Refractory Acute Leukemia [NCT02799147]	Phase 1/Phase 2	27 participants (Actual)	Interventional	2016-06-30	Completed
A Phase I, Dose-escalation Trial of Rituxan and Bendamustine in Combination With Bruton's Tyrosine Kinase Inhibitor, PCI-32765, in Patients With Relapsed Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Indolent Non-Hodgkin's Lymphoma [NCT01479842]	Phase 1	48 participants (Actual)	Interventional	2011-12-07	Active, not recruiting
An Open-label, Phase Ib Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Select Subjects With Lymphoma or Chronic Lymphocytic Leukemia [NCT01871675]	Phase 1	48 participants (Actual)	Interventional	2013-05-31	Completed
A Phase II Open-Label Study of Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL) Which Has Relapsed After Rituximab or a Rituximab Containing Therapy [NCT01294579]	Phase 2	49 participants (Actual)	Interventional	2011-05-17	Completed
A Phase II Study of Bendamustine in the Treatment of Recurrent High-Grade Gliomas (Anaplastic Gliomas and Glioblastoma) [NCT00823797]	Phase 2	45 participants (Actual)	Interventional	2008-10-31	Completed
Department of Hematologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China [NCT04762745]	Phase 1/Phase 2	56 participants (Anticipated)	Interventional	2021-02-28	Not yet recruiting
A Single-arm, Multi-center Phase II Trial of Bendamustine/Rituximab Induction Followed by Venetoclax and Rituximab Consolidation for the Frontline Treatment of Chronic Lymphocytic Leukemia (CLL) [NCT03609593]	Phase 2	42 participants (Actual)	Interventional	2018-11-12	Active, not recruiting
A Dose-Ranging Study of Bendamustine and Rituximab in Chronic Lymphocytic Leukemia (CLL) Patients With Comorbidities and/or Renal Dysfunction [NCT01832922]	Phase 1	8 participants (Actual)	Interventional	2013-04-30	Completed
Phase I Study of the Administration of T Lymphocytes Co-Expressing the CD30 Chimeric Antigen Receptor (CAR) and CCR4 for Relapsed/Refractory CD30+ Hodgkin Lymphoma and Cutaneous T-Cell Lymphoma [NCT03602157]	Phase 1	59 participants (Anticipated)	Interventional	2018-12-12	Recruiting
Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe) [NCT04942730]	Phase 2	40 participants (Anticipated)	Interventional	2021-01-21	Recruiting
Graft-versus-host Disease Prophylaxis With Combination of Post-transplantation Benadamustine and Cyclophosphamide in Patients With Refractory Myeloid Malignancies (PTBCy) [NCT04943757]	Phase 2	50 participants (Anticipated)	Interventional	2021-01-21	Recruiting
A Multi-Center, Open-Label, Phase 1/2 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-101 Monotherapy and AB-101 With Immunotherapy in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma of B-Cell Origin. [NCT04673617]	Phase 1/Phase 2	108 participants (Anticipated)	Interventional	2021-03-29	Recruiting
A Multicenter, Phase III, Open-Label, Randomized Study in Relapsed/Refractory Patients With Chronic Lymphocytic Leukemia to Evaluate the Benefit of Venetoclax (GDC-0199/ABT-199) Plus Rituximab Compared With Bendamustine Plus Rituximab [NCT02005471]	Phase 3	389 participants (Actual)	Interventional	2014-03-17	Completed
A Multi-Center Phase III Study to Investigate the Safety and Efficacy of Treanda™ (Bendamustine HCl) in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Who Are Refractory to Rituximab [NCT00139841]	Phase 3	103 participants (Actual)	Interventional	2005-10-31	Completed
A Multicenter, Phase III, Randomized Study to Evaluate the Efficacy of Response-adapted Strategy to Define Maintenance After Standard Chemoimmunotherapy in Patients With Advanced-stage Follicular Lymphoma. [NCT02063685]	Phase 3	807 participants (Actual)	Interventional	2012-07-31	Completed
A Phase II Study of Bendamustine in Combination With Rituximab as Initial Treatment for Patients With Indolent Non-follicular Non-Hodgkin's Lymphoma [NCT01929265]	Phase 2	73 participants (Actual)	Interventional	2011-01-31	Completed
A Phase 1 Study of Cosibelimab (TG-1501) in Subjects With Relapsed or Refractory Lymphoma [NCT03778073]	Phase 1	18 participants (Actual)	Interventional	2019-04-17	Terminated(stopped due to Strategic/Business Decision)
A Multi-Center Phase II Study to Investigate the Safety and Activity of SDX-105 (Bendamustine) in Combination With Rituximab in Patients With Relapsed Indolent or Mantle Cell Non-Hodgkin's Lymphoma (NHL) [NCT00076349]	Phase 2	66 participants (Actual)	Interventional	2004-04-30	Completed
Treatment of Relapsed / Refractory Chronic Lymphocytic Leukemia (CLL) WITH Bendamustine / Mitoxantrone (BM) [NCT00274963]	Phase 2	60 participants (Anticipated)	Interventional	2004-10-31	Completed
A Prospective, Open-Label, Multicenter Randomized Phase III Study to Compare The Efficacy and Safety of A Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/Bendamustine and Rituximab (BR) in FIT Pati [NCT04285567]	Phase 3	166 participants (Actual)	Interventional	2020-05-28	Active, not recruiting
A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Follicular Lymphoma [NCT05371093]	Phase 3	230 participants (Anticipated)	Interventional	2022-09-12	Recruiting
Phase I/II Study of Bendamustine and Erlotinib for Metastatic or Locally Advanced Triple Negative Breast Cancer [NCT00834678]	Phase 1/Phase 2	11 participants (Actual)	Interventional	2009-04-30	Completed
Ofatumumab and Bendamustine in Previously Treated Chronic Lymphocytic Leukemia/ Small Lymphocytic Leukemia [NCT01010568]	Phase 2	10 participants (Actual)	Interventional	2010-04-30	Terminated(stopped due to Unable to accrue patients due to change in standard CLL therapy)
A Phase I/II Clinical Trial of Fludarabine, Bendamustine, and Rituximab (FBR) in Previously Treated Patients With Chronic Lymphocytic Leukemia (CLL) [NCT01096992]	Phase 1/Phase 2	51 participants (Actual)	Interventional	2010-04-19	Completed
Phase II Study of the Combination of Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis [NCT01222260]	Phase 2	40 participants (Actual)	Interventional	2013-01-31	Completed
A Phase I Study of FT819 in Subjects With B-cell Malignancies [NCT04629729]	Phase 1	396 participants (Anticipated)	Interventional	2021-07-26	Recruiting
Multicenter Phase II Study With Bendamustin for Patients With Refractory Soft Tissue Sarcoma [NCT00204620]	Phase 2	28 participants	Interventional	2002-03-31	Completed
An Open-Label, Multicenter, Phase Ib Trial of GA101 (RO5072759) in Combination With Chemotherapy in Patients With Previously Untreated Chronic Lymphocytic Leukemia [NCT01300247]	Phase 1	41 participants (Actual)	Interventional	2011-05-31	Completed
A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly Patients [NCT03352765]	Phase 1	28 participants (Anticipated)	Interventional	2017-11-20	Active, not recruiting
Brief Induction Chemoimmunotherapy With Rituximab + Bendamustine + Mitoxantrone Followed by Rituximab in Elderly Patients With Advanced Stage Previously Untreated Follicular Lymphoma [NCT01523860]	Phase 2	76 participants (Actual)	Interventional	2009-06-30	Completed
Phase II Multicenter Clinical Trial to Investigate the Efficacy and Safety of Bendamustine, Dexamethasone and Thalidomide in R/R MM Pts After Treatment With Lenalidomide and Bortezomib or Which Are Ineligible to One of These Drugs [NCT01526694]	Phase 2	30 participants (Actual)	Interventional	2012-07-31	Completed
A Multicenter, Open Study to Assess the Tolerability, Pharmacokinetics and Antitumor Effect of Bendamustine Hydrochloride (SyB L-0501: 90 or 120 mg/m2/Day) Administered Intravenously for Two Days in Patients With Indolent Lymphoma [NCT00389051]	Phase 1	9 participants (Actual)	Interventional	2006-10-31	Completed
Multicentre Phase II Trial of Bendamustine in Combination With Rituximab for Patients With Previously Untreated or Relapsed Chronic Lymphocytic Leukemia. CLL2M Protocol of the German CLL-Study Group (GCLLSG) [NCT00274989]	Phase 2	195 participants (Actual)	Interventional	2005-11-30	Completed
Phase II Study to Determine the Efficacy of Bendamustin (Ribomustin) in Patients With Recurrent Small Cell Bronchial Carcinoma After Cytostatic Polychemotherapy [NCT00168922]	Phase 2	50 participants	Interventional	2001-02-28	Recruiting
A Randomised Investigation of Alternative Ofatumumab-containing Regimens in Less Fit Patients With CLL [NCT01678430]	Phase 3	670 participants (Anticipated)	Interventional	2011-12-31	Recruiting
Phase I-II Study of Bendamustine in Patients With Acute Leukemia and High-Risk Myelodysplastic Syndrome (MDS) [NCT00790855]	Phase 1/Phase 2	27 participants (Actual)	Interventional	2008-11-30	Terminated(stopped due to Lack of Response)
Randomized Phase III Trial of Chemotherapy vs. Pembrolizumab Plus Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma [NCT05711628]	Phase 3	0 participants (Actual)	Interventional	2023-08-10	Withdrawn(stopped due to Other - Protocol moved to Withdrawn)
BrUOG 326: A Phase I Dose-Escalation Study of Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With Bendamustine and Rituximab (BRiM) in Indolent Non-Hodgkin Lymphoma [NCT02257242]	Phase 1	11 participants (Actual)	Interventional	2017-05-10	Completed
Phase 1b, Open Label Study to Evaluate Safety and Efficacy of TRU-016 in Combination With Rituximab, Obinutuzumab, Rituximab and Idelalisib, or Ibrutinib in Chronic Lymphocytic Leukemia and With Bendamustine in Peripheral T-cell Lymphoma [NCT01644253]	Phase 1	87 participants (Actual)	Interventional	2012-09-30	Terminated(stopped due to Business decision)
Phase II Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma [NCT01029730]	Phase 2	55 participants (Actual)	Interventional	2010-03-31	Completed
A Phase I/II Clinical Trial of the Combination of Brentuximab Vedotin and Bendamustine in Patients With Relapsed or Refractory Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma [NCT01657331]	Phase 1/Phase 2	71 participants (Actual)	Interventional	2012-07-31	Completed
Study of Bendamustine Hydrochloride Injection in Previously Untreated Chronic Lymphocytic Leukemia Patients [NCT01657955]	Phase 3	96 participants (Anticipated)	Interventional	2011-01-31	Recruiting
A Phase I/II Study of Bendamustine, Lenalidomide and Low-dose Dexamethasone, (BdL) for the Treatment of Patients With Relapsed Myeloma. [NCT01686386]	Phase 1/Phase 2	60 participants (Anticipated)	Interventional	2010-02-28	Recruiting
An Open-label Phase I Drug-drug Interaction Study of Ofatumumab With Bendamustine for the Treatment of Subjects With Indolent B-cell Non-Hodgkin's Lymphoma [NCT01691807]	Phase 1	30 participants (Actual)	Interventional	2013-01-31	Completed
A Phase 1, Open-Label, Dose-Finding Study of INCB050465 in Combination With Investigator Choice of Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112) [NCT03424122]	Phase 1	50 participants (Actual)	Interventional	2018-07-02	Completed
An Open, Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Bendamustine, Lenalidomide (Revlimid®) and Dexamethasone (BRd) as 2nd-line Therapy for Patients With Relapsed or Refractory Multiple Myeloma [NCT01701076]	Phase 2	50 participants (Actual)	Interventional	2012-03-31	Completed
Bendamustine, Lenalidomide and Rituximab (R2-B) Combination as a Second-Line Therapy for First Relapsed-Refractory Mantle Cell Lymphomas: A Phase II Study [NCT01737177]	Phase 2	42 participants (Actual)	Interventional	2012-07-31	Completed
Efficacy and Safety Study of Second-Line Prolgolimab Monotherapy or in Combination With Bendamustine for Relapsed/Refractory Classical Hodgkin Lymphoma [NCT05757466]	Phase 2	30 participants (Anticipated)	Interventional	2023-04-19	Recruiting
Consolidation With ADCT-402 (Loncastuximab Tesirine) After a Short Course of Immunochemotherapy: a Phase II Study in BTKi-treated (or BTKi Intolerant) Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) Patients [NCT05249959]	Phase 2	56 participants (Anticipated)	Interventional	2022-04-21	Recruiting
Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide for Refractory or Relapsed Aggressive B-cell Lymphomas [NCT01458366]	Phase 1/Phase 2	38 participants (Actual)	Interventional	2011-11-09	Completed
HO11415: Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) [NCT01754870]	Phase 2	0 participants (Actual)	Interventional	2013-11-30	Withdrawn(stopped due to slow accrual)
A Multicenter, Open-Label, Single-Arm, Phase IIIb, International Study Evaluating the Safety of Obinutuzumab Alone or in Combination With Chemotherapy in Patients With Previously Untreated or Relapsed/Refractory Chronic Lymphocytic Leukemia [NCT01905943]	Phase 3	979 participants (Actual)	Interventional	2013-11-04	Completed
A Phase I/II Trial of Bendamustine/Treanda®, Rituximab, Etoposide, and Carboplatin for Patients With Relapsed or Refractory Lymphoid Malignancies and Select Untreated Lymphomas (TREC) [NCT01165112]	Phase 1/Phase 2	48 participants (Actual)	Interventional	2010-09-30	Completed
A Multicenter, Open Label, Phase II Study of Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma (Fol-BRITe Study) [NCT01234766]	Phase 2	39 participants (Actual)	Interventional	2010-10-31	Completed
A Phase I/II Study Of Gemcitabine And Bendamustine In Patients With Relapsed Or Refractory Hodgkin's Lymphoma [NCT01535924]	Phase 1/Phase 2	26 participants (Actual)	Interventional	2012-02-09	Completed
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321) [NCT04666038]	Phase 3	250 participants (Anticipated)	Interventional	2021-03-09	Recruiting
A Phase II, Multi-centre Study Investigating the Safety and Efficacy of Ofatumumab and Bendamustine Combination in Patients With Untreated or Relapsed Chronic Lymphocytic Leukaemia (CLL) [NCT01520922]	Phase 2	99 participants (Actual)	Interventional	2012-03-31	Completed
Phase II Study of Bendamustine, Bortezomib, and Dexamethasone (BBD) for Newly Diagnosed Patients With Multiple Myeloma [NCT02224729]	Phase 2	24 participants (Actual)	Interventional	2014-08-25	Completed
A Phase II Study of Brentuximab Vedotin Plus Bendamustine for Relapsed/Refractory Follicular Lymphoma [NCT04587687]	Phase 2	23 participants (Anticipated)	Interventional	2020-12-04	Recruiting
Phase I Study of Autologous Transgenic T-Cells Expressing High Affinity Mesothelin-Specific T-Cell Receptor (TCR) (FH-TCR Tᴍsʟɴ) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma [NCT04809766]	Phase 1	15 participants (Anticipated)	Interventional	2021-12-14	Recruiting
A Pilot Study of Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma [NCT03623373]	Phase 2	13 participants (Actual)	Interventional	2018-11-29	Active, not recruiting
A Multinational, Multicenter, Open-Label Phase II Study of SyB L-0501 in Combination With Rituximab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma [NCT01118845]	Phase 2	63 participants (Actual)	Interventional	2010-04-30	Completed
Phase II Study of Second-Line Bendamustine in Relapsed or Refractory Small Cell Lung Cancer (SCLC). [NCT00984542]	Phase 2	50 participants (Actual)	Interventional	2009-09-30	Completed
A Prospective Clinical Study of Hanlikang and BTK Inhibitors in the Treatment of Newly Diagnosed Mantle Cell Lymphoma [NCT05506410]		100 participants (Anticipated)	Observational [Patient Registry]	2022-08-12	Recruiting
A Phase I/II, Multicenter, Open-label, Dose-escalation Study of Bendamustine in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma [NCT01049945]	Phase 1/Phase 2	70 participants (Actual)	Interventional	2010-02-28	Completed
Phase II Study of Age-Adjusted R-BAC (Rituximab, Bendamustine, Cytarabine) as Induction Therapy in Older Patients With Mantle Cell Lymphoma (MCL) [NCT01662050]	Phase 2	57 participants (Actual)	Interventional	2012-03-20	Completed
A Phase 1 Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma [NCT01317901]	Phase 1	12 participants (Actual)	Interventional	2011-05-31	Completed
A Phase II Study of Bendamustine (B), Etoposide (E), Dexamethasone (D), and GCSF for Peripheral Blood Hematopoietic Stem Cell Mobilization (BED) [NCT01110135]	Phase 2	43 participants (Actual)	Interventional	2010-08-31	Completed
Safety and Clinical Activity of Treanda® (Bendamustine HCL) and Idarubicin in Combination Therapy for Patients Age >= 50 With Previously Untreated Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome [NCT01141725]	Phase 1/Phase 2	39 participants (Actual)	Interventional	2010-09-30	Completed
A Single-Arm Multi-Center Trial of Bendamustine Given With Ofatumumab (BendOfa) in Patients With Refractory or Relapsed Chronic Lymphocytic Leukemia (CLL). EudraCT Number 2009-017663-42. GIMEMA CLL0809 Protocol [NCT01244451]	Phase 2	49 participants (Actual)	Interventional	2010-12-31	Completed
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Either Bendamustine and Rituximab (BR) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednis [NCT01974440]	Phase 3	405 participants (Actual)	Interventional	2014-01-31	Completed
Prospective Randomized Evaluation of Single Agent GA101 Versus GA101 Plus Bendamustine Followed by GA101 [NCT03492775]	Phase 2	46 participants (Actual)	Interventional	2017-12-12	Completed
Prospective Randomised Multicenter Study for Therapy Optimization of Recurrent, Progressive Low Grade Non-Hodgkin Lymphomas and Mantle Cell Lymphomas [NCT01456351]	Phase 3	230 participants (Actual)	Interventional	2003-09-30	Completed
A Phase 2/3, Randomised, Multicentre Study of Tafasitamab With Bendamustine Versus Rituximab With Bendamustine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) Who Are Not Eligible for High-Dose Chemotherapy (HDC) and Auto [NCT02763319]	Phase 2/Phase 3	450 participants (Actual)	Interventional	2016-06-30	Active, not recruiting
A Phase 3, Randomized, Double-Blind Study Comparing Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab (BR), With Placebo and BR for the Treatment of Newly Diagnosed Mantle Cell Lymphoma [NCT04849715]	Phase 3	0 participants (Actual)	Interventional	2022-03-11	Withdrawn(stopped due to business decision; no enrolled patients)
A Prospective Phase II Study of Bendamustine in Patients Aged Over 60 Years With Classical Hodgkin Lymphoma Treated by Prednisone, Vinblastine and Doxorubicin [NCT02414568]	Phase 2	90 participants (Actual)	Interventional	2015-07-17	Completed
An Open Label, Single Arm, Phase I/II in the Combination of Azacytidine, Bendamustine and Piamprizumab in Refractory/Relapsed B-cell Non-Hodgkin's [NCT04897477]	Phase 1/Phase 2	30 participants (Anticipated)	Interventional	2021-04-22	Recruiting
Feasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy Agents Using the CIVO(tm) Microdosing System [NCT01831505]	Phase 1	4 participants (Actual)	Interventional	2012-11-30	Completed
Phase I Study of Everolimus + Bendamustine in Patients With Relapsed/Refractory Hematological Malignancies [NCT02240719]	Phase 1	20 participants (Actual)	Interventional	2014-10-31	Completed
A phaseI/II Safety and Efficacy Trial of a Combination of Bendamustine, Rituximab and Lenalidomide (BRL) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia [NCT01558167]	Phase 1/Phase 2	22 participants (Actual)	Interventional	2011-02-28	Completed
A Multicenter, Single Arm Clinical Trial in Patients With Rituximab Refractory B-cell Indolent Lymphoma [NCT01570049]	Phase 3	100 participants (Anticipated)	Interventional	2010-04-30	Recruiting
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma [NCT01594229]	Phase 1	60 participants (Actual)	Interventional	2012-05-21	Completed
A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular Lymphoma [NCT00636792]	Phase 2	73 participants (Actual)	Interventional	2008-02-29	Completed
Bendamustine Plus Rituximab for Mantle Cell Lymphoma: a Multicenter Retrospective Analysis(BR-MCL) [NCT04127916]		40 participants (Anticipated)	Observational [Patient Registry]	2020-01-30	Recruiting
Study Phase II Non-randomized Prospective Open to Assess the Combination of Rituximab, Bendamustine, Mitoxantrone, Dexamethasone (R-BMD) in Patients With Follicular Lymphoma Refractory or Relapsed [NCT01133158]	Phase 2	61 participants (Actual)	Interventional	2009-07-31	Completed
MRD-Guided Abbreviation of Bendamustine and Rituximab Chemotherapy in Combination With Copanlisib in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma [NCT04155840]	Phase 2	1 participants (Actual)	Interventional	2020-01-31	Terminated(stopped due to Terminated due to low accrual)
A Randomized Study to Assess the Effect on Response Rate of MabThera (Rituximab) Added to a Standard Chemotherapy, Bendamustine or Chlorambucil, in Patients With Chronic Lymphocytic Leukemia [NCT01056510]	Phase 4	357 participants (Actual)	Interventional	2010-03-31	Completed
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy [NCT01056276]	Phase 2	59 participants (Actual)	Interventional	2010-05-31	Completed
Risk-based, Response-adapted, Phase II Open-label Trial of Nivolumab + Brentuximab Vedotin (N + Bv) for Children, Adolescents, and Young Adults With Relapsed/Refractory (R/R) CD30 + Classic Hodgkin Lymphoma (cHL) After Failure of First-line Therapy, Follo [NCT02927769]	Phase 2	72 participants (Actual)	Interventional	2017-03-28	Active, not recruiting
A Phase III, Randomized, Double-blind, Controlled Multicenter Study of Intravenous PI3K Inhibitor Copanlisib in Combination With Standard Immunochemotherapy Versus Standard Immunochemotherapy in Patients With Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL [NCT02626455]	Phase 3	547 participants (Actual)	Interventional	2016-01-06	Terminated(stopped due to The study did not meet the primary endpoint. The addition of copanlisib to standard immunochemo therapy did not improve progression-free survival compared to the control arm. Base on the study results, company decided to terminate the study.)
An Open-Label Phase I/II Study of Bendamustine, Weekly Bortezomib, Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma [NCT01484626]	Phase 1/Phase 2	3 participants (Actual)	Interventional	2011-05-05	Terminated(stopped due to Celgene would no longer supply lenalidomide for the study)
Phase II Trial of Bortezomib and Bendamustine in the Treatment of Relapsed/Refractory Myeloma [NCT01315873]	Phase 2	24 participants (Actual)	Interventional	2011-09-30	Terminated(stopped due to PI left the institution before all data analysis was completed)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Untreated Chronic Lymphocytic Leukemia [NCT01980888]	Phase 3	311 participants (Actual)	Interventional	2014-02-05	Terminated
Phase I Study of Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors in Participants With Metastatic Pancreatic, Colorectal and Non-Small Cell Lung Cancers With KRAS G12V Mutations [NCT06043713]	Phase 1	24 participants (Anticipated)	Interventional	2024-01-01	Recruiting
A Single Arm Phase I/II Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma Big Ten Cancer Research Consortium BTCRC-LYM20-463 [NCT05551936]	Phase 1/Phase 2	42 participants (Anticipated)	Interventional	2023-01-26	Recruiting
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma [NCT01476787]	Phase 3	255 participants (Actual)	Interventional	2011-12-29	Active, not recruiting
Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia [NCT01059786]	Phase 2	68 participants (Actual)	Interventional	2010-07-01	Active, not recruiting
A 3-Arm Randomized Phase II Trial of Bendamustine-Rituximab (BR) Followed by Rituximab vs Bortezomib-BR (BVR) Followed by Rituximab vs BR Followed by Lenalidomide/Rituximab in High Risk Follicular Lymphoma [NCT01216683]	Phase 2	289 participants (Actual)	Interventional	2011-02-09	Completed
Phase II Study for Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHL and Anthracycline Chemotherapy Pretreatment, Who Received or Did Not Qualify for Autologous Stem Cell Transplantation. [NCT00385125]	Phase 2	30 participants	Interventional	2004-08-31	Recruiting
Multicenter Phase II Study of the Bendamustine, Obinutuzumab, and Dexamethasone (BOD) Regimen in Un-fit Elderly ≥ 70 Years of Age Diffuse Large B-Cell Non-Hodgkin Lymphoma (DLBCL) Patients [NCT02420210]	Phase 2	2 participants (Actual)	Interventional	2015-11-30	Terminated(stopped due to Trials was stopped early due to lack of funding.)
An Open-Label Expanded Access Trial for Bendamustine HCl in Patients With Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia [NCT01500083]	Phase 3	90 participants (Actual)	Interventional	2012-03-31	Completed
A Phase 2 Multi-Center Study Evaluating the Safety and Efficacy of CD30-Directed Genetically Modified Autologous T Cells (CD30.CAR-T) in Adult and Pediatric Patients With Relapsed or Refractory Classical Hodgkin Lymphoma [NCT04268706]	Phase 2	97 participants (Anticipated)	Interventional	2021-02-01	Active, not recruiting
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia [NCT01569295]	Phase 3	416 participants (Actual)	Interventional	2012-06-15	Completed
A Phase I, Open-Label, Multicenter Study of FT596 as a Monotherapy and in Combination With Rituximab or Obinutuzumab in Subjects With Relapsed/Refractory B-cell Lymphoma and Chronic Lymphocytic Leukemia [NCT04245722]	Phase 1	98 participants (Actual)	Interventional	2020-03-19	Terminated(stopped due to The study was terminated by the Sponsor.)
A Phase I Study of FT516 as Monotherapy in Relapsed/Refractory Acute Myelogenous Leukemia and in Combination With Monoclonal Antibodies in Relapsed/Refractory B-Cell Lymphoma [NCT04023071]	Phase 1	72 participants (Actual)	Interventional	2019-10-04	Terminated(stopped due to The study was terminated by the Sponsor.)
Weekly Bendamustine and Bortezomib Combination Therapy in Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or B-CLL: A Single-Center Phase 2 Study [NCT00426855]	Phase 1/Phase 2	12 participants (Actual)	Interventional	2007-01-31	Completed
A Phase 2 Open-label Study of MEDI-551 and Bendamustine vs Rituximab and Bendamustine in Adults With Relapsed or Refractory CLL [NCT01466153]	Phase 2	183 participants (Actual)	Interventional	2012-02-07	Completed
Observation of the Efficacy of BAd Regimen in the Treatment of Relapsed and Refractory Multiple Myeloma [NCT05006469]	Phase 3	10 participants (Anticipated)	Interventional	2021-06-01	Recruiting
A Phase I/II Clinical Trial to Evaluate the Safety and Efficacy of Bendamustine, Gemcitabine, Rituximab, Nivolumab Combination (BeGeRN) in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma [NCT03259529]	Phase 1/Phase 2	30 participants (Actual)	Interventional	2017-03-27	Completed
A Phase II, Open-label Study of Polatuzumab-vedotin (PV) in Combination With Bendamustine and Rituximab for Patients With Mantle Cell Lymphoma, Who Relapse After Previous Therapy With Bruton Tyrosine Kinase Inhibitor [NCT04913103]	Phase 2	21 participants (Anticipated)	Interventional	2021-09-01	Not yet recruiting
A Randomized, Open Label, Phase 2 Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for Relapsed or Refractory CD30-Positive Diffuse Large B-Cell Lymphoma [NCT02594163]	Phase 2	25 participants (Actual)	Interventional	2015-10-31	Terminated(stopped due to Sponsor decision based on portfolio prioritization)
A Phase IB/II Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus CHOP in Patients With Follicular Lymphoma or Rituximab Plus CHOP in Patients With Diffuse Large B-Cell Ly [NCT02596971]	Phase 1/Phase 2	91 participants (Actual)	Interventional	2015-12-22	Completed
Phase II Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy [NCT01626352]	Phase 2	22 participants (Actual)	Interventional	2012-10-31	Completed
A Randomized Phase II Trial Comparing Bendamustine and Melphalan With Melphalan Alone as Conditioning Regimen for Autologous Stem Cell Transplantation (ASCT) in Myeloma Patients [NCT03187223]	Phase 2	121 participants (Actual)	Interventional	2017-07-20	Completed
Prospective Multicenter Study: Bendamustine in Combination With Rituximab as a First-line Therapy Followed by Maintenance Therapy With Rituximab in Patients With Follicular Lymphoma [NCT02423837]	Phase 3	200 participants (Anticipated)	Interventional	2013-12-31	Recruiting
A Pivotal Phase II Randomised, Multi-centre, Open-label Study to Evaluate the Efficacy and Safety of MB-CART2019.1 Compared to SoC Therapy in Participants With r/r DLBCL, Who Are Not Eligible for HDC and ASCT [NCT04844866]	Phase 2	168 participants (Anticipated)	Interventional	2021-08-18	Recruiting
A Real-world Study of the Efficacy and Safety of Obinutuzumab-based Therapy for Previously Untreated Follicular Lymphoma [NCT05899621]		332 participants (Anticipated)	Observational	2023-06-01	Recruiting
Observational Study in Comorbid Patients With Chronic Lymphocytic Leukemia Receiving First-line Bendamustine With Rituximab [NCT02381899]		83 participants (Actual)	Observational	2014-09-30	Completed
Phase II Clinical Study of Zanubrutinib Combined With Bendamustine and Rituximab (ZBR) for Time-limited Treatment of Waldenstrom Macroglobulinemia [NCT05914662]	Phase 2	30 participants (Anticipated)	Interventional	2023-02-15	Recruiting
A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients &l [NCT04115631]	Phase 2	360 participants (Actual)	Interventional	2019-12-13	Active, not recruiting
A Prospective, Open-label, Multicenter Phase-II Trial to Evaluate the Efficacy and Safety of a Sequential Regimen of Bendamustine Followed by GA101 and Ibrutinib (BIG) Followed by GA101 and Ibrutinib Maintenance in CLL Patients (CLL2-BIG Protocol) [NCT02345863]	Phase 2	66 participants (Actual)	Interventional	2015-01-16	Completed
Phase I/II Study of the Combination of Bendamustine, Rituximab and Pixantrone in Patients With Relapsed/Refractory B Cell Non-Hodgkin's Lymphoma [NCT01491841]	Phase 1	33 participants (Actual)	Interventional	2011-11-01	Completed
A Phase II, Trial of Chloroquine in Combination With VELCADE and Cyclophosphamide in Patients With Relapsed and Refractory Myeloma [NCT01438177]	Phase 2	11 participants (Actual)	Interventional	2011-10-31	Terminated(stopped due to PI left institution.)
A Randomized Phase II Trial of R-HCVAD/MTX/ARA-C Induction Followed by Consolidation With an Autologous Stem Cell Transplant Vs. R-Bendamustine Induction Followed by Consolidation With an Autologous Stem Cell Transplant for Patients ≤ 65 Years of Age With [NCT01412879]	Phase 2	53 participants (Actual)	Interventional	2011-11-30	Completed
A Phase 1/2 Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Brentuximab Vedotin in Combination With Bendamustine in Patients With Relapsed or Refractory Hodgkin Lymphoma (HL) [NCT01874054]	Phase 1/Phase 2	55 participants (Actual)	Interventional	2013-06-30	Completed
A Phase IB, Open-Label Study Evaluating the Safety and Pharmacokinetics of Venetoclax (GDC-0199, ABT-199) in Combination With Bendamustine+Rituximab (BR) or Bendamustine+Obinutuzumab (BG) in Patients With Relapsed/Refractory or Previously Untreated Chroni [NCT01671904]	Phase 1	84 participants (Actual)	Interventional	2014-01-13	Completed
A Phase II, Open-Label Study Evaluating the Safety and Efficacy of GDC-0199 (ABT-199) Plus Bendamustine Plus Rituximab (BR) in Comparison With BR Alone or GDC-0199 Plus Rituximab (R) in Patients With Relapsed and Refractory Follicular Non-Hodgkin's Lympho [NCT02187861]	Phase 2	163 participants (Actual)	Interventional	2014-12-01	Completed
A Prospective, Open-label, Multicenter Phase-II Trial to Evaluate the Efficacy and Safety of a Sequential Regimen of Bendamustine Followed by GA101 (Obinutuzumab), Acalabrutinib (ACP-196) and ABT-199 (Venetoclax) in Patients With Relapsed/Refractory CLL ( [NCT03787264]	Phase 2	46 participants (Actual)	Interventional	2019-01-14	Completed
A Phase I-II Study of the Combination of Bendamustine and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma [NCT01754402]	Phase 1/Phase 2	56 participants (Actual)	Interventional	2013-01-07	Active, not recruiting
Phase III, Multicenter, Open Label, Randomized, Controlled Study Investigating Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma [NCT06006117]	Phase 3	260 participants (Anticipated)	Interventional	2023-09-05	Recruiting
BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Versus CEM (Carboplatin, Etoposide, Melphalan) in Lymphoma Patients as a Conditioning Regimen Before Autologous Hematopoietic Cell Transplantation [NCT05813132]		60 participants (Actual)	Interventional	2022-12-01	Completed
Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17 [NCT03755804]	Phase 2	250 participants (Anticipated)	Interventional	2018-12-12	Recruiting
A Phase I Study of Autologous Activated T-cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch in Subjects With Relapsed/Refractory B-cell Lymphoma [NCT03696784]	Phase 1	30 participants (Anticipated)	Interventional	2019-03-12	Recruiting
A Single Arm, Multicentre, Phase IIIB Study to Evaluate Safety, Efficacy and Pharmacokinetic (PK) of Subcutaneous (SC) Rituximab Administered During Induction Phase or Maintenance in Previously Untreated Patients With CD20+ Diffuse Large B Cell Lymphoma ( [NCT01889069]	Phase 3	159 participants (Actual)	Interventional	2013-07-31	Completed
An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL) [NCT03336333]	Phase 3	590 participants (Actual)	Interventional	2017-10-31	Active, not recruiting
A Phase 1B/2 Randomized, Multicenter, Open-Label Study Of Iberdomide (CC-220) In Combination With Polatuzumab Vedotin Plus Rituximab Or Tafasitamab Or Rituximab Plus Chemotherapy For Subjects With Relapsed Or Refractory Aggressive B-Cell Lymphoma [NCT04882163]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2021-10-10	Withdrawn(stopped due to Business objectives have changed)
Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination With Bendamustine and Rituximab (BR) in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic [NCT01611090]	Phase 3	578 participants (Actual)	Interventional	2012-09-19	Completed
Dose-Intense Yttrium-90 Ibritumomab Tiuxetan (Zevalin)-Containing Non-Myeloablative Conditioning for Allogeneic Stem Cell Transplantation in B-cell Malignancies [NCT01490723]	Phase 2	20 participants (Actual)	Interventional	2013-01-31	Completed
A Prospective, Open-label, Multicenter Study of Zanubrutinib Combined With BR (Bendamustine/Rituximab) Regimen in Subjects With Newly-diagnosed Waldenström's Macroglobulinemia [NCT05979948]	Phase 2	60 participants (Anticipated)	Interventional	2023-08-01	Recruiting
Observational Study to Assess the Efficacy and Safety of Bendamustine Plus Rituximab in Patients Affected by Chronic Lymphocytic Leukemia [NCT02491398]		494 participants (Actual)	Observational	2016-02-29	Completed
Capecitabine in Combination With Bendamustine in Women With Pretreated Locally Advanced or Metastatic Her2-negative Breast Cancer, a Phase II Trial [NCT01891227]	Phase 2	40 participants (Actual)	Interventional	2013-08-09	Completed
A Randomized, Open-label, Mutli-centre Study to Evaluate Patient Preference With Subcutaneous Administration of Rituximab Versus Intravenous Rituximab in Previously Untreated Patients With CD20+ Diffuse Large B-cell Lymphoma or CD20+ Follicular Non-Hodgki [NCT01724021]	Phase 3	743 participants (Actual)	Interventional	2012-12-31	Completed
A Phase 1 Study of FT522 in Combination With Rituximab in Participants With Relapsed/Refractory B-Cell Lymphoma [NCT05950334]	Phase 1	322 participants (Anticipated)	Interventional	2023-11-01	Recruiting
A Phase 1, Multicenter, Open-Label Study of CC-95266 in Subjects With Relapsed and/or Refractory Multiple Myeloma [NCT04674813]	Phase 1	180 participants (Anticipated)	Interventional	2021-02-24	Recruiting
A Pilot Study of Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma [NCT02728531]	Phase 1	18 participants (Actual)	Interventional	2016-04-18	Completed
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas [NCT01732926]	Phase 3	475 participants (Actual)	Interventional	2013-01-02	Terminated
Compassionate Use Re-Infusion of ATLCAR.CD30 [NCT03914885]		0 participants	Expanded Access		No longer available
Phase I Dose Escalation Trial of CD19 Directed Chimeric Antigen Receptor T Cell Therapy in the Treatment of Relapsed/Refractory B Cell Malignancies [NCT04892277]	Phase 1	25 participants (Anticipated)	Interventional	2022-07-14	Recruiting
Phase II Trial to Evaluate The Efficacy of Obinutuzumab (RO5072759) + Bendamustine Treatment in Patients With Refractory Or Relapsed Chronic Lymphocytic Leukemia [NCT02071225]	Phase 2	72 participants (Actual)	Interventional	2014-04-09	Completed
Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age [NCT03834688]	Phase 2	33 participants (Actual)	Interventional	2020-01-13	Active, not recruiting
Phase I/II Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma [NCT02477215]	Phase 1/Phase 2	38 participants (Actual)	Interventional	2015-10-09	Completed
A Pilot Study of a Sequential Regimen of Intensive Chemotherapy Followed by Autologous or Allogeneic Transplantation for Refractory Lymphoma (Non-Hodgkin's and Hodgkin's) and Phase 2 Expansion Cohort [NCT02059239]	Phase 1/Phase 2	34 participants (Actual)	Interventional	2014-06-04	Completed
A Phase IB/II Study Evaluating The Safety, Tolerability and Anti-Tumor Activity of Polatuzumab Vedotin in Combination With Rituximab (R) or Obinutuzumab (G) Plus Bendamustine (B) in Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma [NCT02257567]	Phase 1/Phase 2	331 participants (Actual)	Interventional	2014-10-15	Completed
A Phase I/II Trial of Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma [NCT04083898]	Phase 1	15 participants (Actual)	Interventional	2020-04-03	Active, not recruiting
A Phase II, Open-Label Study of Obinutuzumab Plus Bendamustine (BG) in Patients With Previously Untreated Chronic Lymphocytic Leukemia [NCT02320487]	Phase 2	102 participants (Actual)	Interventional	2015-03-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00426855 (1) [back to overview]	Optimal Bendamustine Dosage for Further Studies
NCT00547534 (3) [back to overview]	Number of Participants With Progression Free Survival at 2 Years
NCT00547534 (3) [back to overview]	Toxicity of Drug Combination in the Subjects
NCT00547534 (3) [back to overview]	Overall Response Rate (ORR)
NCT00636792 (2) [back to overview]	Number of Participants With Overall Response (Complete and Partial Response)
NCT00636792 (2) [back to overview]	Number of Participants With Complete Response
NCT00705250 (1) [back to overview]	Determine the Overall Response Rate (RR) to Bendamustine HCL in Patients With Relapsed and Primary Refractory HL.
NCT00790855 (2) [back to overview]	Number of Participants With a Response
NCT00790855 (2) [back to overview]	Maximum Tolerated Dose (MTD)
NCT00823797 (4) [back to overview]	Overall Survival
NCT00823797 (4) [back to overview]	PFS
NCT00823797 (4) [back to overview]	PFS-6
NCT00823797 (4) [back to overview]	Toxic Death
NCT00834678 (7) [back to overview]	Objective Response Rate (ORR)
NCT00834678 (7) [back to overview]	Progression-free Survival at 6 Months and 12 Months (Phase II)
NCT00834678 (7) [back to overview]	Overall Survival (OS)
NCT00834678 (7) [back to overview]	Maximum-tolerated Dose of Erlotinib Hydrochloride (Phase I)
NCT00834678 (7) [back to overview]	Maximum-tolerated Dose of Bendamustine Hydrochloride (Phase I)
NCT00834678 (7) [back to overview]	Duration of Response (DR)
NCT00834678 (7) [back to overview]	Dose-limiting Toxicity (Phase I)
NCT00856830 (3) [back to overview]	Number of Patients With Adverse Events - Phase II
NCT00856830 (3) [back to overview]	Number of Participants Experiencing Dose Limiting Toxicity Regimen A - Phase I
NCT00856830 (3) [back to overview]	Progression Free Survival
NCT00867503 (3) [back to overview]	Toxicities of Patients Treated With Bendamustine.
NCT00867503 (3) [back to overview]	Overall Survival in Patients With Platinum and Taxane Refractory Ovarian Cancer, Fallopian Tube Cancer and Primary Peritoneal Cancer With Bendamustine Treatment.
NCT00867503 (3) [back to overview]	Progression Free Survival in Patients With Platinum and Taxane Refractory Ovarian Cancer, Fallopian Tube Cancer and Primary Peritoneal Cancer With Bendamustine Treatment.
NCT00877006 (17) [back to overview]	Participants With Disease Progression, Relapse or Death At the End of the Treatment Period or the Long-Term Follow-up Period
NCT00877006 (17) [back to overview]	Overall Survival (OS)
NCT00877006 (17) [back to overview]	Kaplan-Meier Estimate for Progression-free Survival (PFS)
NCT00877006 (17) [back to overview]	Kaplan-Meier Estimate for Event-free Survival (EFS)
NCT00877006 (17) [back to overview]	Change From Baseline to End of Treatment in the Global Health Status Score of the European Organization for Research and Treatment of Cancer (EORTC) 30-item Core Quality of Life Questionnaire (QLQ-C30)
NCT00877006 (17) [back to overview]	Kaplan-Meier Estimate for Duration of Response (DOR)
NCT00877006 (17) [back to overview]	Therapeutic Classification of Prior Medications
NCT00877006 (17) [back to overview]	Worst Overall CTCAE Grade for Hematology Laboratory Test Results
NCT00877006 (17) [back to overview]	Eastern Cooperative Oncology Group (ECOG) Performance Status at the End of Treatment Period
NCT00877006 (17) [back to overview]	Worst Overall Common Terminology Criteria for Adverse Events (CTCAE) Grades for Serum Chemistry Laboratory Test Results
NCT00877006 (17) [back to overview]	Therapeutic Classification of Concomitant Medications
NCT00877006 (17) [back to overview]	Potentially Clinically Significant Abnormal Weight
NCT00877006 (17) [back to overview]	Participants Who Died At the End of the Treatment Period or the Long-Term Follow-up Period
NCT00877006 (17) [back to overview]	Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths and Discontinuations Due to AEs at End of Treatment Period
NCT00877006 (17) [back to overview]	Clinically Significant Abnormal Vital Signs
NCT00877006 (17) [back to overview]	Percentage of Participants With Overall Response at End of Treatment Period
NCT00877006 (17) [back to overview]	Percentage of Participants With Complete Response (CR) at End of Treatment Period
NCT00891839 (6) [back to overview]	Kaplan-Meier Estimate for Duration of Response
NCT00891839 (6) [back to overview]	Kaplan-Meier Estimate for Overall Survival
NCT00891839 (6) [back to overview]	Kaplan-Meier Estimate for Progression-Free Survival
NCT00891839 (6) [back to overview]	Overall Response Rate (Complete Response + Partial Response) at the End of Cycles 3 and 6 Using the 2007 International Working Group Criteria
NCT00891839 (6) [back to overview]	Shifts in Baseline Eastern Cooperative Oncology Group (ECOG) Performance Status
NCT00891839 (6) [back to overview]	Shifts in Baseline to Post-Treatment in Positron Emission Tomography (PET)
NCT00899431 (1) [back to overview]	Percentage of Participants With GVHD (Graft Versus Host Disease)
NCT00901927 (3) [back to overview]	Complete Response Rate of the Combination of BMR (Bendamustine + Mitoxantrone + Rituximab)
NCT00901927 (3) [back to overview]	Participants With Adverse Events
NCT00901927 (3) [back to overview]	Time to Progression (TTP) for Participants Treated With BMR (Bendamustine, Mitoxantrone, and Rituximab)
NCT00916058 (6) [back to overview]	Maximum Tolerated Dose (Phase 1)
NCT00916058 (6) [back to overview]	Progression-Free Survival (Phase 2)
NCT00916058 (6) [back to overview]	Progression-Free Survival (Phase 1)
NCT00916058 (6) [back to overview]	Overall Response Rate (Phase 2) - Number of Participants Achieving at Least a Partial Response or Better in Disease Status at Day 100 Post-transplant
NCT00916058 (6) [back to overview]	Overall Survival at 2 Years (Phase 1)
NCT00916058 (6) [back to overview]	Overall Survival at 3 Years (Phase 2)
NCT00920855 (9) [back to overview]	Kaplan-Meier Estimate for Time to Progression (TTP)
NCT00920855 (9) [back to overview]	Participants With Dose Limiting Toxicity (DLT)
NCT00920855 (9) [back to overview]	Percentage of Participants With An Overall Tumor Response As Assessed By the Investigator
NCT00920855 (9) [back to overview]	Time to the First Response
NCT00920855 (9) [back to overview]	Kaplan-Meier Estimate for Duration of Response
NCT00920855 (9) [back to overview]	Participants' Best Tumor Response as Assessed by the Investigator
NCT00920855 (9) [back to overview]	Summary of Participants With Adverse Events (AEs)
NCT00920855 (9) [back to overview]	Kaplan-Meier Estimate for Overall Survival (OS)
NCT00920855 (9) [back to overview]	Kaplan-Meier Estimate for Progression-Free Survival
NCT00974233 (5) [back to overview]	Progression Free Survival
NCT00974233 (5) [back to overview]	Progression-free Survival
NCT00974233 (5) [back to overview]	Toxicities Observed With Induction Chemotherapy and Maintenance Therapy
NCT00974233 (5) [back to overview]	Objective Response Rate (Complete + Partial Responses)
NCT00974233 (5) [back to overview]	Overall Survival
NCT00984542 (5) [back to overview]	Overall Survival
NCT00984542 (5) [back to overview]	Number of Patients With Each Worst-grade Toxicity
NCT00984542 (5) [back to overview]	Time to Progression
NCT00984542 (5) [back to overview]	Best Response
NCT00984542 (5) [back to overview]	Progression-free Survival
NCT01010568 (3) [back to overview]	Complete Response Rate
NCT01010568 (3) [back to overview]	Median PFS
NCT01010568 (3) [back to overview]	Overall Response Rate
NCT01029730 (4) [back to overview]	Complete Response Rate
NCT01029730 (4) [back to overview]	Median Progression-free Survival
NCT01029730 (4) [back to overview]	Overall Response Rate
NCT01029730 (4) [back to overview]	Number of Participants With Adverse Events as a Measure of Safety.
NCT01049945 (6) [back to overview]	Progression Free Survival (Phase II)
NCT01049945 (6) [back to overview]	Overall Survival (Phase II)
NCT01049945 (6) [back to overview]	Event Free Survival (Phase II)
NCT01049945 (6) [back to overview]	Duration of Response (DOR) (Phase II)
NCT01049945 (6) [back to overview]	Dose Limiting Toxicity of Bendamustine Hydrochloride and Lenalidomide in Combination With Dexamethasone (Phase I)
NCT01049945 (6) [back to overview]	Confirmed Response Rate (Dose Level 4) Reported as the Percentage of Patients Achieving a Confirmed Response (sCR, CR, VGPR, or PR).
NCT01056276 (5) [back to overview]	Complete Response Rate
NCT01056276 (5) [back to overview]	Progression Free Survival
NCT01056276 (5) [back to overview]	Overall Response Rate
NCT01056276 (5) [back to overview]	Number of Patients Who Experienced Serious and Non-serious Adverse Events
NCT01056276 (5) [back to overview]	Overall Survival
NCT01056510 (20) [back to overview]	Percentage of Participants by Disease Response Category in the First-Line Subpopulation
NCT01056510 (20) [back to overview]	Percentage of Participants Achieving Molecular Response in the First-Line Subpopulation
NCT01056510 (20) [back to overview]	Percentage of Participants Achieving Confirmed CR According to IWCLL 2008 Guidelines in the Second-Line Subpopulation After 6 Cycles of Therapy
NCT01056510 (20) [back to overview]	Percentage of Participants Achieving Confirmed CR According to IWCLL 2008 Guidelines in the Pooled Population After 6 Cycles of Therapy
NCT01056510 (20) [back to overview]	Percentage of Participants Achieving Confirmed Complete Response (CR) According to International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 Guidelines in the First-Line Subpopulation After 6 Cycles of Therapy
NCT01056510 (20) [back to overview]	Percentage of Participants Achieving a Best Overall Response of CR, CR With Incomplete Marrow Recovery (CRi), Partial Response (PR), or Nodular PR (nPR) in the First-Line Subpopulation
NCT01056510 (20) [back to overview]	Event-Free Survival (EFS) in the First-Line Subpopulation
NCT01056510 (20) [back to overview]	Overall Survival (OS) in the First-Line Subpopulation
NCT01056510 (20) [back to overview]	Percentage of Participants Experiencing Death in the First-Line Subpopulation
NCT01056510 (20) [back to overview]	Percentage of Participants Experiencing PD or Death in the First-Line Subpopulation
NCT01056510 (20) [back to overview]	Percentage of Participants Experiencing PD, Documented Intake of New Leukemia Therapy, or Death in the First-Line Subpopulation
NCT01056510 (20) [back to overview]	Percentage of Participants With Documented Intake of New Leukemia Therapy in the First-Line Subpopulation
NCT01056510 (20) [back to overview]	Percentage of Participants With Tumor Response of CR or CRi Experiencing PD or Death in the First-Line Subpopulation
NCT01056510 (20) [back to overview]	Progression-Free Survival (PFS) in the First-Line Subpopulation
NCT01056510 (20) [back to overview]	Proportion of Malignant B-cells in Normal B-cells Among Participants With a Positive Outcome for MRD in the First-Line Subpopulation
NCT01056510 (20) [back to overview]	Time to Next Leukemia Treatment (TNLT) in the First-Line Subpopulation
NCT01056510 (20) [back to overview]	Number of Participants With Positive and Negative Outcome for MRD in the First-Line Subpopulation
NCT01056510 (20) [back to overview]	Percentage of Participants With Tumor Response of CR, CRi, PR, or nPR Experiencing PD or Death in the First-Line Subpopulation
NCT01056510 (20) [back to overview]	Disease-Free Survival (DFS) in the First-Line Subpopulation
NCT01056510 (20) [back to overview]	Duration of Response in the First-Line Subpopulation
NCT01059630 (37) [back to overview]	Percentage of Participants With Best Overall Response (BOR) as Assessed by IRC
NCT01059630 (37) [back to overview]	Percentage of Participants With Best Overall Response (BOR) as Assessed by Investigator
NCT01059630 (37) [back to overview]	Change From Baseline (CFB) in Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym)-Physical Well Being Sub-scale Score
NCT01059630 (37) [back to overview]	CFB in Functional Assessment of Cancer Therapy - Generic (FACT-G) Score
NCT01059630 (37) [back to overview]	CFB in FACT-Lym-Social/Family Well-being Sub-scale Score
NCT01059630 (37) [back to overview]	Percentage of Participants With BOR at the End of Induction Treatment as Assessed by Investigator
NCT01059630 (37) [back to overview]	CFB in FACT-Lym-Lymphoma Sub-scale Score
NCT01059630 (37) [back to overview]	Percentage of Participants With BOR at the End of Induction Treatment as Assessed by IRC
NCT01059630 (37) [back to overview]	Percentage of Participants With Definitive Improvement (DI) From Baseline in FACT-Lym Instrument Scores
NCT01059630 (37) [back to overview]	CFB in FACT-Lym-Functional Well-Being Sub-scale Score
NCT01059630 (37) [back to overview]	CFB in FACT-Lym-Emotional Well-Being Sub-scale Score
NCT01059630 (37) [back to overview]	Duration of Response (DoR) as Assessed by IRC
NCT01059630 (37) [back to overview]	Duration of Response (DoR) as Assessed by Investigator
NCT01059630 (37) [back to overview]	Disease-Free Survival (DFS) in Participants With CR as Assessed by IRC
NCT01059630 (37) [back to overview]	Disease-Free Survival (DFS) in Participants With CR as Assessed by Investigator
NCT01059630 (37) [back to overview]	CFB in EQ-5D Visual Analogue Scale (VAS) Score During Induction Phase
NCT01059630 (37) [back to overview]	CFB in EQ-5D Visual Analogue Scale (VAS) Score During Induction Phase
NCT01059630 (37) [back to overview]	CFB in Euro Quality of Life 5 Dimension (EuroQoL-5D/EQ-5D) - Health State Profile Utility Score During Induction Phase
NCT01059630 (37) [back to overview]	CFB in EQ-5D VAS Score During Maintenance Phase
NCT01059630 (37) [back to overview]	CFB in Euro Quality of Life 5 Dimension (EuroQoL-5D/EQ-5D) - Health State Profile Utility Score During Induction Phase
NCT01059630 (37) [back to overview]	CFB in EuroQol 5D (EQ-5D) - Health State Profile Utility Score During Maintenance Phase
NCT01059630 (37) [back to overview]	CFB in EuroQol 5D (EQ-5D) - Health State Profile Utility Score During Maintenance Phase
NCT01059630 (37) [back to overview]	CFB in EQ-5D VAS Score During Maintenance Phase
NCT01059630 (37) [back to overview]	Progression-Free Survival (PFS) as Assessed by IRC
NCT01059630 (37) [back to overview]	PFS as Assessed by Investigator
NCT01059630 (37) [back to overview]	CFB in FACT-Lym Total Score
NCT01059630 (37) [back to overview]	Time to Deterioration of FACT-Lym TOI
NCT01059630 (37) [back to overview]	CFB in FACT-Lym Trial Outcome Index (TOI)
NCT01059630 (37) [back to overview]	Percentage of Participants With Objective Response at the End of Induction Treatment as Assessed by IRC
NCT01059630 (37) [back to overview]	Percentage of Participants With Objective Response at the End of Induction Treatment as Assessed by Investigator
NCT01059630 (37) [back to overview]	Percentage of Participants With Objective Response as Assessed by IRC
NCT01059630 (37) [back to overview]	Percentage of Participants With Objective Response as Assessed by Investigator
NCT01059630 (37) [back to overview]	Percentage of Participants Who Died
NCT01059630 (37) [back to overview]	Overall Survival (OS)
NCT01059630 (37) [back to overview]	Number of Participants With Progressive Disease (PD) as Assessed by Independent Review Committee (IRC) or Death
NCT01059630 (37) [back to overview]	Number of Participants With PD or Death as Assessed by Investigator
NCT01059630 (37) [back to overview]	Event-free Survival (EFS) as Assessed by IRC
NCT01073163 (13) [back to overview]	Worst Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 Grades for Hematology Laboratory Tests Results Overall
NCT01073163 (13) [back to overview]	Change From Baseline in QTcF at Maximum Concentration (Cmax) of Bendamustine and Its Metabolites (M3 and M4)
NCT01073163 (13) [back to overview]	Model-predicted Bayesian Bendamustine Clearance in the Presence of Rituximab
NCT01073163 (13) [back to overview]	Number of Participants With New Onset ECG Waveform Morphological Changes
NCT01073163 (13) [back to overview]	Percentage of Participants With Complete Response (CR)
NCT01073163 (13) [back to overview]	Percentage of Participants With Overall Response
NCT01073163 (13) [back to overview]	Eastern Cooperative Oncology Group (ECOG) Performance Status at Endpoint
NCT01073163 (13) [back to overview]	Mean Change From Baseline in QT Interval as Corrected by the Fridericia Method (QTcF) at End of Infusion
NCT01073163 (13) [back to overview]	Mean Change From Baseline in QTcF at 1 Hour Postinfusion
NCT01073163 (13) [back to overview]	Number of Participants With QTcF New Outlier Events at End of Infusion and 1 Hour Postinfusion
NCT01073163 (13) [back to overview]	Number of Participants With Treatment-Emergent Cardiac Disorders
NCT01073163 (13) [back to overview]	Overview of Adverse Events
NCT01073163 (13) [back to overview]	Rituximab Concentrations at 0.5 Hours, 24 Hours, and 7 Days Postinfusion
NCT01077518 (29) [back to overview]	Progression-free Survival (PFS) in Participants With Follicular Lymphoma (FL) Per IRC
NCT01077518 (29) [back to overview]	Reduction in Tumor Size
NCT01077518 (29) [back to overview]	Time to Next Therapy in All Participants Per IRC
NCT01077518 (29) [back to overview]	Time to Next Therapy in Participants With FL Per IRC
NCT01077518 (29) [back to overview]	Time to Progression in All Participants Per IRC
NCT01077518 (29) [back to overview]	Time to Progression in Participants With FL Per IRC
NCT01077518 (29) [back to overview]	Time to Response in All Participants Per IRC
NCT01077518 (29) [back to overview]	Time to Response in Participants With FL Per IRC
NCT01077518 (29) [back to overview]	B-cell Monitoring (CD19+, CD20+)
NCT01077518 (29) [back to overview]	B-cell Monitoring (CD19+, CD20+)
NCT01077518 (29) [back to overview]	Human Anti-chimeric Antibodies (HACA) Over Time
NCT01077518 (29) [back to overview]	Plasma Ofatumumab Concentrations
NCT01077518 (29) [back to overview]	PRO - Change From Baseline in Health Related Quality of Life (HRQL) Measures in All Participants: The FACT-Lym
NCT01077518 (29) [back to overview]	PRO - Change From Baseline in Health Related Quality of Life (HRQL) Measures in Participants With FL: The FACT-Lym
NCT01077518 (29) [back to overview]	PRO - Change From Baseline in HRQL Measures in All Participants: The EQ-5D
NCT01077518 (29) [back to overview]	PRO - Change From Baseline in HRQL Measures in Participants With FL: The EQ-5D
NCT01077518 (29) [back to overview]	PRO - Change in Health Treatment in HRQL Measures in All Participants: The Health Change Questionnaire (HCQ)
NCT01077518 (29) [back to overview]	PRO - Change in Health Treatment in HRQL Measures in Participants With FL: The Health Change Questionnaire (HCQ)
NCT01077518 (29) [back to overview]	Quantitative Assessments of Immunoglobulins A, G and M (IgA, IgG, IgM)
NCT01077518 (29) [back to overview]	Summary of Change in Eastern Cooperative Oncology Group (ECOG) Performance Status
NCT01077518 (29) [back to overview]	Summary of Number of Participants With Human Anti-Human Antibodies (HAHA)
NCT01077518 (29) [back to overview]	Overall Response Rate (ORR) in Participants With FL Per IRC
NCT01077518 (29) [back to overview]	Overall Survival (OS) in Participants With FL
NCT01077518 (29) [back to overview]	Overall Response Rate (ORR) to Optional Ofatumumab Monotherapy in Subjects Who Progressed During or Following Single-agent Bendamustine
NCT01077518 (29) [back to overview]	Overall Survival (OS) in All Participants
NCT01077518 (29) [back to overview]	Overall Response Rate (ORR) in All Participants Per IRC
NCT01077518 (29) [back to overview]	Duration of Response in Participants With FL Per IRC
NCT01077518 (29) [back to overview]	Duration of Response in All Participants Per IRC
NCT01077518 (29) [back to overview]	Progression-free Survival (PFS) as Assessed by the Independent Review Committee (IRC)
NCT01088048 (15) [back to overview]	Plasma Concentration of Lenalidomide
NCT01088048 (15) [back to overview]	Sub-study: Plasma Concentration of IDELA (Cohorts 1-4)
NCT01088048 (15) [back to overview]	Plasma Concentration of IDELA (Cohort 1, Cohorts 2 and 3, Cohort 5)
NCT01088048 (15) [back to overview]	Plasma Concentration of IDELA (Cohort 6)
NCT01088048 (15) [back to overview]	Plasma Concentration of IDELA (Cohort 7)
NCT01088048 (15) [back to overview]	Plasma Concentration of IDELA (Cohort 4)
NCT01088048 (15) [back to overview]	Duration of Exposure to IDELA
NCT01088048 (15) [back to overview]	Plasma Concentration of Everolimus
NCT01088048 (15) [back to overview]	Plasma Concentration of Bendamustine
NCT01088048 (15) [back to overview]	Duration of Response
NCT01088048 (15) [back to overview]	Overall Response Rate
NCT01088048 (15) [back to overview]	Overall Survival
NCT01088048 (15) [back to overview]	Progression-free Survival
NCT01088048 (15) [back to overview]	Time to Response
NCT01088048 (15) [back to overview]	Toxicity of Administration of IDELA
NCT01088984 (8) [back to overview]	Recommended Phase II Dose (RP2D) of Bendamustine
NCT01088984 (8) [back to overview]	Area Under the Plasma Drug Concentration by Time Curve From Time 0 Until 24 Hours After Study Drug Administration (AUC0-24) for Bendamustine and Its Metabolites (M3 and M4)
NCT01088984 (8) [back to overview]	Area Under the Plasma Drug Concentration by Time Curve From Time 0 Until the Last Measurable Plasma Concentration (AUC0-t) for Bendamustine and Its Metabolites (M3 and M4)
NCT01088984 (8) [back to overview]	Maximum Observed Plasma Drug Concentration (Cmax) for Bendamustine and Its Metabolites (M3 and M4)
NCT01088984 (8) [back to overview]	Time to Maximum Plasma Drug Concentration (Tmax) for Bendamustine and Its Metabolites (M3 and M4)
NCT01088984 (8) [back to overview]	Best Overall Tumor Response Rate
NCT01088984 (8) [back to overview]	Overall Response Rate (ORR)
NCT01088984 (8) [back to overview]	Best Overall Tumor Response Rate, by Phase
NCT01096992 (2) [back to overview]	Maximum Tolerated Dose (MTD) of Bendamustine Combined With Fixed-Dose Fludarabine and Rituximab (FBR)
NCT01096992 (2) [back to overview]	Overall Response Rate of Bendamustine Combined With Fixed-Dose Fludarabine and Rituximab (FBR)
NCT01108341 (2) [back to overview]	Percentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR), as Determined by the International Working Group (IWG) Criteria As Assessed by Investigators
NCT01108341 (2) [back to overview]	Percentage of Participants With a Best Overall Response of Complete Response (CR), as Determined by the International Working Group (IWG) Criteria As Assessed by Investigators
NCT01110135 (1) [back to overview]	Successful Mobilization and Collection of PBSCs
NCT01118845 (16) [back to overview]	The Maximum Concentration (Cmax) of Unchanged SyB L-0501 in Korea
NCT01118845 (16) [back to overview]	The Maximum Drug Concentration Time (Tmax) of Unchanged SyB L-0501 in Japan
NCT01118845 (16) [back to overview]	The Overall Response Rate [Complete Response (CR) + Partial Response (PR)] Determined on the Basis of Revised Response Criteria for Malignant Lymphoma
NCT01118845 (16) [back to overview]	Concomitant Medication Usage
NCT01118845 (16) [back to overview]	Number of Adverse Events
NCT01118845 (16) [back to overview]	Number of Subjects With Abnormality (Grade ≥3) in Laboratory Test Values
NCT01118845 (16) [back to overview]	Number of Subjects With Adverse Event
NCT01118845 (16) [back to overview]	Number of Subjects With Grade ≥3 Physical Examination Finding
NCT01118845 (16) [back to overview]	The Maximum Drug Concentration Time (Tmax) of Unchanged SyB L-0501 in Korea
NCT01118845 (16) [back to overview]	Progression Free Survival (PFS)
NCT01118845 (16) [back to overview]	The Area Under the Curve (AUC) for Unchanged SyB L-0501 in Japan
NCT01118845 (16) [back to overview]	The Area Under the Curve (AUC) for Unchanged SyB L-0501 in Korea
NCT01118845 (16) [back to overview]	The Complete Response (CR) Rate Determined on the Basis of Revised Response Criteria for Malignant Lymphoma
NCT01118845 (16) [back to overview]	The Half-life Period (t1/2) of Unchanged SyB L-0501 in Japan
NCT01118845 (16) [back to overview]	The Half-life Period (t1/2) of Unchanged SyB L-0501 in Korea
NCT01118845 (16) [back to overview]	The Maximum Concentration (Cmax) of Unchanged SyB L-0501 in Japan
NCT01133158 (2) [back to overview]	Response Rate
NCT01133158 (2) [back to overview]	Secondary Endpoints Included an Assessment of the Following Parameters: Progression-Free Survival, Disease-Free Survival, Global Survival, Duration of the Response.
NCT01141725 (4) [back to overview]	Median Survival
NCT01141725 (4) [back to overview]	Incidence of Greater Than or Equal to Grade 3 Toxicity
NCT01141725 (4) [back to overview]	Disease-free Survival (DFS)
NCT01141725 (4) [back to overview]	Maximum Tolerated Dose
NCT01165112 (4) [back to overview]	Maximally Tolerated Dose of Bendamustine Hydrochloride That Can be Combined With Rituximab, Carboplatin, and Etoposide Chemotherapy in Patients With Relapsed or Refractory Lymphoid Malignancies
NCT01165112 (4) [back to overview]	Ability to Proceed to Peripheral Blood Stem Cell (PBSC) Collection Following Treatment (Impact of This Regimen on Stem Cell Reserve)
NCT01165112 (4) [back to overview]	Safety and Toxicity of This Regimen
NCT01165112 (4) [back to overview]	Preliminary Assessment of the Efficacy of This Regimen
NCT01177683 (6) [back to overview]	Phase I & Phase II : Toxicity of Treatment Regimen
NCT01177683 (6) [back to overview]	Phase II: Duration of Survival
NCT01177683 (6) [back to overview]	Phase II: Overall Survival
NCT01177683 (6) [back to overview]	Phase II: Progression-free Survival (PFS)
NCT01177683 (6) [back to overview]	Phase II : Time to Progression
NCT01177683 (6) [back to overview]	Phase I: MTD of Bendamustine When Combined With Bortezomib and Pegylated Liposomal Doxorubicin.
NCT01188681 (2) [back to overview]	Response Per International Workshop on Chronic Lymphocytic Leukemia (IWCLL) Criteria
NCT01188681 (2) [back to overview]	Response Per NCI Criteria
NCT01216683 (25) [back to overview]	Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) Subscale Score at Mid-induction Treatment
NCT01216683 (25) [back to overview]	Progression-free Survival
NCT01216683 (25) [back to overview]	Proportion of Patients With Grade 3 or Higher Peripheral Neuropathy
NCT01216683 (25) [back to overview]	1-year Disease-free Survival (DFS) Rate
NCT01216683 (25) [back to overview]	5-year Overall Survival Rate
NCT01216683 (25) [back to overview]	Functional Assessment of Cancer Therapy - General (FACT-G) Total Score at Baseline
NCT01216683 (25) [back to overview]	Functional Assessment of Cancer Therapy - General (FACT-G) Total Score at End of Induction Treatment
NCT01216683 (25) [back to overview]	Functional Assessment of Cancer Therapy - General (FACT-G) Total Score at Mid-treatment
NCT01216683 (25) [back to overview]	Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym) Subscale Score at Baseline
NCT01216683 (25) [back to overview]	1-year Disease-free Survival (DFS) Rate
NCT01216683 (25) [back to overview]	Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym) Subscale Score at Mid-induction Treatment
NCT01216683 (25) [back to overview]	5-year Overall Survival Rate
NCT01216683 (25) [back to overview]	Complete Remission (CR) Rate
NCT01216683 (25) [back to overview]	Complete Remission (CR) Rate
NCT01216683 (25) [back to overview]	Complete Remission (CR) Rate
NCT01216683 (25) [back to overview]	5-year Overall Survival Rate
NCT01216683 (25) [back to overview]	Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym) Subscale Score at End of Induction Treatment
NCT01216683 (25) [back to overview]	3-year Progression-free Survival Rate
NCT01216683 (25) [back to overview]	3-year Progression-free Survival Rate
NCT01216683 (25) [back to overview]	1-year Post-induction Disease-free Survival (DFS) Rate
NCT01216683 (25) [back to overview]	Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - Neurotoxicity (FACT-GOG-NTX) Subscale Score at Baseline
NCT01216683 (25) [back to overview]	Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - Neurotoxicity (FACT-GOG-NTX) Subscale Score at Mid-induction Treatment
NCT01216683 (25) [back to overview]	Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - Neurotoxicity (FACT-GOG-NTX) Subscale Score at the End of Induction Treatment
NCT01216683 (25) [back to overview]	Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) Subscale Score at Baseline
NCT01216683 (25) [back to overview]	Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) Subscale Score at End of Induction Treatment
NCT01222260 (4) [back to overview]	Median Overall Survival (OS)
NCT01222260 (4) [back to overview]	Organ Response Rate (ORR)
NCT01222260 (4) [back to overview]	Overall Hematologic Response Rate (OHR)
NCT01222260 (4) [back to overview]	Partial Hematologic Response (PHR) Rate
NCT01232556 (8) [back to overview]	Duration of Response
NCT01232556 (8) [back to overview]	Health Related Quality of Life as Assessed by the Functional Assessment of Cancer Therapy for Lymphoma (FACT-Lym) Questionnaire
NCT01232556 (8) [back to overview]	Health Status as Assessed by the European Quality of Life 5 Dimension (EQ-5D) Questionnaire
NCT01232556 (8) [back to overview]	Overall Survival
NCT01232556 (8) [back to overview]	Percentage of Participants With A Best Overall Response of CR, Unconfirmed CR (unCR), PR, or Unconfirmed PR (unPR) Per NCI International Response Criteria for NHL
NCT01232556 (8) [back to overview]	Percentage of Participants With A Best Overall Response of CR or Partial Response (PR) Per NCI International Response Criteria for NHL
NCT01232556 (8) [back to overview]	Percentage of Participants With a Treatment Emergent Adverse Event (TEAE) (Safety Population)
NCT01232556 (8) [back to overview]	Progression-Free Survival (PFS)
NCT01234467 (6) [back to overview]	Evaluate the Toxicity and Tolerability of Bendamustine in Combination With Rituximab
NCT01234467 (6) [back to overview]	Overall Survival
NCT01234467 (6) [back to overview]	Partial Response Rate
NCT01234467 (6) [back to overview]	Overall Response Rate (ORR)
NCT01234467 (6) [back to overview]	Estimate of Progression-Free Survival
NCT01234467 (6) [back to overview]	Complete Response (CR) Rate as Defined by The International Harmonization Project for Response Criteria
NCT01234766 (1) [back to overview]	Number of Participants With Complete Response at 3 Years
NCT01244451 (4) [back to overview]	Toxicity According to CTCAE Version 4.0
NCT01244451 (4) [back to overview]	Progression Free Survival
NCT01244451 (4) [back to overview]	Overall Survival
NCT01244451 (4) [back to overview]	Number of Participants Contributing to the Overall Response Rate
NCT01286272 (3) [back to overview]	The Number of Patients Who Experienced Grade 3+ Hematologic and Non-hematologic Adverse Events at Least Possibly Related to Treatment
NCT01286272 (3) [back to overview]	Progression-free Survival (PFS)
NCT01286272 (3) [back to overview]	Complete Response Rate
NCT01294579 (6) [back to overview]	Kaplan-Meier Estimates of Progression Free Survival up to 30 Months (FAS)
NCT01294579 (6) [back to overview]	All Deaths by Preferred Term (Safety Set) up to Approximately 30 Months
NCT01294579 (6) [back to overview]	Percentage of Participants With Progression Free Survival (PFS) up to 30 Months (FAS)
NCT01294579 (6) [back to overview]	Overall Response Rate (ORR) During Induction Phase After Cycle 6 (FAS)
NCT01294579 (6) [back to overview]	Complete Remission (CR) Rate of Induction Therapy After Cycle 6 (28 Days) (FAS)
NCT01294579 (6) [back to overview]	Conversion Rate of Partial Response in Induction Phase to Complete Response With Maintenance Ofatumumab (FAS)
NCT01300247 (7) [back to overview]	Percentage of Participants Who Were Alive
NCT01300247 (7) [back to overview]	Percentage of Participants With Objective Response, Assessed According to International Workshop on Chronic Lymphocytic Leukemia (IWCLL) Guidelines
NCT01300247 (7) [back to overview]	Number of Participants With Human Anti-Human Antibodies (HAHAs)
NCT01300247 (7) [back to overview]	Percentage of Participants Who Had B-Cell Recovery
NCT01300247 (7) [back to overview]	Percentage of Participants Who Had B-Cell Depletion
NCT01300247 (7) [back to overview]	Percentage of Participants Who Were Alive and Progression Free
NCT01300247 (7) [back to overview]	Duration of Objective Response (DOR), Assessed by the Investigator According to IWCLL Guidelines
NCT01317901 (1) [back to overview]	Response
NCT01326702 (7) [back to overview]	Maximum Tolerated Dose of Veliparib When Combined With Bendamustine Hydrochloride
NCT01326702 (7) [back to overview]	Progression-free Survival Using RECIST Version 1.1 (Phase IIa)
NCT01326702 (7) [back to overview]	Complete Response (CR) to Study Treatment (Phase IIa)
NCT01326702 (7) [back to overview]	Number of Participants With Adverse Events
NCT01326702 (7) [back to overview]	Participants With Dose Limiting Toxicities
NCT01326702 (7) [back to overview]	Pharmacokinetic Parameters of Veliparib (Phase Ib)
NCT01326702 (7) [back to overview]	Response Rate
NCT01332968 (32) [back to overview]	Change From Baseline in Euro-Quality of Life-5 Dimensions (EQ-5D) Questionnaire Summary Score (Follicular Lymphoma Population) During Follow Up Phase
NCT01332968 (32) [back to overview]	Complete Response (Overall Study Population), Investigator-Assessed
NCT01332968 (32) [back to overview]	Change From Baseline in All Domains of FACT-G (Follicular Lymphoma Population)
NCT01332968 (32) [back to overview]	Time to Next Anti-Lymphoma Treatment (Overall Study Population)
NCT01332968 (32) [back to overview]	Time to Next Anti-Lymphoma Treatment (Follicular Lymphoma Population)
NCT01332968 (32) [back to overview]	Progression-Free Survival in the Follicular Lymphoma Population, Investigator-Assessed
NCT01332968 (32) [back to overview]	Progression-Free Survival in the Follicular Lymphoma Population, Investigator-Assessed
NCT01332968 (32) [back to overview]	Progression-Free Survival (Overall Study Population), Assessed by Independent Review Committee (IRC)
NCT01332968 (32) [back to overview]	Percentage of Participants With Adverse Events
NCT01332968 (32) [back to overview]	Overall Survival (Overall Study Population)
NCT01332968 (32) [back to overview]	Disease-Free Survival (Overall Study Population)
NCT01332968 (32) [back to overview]	Overall Response (Overall Study Population), IRC-Assessed
NCT01332968 (32) [back to overview]	Overall Response (Overall Study Population), Investigator-Assessed
NCT01332968 (32) [back to overview]	Duration of Response (DOR) (Overall Study Population), Investigator-Assessed
NCT01332968 (32) [back to overview]	Duration of Response (DOR) (Follicular Lymphoma Population), Investigator-Assessed
NCT01332968 (32) [back to overview]	Complete Response (Follicular Lymphoma Population), IRC-Assessed
NCT01332968 (32) [back to overview]	Disease-Free Survival (Follicular Lymphoma Population)
NCT01332968 (32) [back to overview]	Event-Free Survival (Follicular Lymphoma Population)
NCT01332968 (32) [back to overview]	Event-Free Survival (Overall Study Population)
NCT01332968 (32) [back to overview]	Overall Response (Follicular Lymphoma Population), IRC-Assessed
NCT01332968 (32) [back to overview]	Overall Response (Follicular Lymphoma Population), Investigator-Assessed
NCT01332968 (32) [back to overview]	Overall Survival (Follicular Lymphoma Population)
NCT01332968 (32) [back to overview]	Complete Response (Overall Study Population), IRC-Assessed
NCT01332968 (32) [back to overview]	Progression-Free Survival (Follicular Lymphoma Population), IRC-Assessed
NCT01332968 (32) [back to overview]	Complete Response (Follicular Lymphoma Population), Investigator-Assessed
NCT01332968 (32) [back to overview]	Change From Baseline in Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) Total Score (Follicular Population)
NCT01332968 (32) [back to overview]	Progression-Free Survival in the Overall Study Population, Investigator-Assessed
NCT01332968 (32) [back to overview]	Change From Baseline in FACT-Lym Individual Subscale Lymphoma Score (Follicular Population)
NCT01332968 (32) [back to overview]	Change From Baseline in Euro-Quality of Life-5 Dimensions (EQ-5D) Questionnaire Summary Score (Follicular Lymphoma Population) During Maintenance/Observation Phase
NCT01332968 (32) [back to overview]	Change From Baseline in Euro-Quality of Life-5 Dimensions (EQ-5D) Questionnaire Summary Score (Follicular Lymphoma Population) During Induction Phase
NCT01332968 (32) [back to overview]	Change From Baseline in Euro-Quality of Life-5 Dimensions (EQ-5D) Questionnaire Summary Score (Follicular Lymphoma Population) During Induction Phase
NCT01332968 (32) [back to overview]	Change From Baseline in FACT-Lym Total Outcome Index (TOI) Score (Follicular Lymphoma Population)
NCT01369849 (7) [back to overview]	Number of Phase I Participants With Dose-Limiting Toxicity Events (Phase I)
NCT01369849 (7) [back to overview]	Overall Response Rate
NCT01369849 (7) [back to overview]	Proportion of Complete Response Defined to be a CR or CRi Noted as the Objective Status (Phase II)
NCT01369849 (7) [back to overview]	Treatment-free Survival
NCT01369849 (7) [back to overview]	Biomarker Analysis (CD38, CD49d, and ZAP-70)
NCT01369849 (7) [back to overview]	Duration of Response
NCT01369849 (7) [back to overview]	Minimal-residual Disease
NCT01412879 (4) [back to overview]	5-year Overall Survival (OS)
NCT01412879 (4) [back to overview]	Progression-Free Survival (PFS) at 2 Years
NCT01412879 (4) [back to overview]	Response Rate (Complete and Partial Response)
NCT01412879 (4) [back to overview]	Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug
NCT01438177 (3) [back to overview]	Median Duration of Response of This Regimen
NCT01438177 (3) [back to overview]	Response Rate (CR + PR After 2 Cycles)
NCT01438177 (3) [back to overview]	Number of Participants With Adverse Events of Grade 3 or Higher
NCT01458366 (8) [back to overview]	Overall Safety and Tolerability of the Combination of Bendamustine, Ofatumumab, Carboplatin, and Etoposide
NCT01458366 (8) [back to overview]	Overall Proportion of Patients Who Are Able to Undergo Stem Cell Transplant (SCT)
NCT01458366 (8) [back to overview]	Overall Complete Response (CR) and Partial Response (PR) Rate
NCT01458366 (8) [back to overview]	Overall Progression-Free Survival
NCT01458366 (8) [back to overview]	Overall Frequency of Response With Combination of Bendamustine, Ofatumumab, Carboplatin, and Etoposide at Maximum Tolerated Dose (MTD)
NCT01458366 (8) [back to overview]	Total Overall Survival for Transplant vs Non-transplant
NCT01458366 (8) [back to overview]	Phase I: Overall Frequency of Response
NCT01458366 (8) [back to overview]	Phase I: Maximum-Tolerated Dose of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide (BOCE)
NCT01466153 (13) [back to overview]	Number of Participants Who Developed Detectable Anti-drug Antibodies (ADA)
NCT01466153 (13) [back to overview]	Objective Response Rate
NCT01466153 (13) [back to overview]	Overall Survival (OS)
NCT01466153 (13) [back to overview]	Terminal Half Life (t1/2) of MEDI-551
NCT01466153 (13) [back to overview]	Time to Disease Progression (TTP)
NCT01466153 (13) [back to overview]	Time to Response
NCT01466153 (13) [back to overview]	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as AEs
NCT01466153 (13) [back to overview]	Complete Response Rate
NCT01466153 (13) [back to overview]	Minimal Residual Disease Negative Complete Response (CR) Rate
NCT01466153 (13) [back to overview]	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as AEs
NCT01466153 (13) [back to overview]	Number of Participants With Abnormal Vital Signs and Electrocardiogram Reported as AEs
NCT01466153 (13) [back to overview]	Number of Participants With Treatment Emergent Adverse Events (TEAEs), Treatment Emergent Serious Adverse Events (TESAEs) and Adverse Events of Special Interest (AESIs)
NCT01466153 (13) [back to overview]	Progression Free Survival (PFS)
NCT01490723 (2) [back to overview]	Treatment-Related Mortality (TRM)
NCT01490723 (2) [back to overview]	Overall Survival (OS)
NCT01491841 (5) [back to overview]	Toxicity
NCT01491841 (5) [back to overview]	Progression Free Survival
NCT01491841 (5) [back to overview]	Overall Survival
NCT01491841 (5) [back to overview]	Maximum Tolerated Dose
NCT01491841 (5) [back to overview]	Overall Response
NCT01500083 (1) [back to overview]	Number of Adverse Events
NCT01520922 (28) [back to overview]	Investigator-assessed Kaplan-meier Estimates of Time to Response
NCT01520922 (28) [back to overview]	Number of Participants With Autoimmune Hemolytic Anaemia (AIHA) Disease
NCT01520922 (28) [back to overview]	Number of Participants With the Indicated Grade 3 or Grade 4 Adverse Event of Infection
NCT01520922 (28) [back to overview]	Time to Next Therapy
NCT01520922 (28) [back to overview]	Change From Baseline in Cluster of Differentiation (CD) CD5-CD19+ Cell Counts up to 36 Months
NCT01520922 (28) [back to overview]	Change From Baseline in Cluster of Differentiation (CD) CD5+CD19+ Cell Counts up to 36 Months
NCT01520922 (28) [back to overview]	Change From Baseline in the Immunoglobulin (Ig) Antibodies to End of Study Treatment
NCT01520922 (28) [back to overview]	Maximum Decrease in Sum of the Product of the Diameter (SPD) From Baseline in Participants With Lymphadenopathy at Baseline
NCT01520922 (28) [back to overview]	Number of Participants Who Received no Transfusion or at Least One Transfusion During the Study
NCT01520922 (28) [back to overview]	Number of Participants Who Were Negative or Positive for Minimal Residual Disease (MRD) and Achieved a Bone Marrow Biopsy Confirmed Complete Response (CR) up to 36-Month Follow-up
NCT01520922 (28) [back to overview]	Number of Participants With an Adverse Event of Any Infusion Reactions (IR) or Serious Infusion Reactions (SIR)
NCT01520922 (28) [back to overview]	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)
NCT01520922 (28) [back to overview]	Investigator-assessed of Kaplan-meier Estimates of Progression-free Survival (PFS)
NCT01520922 (28) [back to overview]	Number of Participants With Complete Response (CR) With and Without a CT Scan Assessment After the Last Dose of Study Treatment, as Assessed by the Investigator
NCT01520922 (28) [back to overview]	Number of Participants With the Indicated Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)
NCT01520922 (28) [back to overview]	Number of Participants With Zeta-chain-associated Protein Kinase (ZAP) 70 Testing at Baseline Who Also Had a Clinical Response After Last Dose of Study Treatment
NCT01520922 (28) [back to overview]	Number of Participants With the Indicated Reduction in Organomegaly (Spleen and Liver)
NCT01520922 (28) [back to overview]	Number of Participants With the Indicated Immunoglobulin Heavy Chain Variable Region (IgVH) Testing at Baseline Who Also Had a Clinical Response After Last Dose of Study Treatment
NCT01520922 (28) [back to overview]	Number of Participants With the Indicated Grade 3 or Grade 4 Myelosuppression (Anemia, Neutropenia, and Thrombocytopenia), as Assessed by the Investigator
NCT01520922 (28) [back to overview]	Number of Participants With the Indicated Cytogenetics Testing at Baseline Who Also Had a Clinical Response After Last Dose of Study Treatment
NCT01520922 (28) [back to overview]	Number of Participants With the Indicated Constitutional or B-symptoms
NCT01520922 (28) [back to overview]	Number of Participants With the Indicated Beta 2 Microglobulin (B2M) at Baseline Who Also Had a Clinical Response After the Last Dose of Study Treatment
NCT01520922 (28) [back to overview]	Number of Participants With Overall Response (OR), as Assessed by the Investigator
NCT01520922 (28) [back to overview]	Number of Participants With Overall Response (OR) With Computed Tomography (CT) Scan (CT Scan) Assessment, as Assessed by the Investigator
NCT01520922 (28) [back to overview]	Number of Participants With Confirmed Positive Response for Human Anti-human Antibodies (HAHA) at the Indicated Time Points
NCT01520922 (28) [back to overview]	Investigator-assessed Kaplan-meier Estimates of Duration of Response
NCT01520922 (28) [back to overview]	Investigator-assessed Kaplan-meier Estimates of Overall Survival
NCT01520922 (28) [back to overview]	Investigator-Assessed Kaplan-Meier Estimates of Time to Progression
NCT01535924 (2) [back to overview]	Adverse Events in Terms of Dose-limiting Toxicity (DLT) and MTD of Bendamustine Hydrochloride (Phase I)
NCT01535924 (2) [back to overview]	Overall Response Rate (ORR) of Bendamustine Hydrochloride and Gemcitabine Hydrochloride in Patients With Relapsed or Refractory Hodgkin Lymphoma (Phase II)
NCT01569295 (5) [back to overview]	Progression-Free Survival (PFS)
NCT01569295 (5) [back to overview]	Lymph Node Response Rate
NCT01569295 (5) [back to overview]	Overall Response Rate (ORR)
NCT01569295 (5) [back to overview]	Overall Survival
NCT01569295 (5) [back to overview]	Complete Response Rate
NCT01596621 (13) [back to overview]	Maximum Observed Plasma Concentration (Cmax) of Bendamustine
NCT01596621 (13) [back to overview]	Time to Reach Cmax (Tmax) of Bendamustine
NCT01596621 (13) [back to overview]	Duration of Response (DOR) (Assessed by IRC)
NCT01596621 (13) [back to overview]	Number of Participants With Adverse Events (AEs)
NCT01596621 (13) [back to overview]	Rate Constant for Elimination (λz) of Bendamustine
NCT01596621 (13) [back to overview]	Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Measurable Drug Concentration (AUC0-t) of Bendamustine
NCT01596621 (13) [back to overview]	Progression-Free Survival (Assessed by IRC)
NCT01596621 (13) [back to overview]	Percentage of the AUC0-∞ Based on Extrapolation (%AUCext)
NCT01596621 (13) [back to overview]	Overall Response Rate (ORR) (Assessed by Independent Review Committee [IRC])
NCT01596621 (13) [back to overview]	Number of Participants With Concomitant Medication Usage
NCT01596621 (13) [back to overview]	Number of Participants Who Need At Least 1 Hematologic Supportive Care (Plasma, Blood Cells, or Cytokines)
NCT01596621 (13) [back to overview]	Half-Life (t½) of Bendamustine
NCT01596621 (13) [back to overview]	Area Under the Plasma Concentration Versus Time Curve From Time 0 to Infinity (AUC0-∞) of Bendamustine
NCT01611090 (14) [back to overview]	Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) Visual Analog Scale at End of Treatment
NCT01611090 (14) [back to overview]	Change From Baseline in FACIT-Fatigue Scale at End of Treatment
NCT01611090 (14) [back to overview]	Change From Baseline in EORTC QLQ-C30 Physical Functioning Score at End of Treatment
NCT01611090 (14) [back to overview]	Number of Participants Who Received Subsequent Antineoplastic Therapy
NCT01611090 (14) [back to overview]	Number of Participants With Clinically Relevant Shifts in Disease-Related Symptoms
NCT01611090 (14) [back to overview]	Overall Response Rate (ORR)
NCT01611090 (14) [back to overview]	Overall Survival (OS)
NCT01611090 (14) [back to overview]	Percentage of Participants With Minimal Residual Disease (MRD)-Negative Response
NCT01611090 (14) [back to overview]	Progression-free Survival (PFS)
NCT01611090 (14) [back to overview]	Change From Baseline in EORTC QLQ-CLL 16 Domain Scores at End of Treatment
NCT01611090 (14) [back to overview]	Percentage of Participants With Sustained Hematologic Improvement
NCT01611090 (14) [back to overview]	Median Time to Clinically Meaningful Improvement in FACIT-Fatigue Scale
NCT01611090 (14) [back to overview]	Change From Baseline in Beta2 Microglobulin at End of Treatment (EOT)
NCT01611090 (14) [back to overview]	Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) Utility Score Scale at End of Treatment
NCT01626352 (7) [back to overview]	Time to Progression (TTP)
NCT01626352 (7) [back to overview]	Progression-free Survival
NCT01626352 (7) [back to overview]	Overall Survival (OS)
NCT01626352 (7) [back to overview]	Overall Response (OR)
NCT01626352 (7) [back to overview]	Number of Patients With Treatment-Related Adverse Events (AEs) as a Measure of Safety
NCT01626352 (7) [back to overview]	Number of Patients With a Complete Response
NCT01626352 (7) [back to overview]	Duration of Response
NCT01661881 (3) [back to overview]	Complete Remission (CR) Rate After 6 Cycles
NCT01661881 (3) [back to overview]	Autologous Stem Cell Transplant (ASCT) Rate
NCT01661881 (3) [back to overview]	1 Year Progression-Free Survival
NCT01724021 (14) [back to overview]	Number of Participants With Treatment Emergent Adverse Events (AEs)
NCT01724021 (14) [back to overview]	Event-free Survival (EFS)
NCT01724021 (14) [back to overview]	Percentage of Participants With Anti-Recombinant Human Hyaluronidase (rHuPH20) Antibodies Over Time
NCT01724021 (14) [back to overview]	Overall Survival (OS)
NCT01724021 (14) [back to overview]	Percentage of Participants Indicating a Preference for Rituximab Subcutaneous (SC) Over Rituximab Intravenously (IV) at Cycle 6
NCT01724021 (14) [back to overview]	Cancer Therapy Satisfaction Questionnaire (CTSQ) Score
NCT01724021 (14) [back to overview]	Percentage of Participants Indicating a Preference for Rituximab Subcutaneous (SC) Over Rituximab Intravenously (IV) at Cycle 8
NCT01724021 (14) [back to overview]	Complete Response (CR) Rate
NCT01724021 (14) [back to overview]	Disease-free Survival (DFS)
NCT01724021 (14) [back to overview]	Summary of Observed Serum Rituximab Concentration
NCT01724021 (14) [back to overview]	Rituximab Administration Satisfaction Questionnaire (RASQ) Score
NCT01724021 (14) [back to overview]	Percentage of Participants With Anti-Rituximab Antibodies Over Time
NCT01724021 (14) [back to overview]	Progression-free Survival (PFS)
NCT01724021 (14) [back to overview]	Time Required for Rituximab Administration (Subcutaneous [SC] or Intravenous [IV])
NCT01754402 (2) [back to overview]	Maximum Tolerated Dose of Pomalidomide and Bendamustine
NCT01754402 (2) [back to overview]	Initial Response Rate
NCT01754857 (2) [back to overview]	Time to Progression
NCT01754857 (2) [back to overview]	Count of Events Related to Toxicity
NCT01776840 (16) [back to overview]	Overall Survival
NCT01776840 (16) [back to overview]	Percentage of Participants With Overall Response
NCT01776840 (16) [back to overview]	Maximum Observed Plasma Concentration of Ibrutinib
NCT01776840 (16) [back to overview]	Time-to-Next Treatment
NCT01776840 (16) [back to overview]	Oral Volume of Distribution at Steady State of Ibrutinib
NCT01776840 (16) [back to overview]	Duration of Response (DoR)
NCT01776840 (16) [back to overview]	Duration of Complete Response (DoCR)
NCT01776840 (16) [back to overview]	Complete Response Rate
NCT01776840 (16) [back to overview]	Area Under the Concentration Curve of Ibrutinib During 24 Hours After Dosing at Steady State
NCT01776840 (16) [back to overview]	Number of Participants With Treatment-emergent Adverse Events (TEAEs)
NCT01776840 (16) [back to overview]	Minimum Observed Plasma Concentration of Ibrutinib
NCT01776840 (16) [back to overview]	Minimal Residual Disease (MRD)-Negative Response Rate
NCT01776840 (16) [back to overview]	Oral Plasma Clearance (CL/F) of Ibrutinib
NCT01776840 (16) [back to overview]	Time to Worsening (TTW) in the Lymphoma (Lym) Subscale of the Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) Questionnaire
NCT01776840 (16) [back to overview]	Time to Response
NCT01776840 (16) [back to overview]	Progression-free Survival (PFS)
NCT01874054 (5) [back to overview]	Progression-free Survival
NCT01874054 (5) [back to overview]	Incidence of Dose-limiting Toxicities
NCT01874054 (5) [back to overview]	Duration of Response
NCT01874054 (5) [back to overview]	Complete Remission Rate
NCT01874054 (5) [back to overview]	Incidence of Adverse Events (AEs)
NCT01886872 (9) [back to overview]	Percentage of Patients Achieving a Biopsy-proven Complete Response (CR)
NCT01886872 (9) [back to overview]	Duration of Response (DOR) (Complete Response [CR], CCR, Nodular Partial Response [nPR], Partial Response [PR], and PRL)
NCT01886872 (9) [back to overview]	The Rate of Grade 3, 4, or 5 Treatment-related Non-hematologic Adverse Events (Toxicities)
NCT01886872 (9) [back to overview]	Overall Survival (OS) at 2 Years
NCT01886872 (9) [back to overview]	Progression Free Survival (PFS) Rate at 2 Years
NCT01886872 (9) [back to overview]	Progression Free Survival (PFS)
NCT01886872 (9) [back to overview]	Percentage of Patients Achieving Any Response to Treatment (Overall Response Rate [ORR] [Complete Response [CR], CCR, Nodular Partial Response [nPR], Partial Response [PR], and PRL])
NCT01886872 (9) [back to overview]	Percentage of Patients Achieving Complete (CR and CCR) or Nodular Partial Response (nPR)
NCT01886872 (9) [back to overview]	Percentage of Patients Who Attain Minimal Residual Disease (MRD) Negative Status
NCT01889069 (23) [back to overview]	FL: Plasma Trough Concentrations of Rituximab in Participants With Complete Response/Complete Response Unconfirmed (CR/CRu)
NCT01889069 (23) [back to overview]	FL: Plasma Trough Concentrations of Rituximab
NCT01889069 (23) [back to overview]	DLBCL: Plasma Trough Concentrations of Rituximab in Participants With Complete Response/Complete Response Unconfirmed (CR/CRu)
NCT01889069 (23) [back to overview]	DLBCL: Plasma Trough Concentrations of Rituximab
NCT01889069 (23) [back to overview]	DLBCL: Plasma Concentrations of Rituximab
NCT01889069 (23) [back to overview]	DLBCL: Plasma Concentrations During Different Scheduling of Rituximab SC R-CHOP-14 or R-CHOP-21
NCT01889069 (23) [back to overview]	DLBCL: Plasma Concentrations During Different Scheduling of Rituximab SC R-CHOP-14 or R-CHOP-21
NCT01889069 (23) [back to overview]	Percentage of Participants With Progression-Free Survival (PFS) According to IWG Response Criteria
NCT01889069 (23) [back to overview]	Percentage of Participants With Overall Survival (OS)
NCT01889069 (23) [back to overview]	Percentage of Participants With Event-Free Survival (EFS) According to IWG Response Criteria
NCT01889069 (23) [back to overview]	Percentage of Participants With Disease-Free Survival (DFS) According to IWG Response Criteria
NCT01889069 (23) [back to overview]	Percentage of Participants With Complete Response (CR) According to IWG Response Criteria
NCT01889069 (23) [back to overview]	Percentage of Participants With At Least One Treatment-Emergent Serious Adverse Events
NCT01889069 (23) [back to overview]	Percentage of Participants With At Least One Grade ≥ 3 Treatment-Emergent Adverse Events (TEAEs)
NCT01889069 (23) [back to overview]	Percentage of Participants With At Least One Grade ≥ 3 Infusion/ Injection Related Reactions (IIRRs)
NCT01889069 (23) [back to overview]	FL: Overall Geometric Least Square (LS) Mean Plasma Trough Concentrations of Rituximab
NCT01889069 (23) [back to overview]	DLBCL: Overall Geometric Least Square (LS) Mean Plasma Trough Concentrations of Rituximab
NCT01889069 (23) [back to overview]	DLBCL: Maximum Plasma Concentration (Cmax) of Rituximab
NCT01889069 (23) [back to overview]	DLBCL: Area Under the Plasma Concentration-Time Curve (AUC) of Rituximab
NCT01889069 (23) [back to overview]	DLBCL: Apparent Total Clearance (CL/F) of Rituximab
NCT01889069 (23) [back to overview]	Rituximab Administration Satisfaction Questionnaire (RASQ) Convenience and Satisfaction Domain Scores
NCT01889069 (23) [back to overview]	Rituximab Administration Satisfaction Questionnaire (RASQ) Convenience and Satisfaction Domain Scores
NCT01889069 (23) [back to overview]	Percentage of Participants With Administration-Associated Reactions (AAR)
NCT01905943 (12) [back to overview]	Number of Participants With Adverse Events of Particular Interest (AEPIs)
NCT01905943 (12) [back to overview]	Number of Participants With Adverse Events (AEs)
NCT01905943 (12) [back to overview]	Percentage of Participants With Overall Response (OR) at Final Response Assessment (FRA)
NCT01905943 (12) [back to overview]	Percentage of Participants With Best Overall Response (BOR)
NCT01905943 (12) [back to overview]	Median Time to Response (TTR)
NCT01905943 (12) [back to overview]	Median Time to Progression-Free Survival (PFS)
NCT01905943 (12) [back to overview]	Median Time to New Anti-Leukemia Therapy (TTNT)
NCT01905943 (12) [back to overview]	Median Time to Event-Free Survival (EFS)
NCT01905943 (12) [back to overview]	Median Time to Duration of Response (DoR)
NCT01905943 (12) [back to overview]	Percentage of Participants With Minimal Residual Disease (MRD)-Negativity as Assessed by Flow Cytometry
NCT01905943 (12) [back to overview]	Median Time to Overall Survival (OS)
NCT01905943 (12) [back to overview]	Number of Participants With Adverse Events of Special Interest (AESIs)
NCT01974440 (14) [back to overview]	Primary Analysis: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
NCT01974440 (14) [back to overview]	Primary Analysis: Complete Response Rate (CRR): Stratified Analysis
NCT01974440 (14) [back to overview]	Primary Analysis: Duration of Response (DOR): Stratified Analysis
NCT01974440 (14) [back to overview]	Supplementary Analysis: Progression Free Survival: Unstratified Analysis - Participants With Marginal Zone Lymphoma (MZL)
NCT01974440 (14) [back to overview]	Primary Analysis: Overall Response Rate (ORR): Stratified Analysis
NCT01974440 (14) [back to overview]	Primary Analysis: Overall Survival (OS): Stratified Analysis
NCT01974440 (14) [back to overview]	Primary Analysis: Progression Free Survival (PFS): Stratified Analysis
NCT01974440 (14) [back to overview]	Primary Analysis: Time to Worsening (TTW) in the Lymphoma (Lym) Subscale of the Functional Assessment of Cancer Therapy - Lymphoma Subscale (FACT-LymS) Questionnaire
NCT01974440 (14) [back to overview]	Supplementary Analysis: Duration of Response: Unstratified Analysis - Participants With MZL
NCT01974440 (14) [back to overview]	Supplementary Analysis: Number of Participants With TEAEs: Participants With MZL
NCT01974440 (14) [back to overview]	Supplementary Analysis: Overall Response Rate: Unstratified Analysis - Participants With MZL
NCT01974440 (14) [back to overview]	Supplementary Analysis: Overall Survival: Unstratified Analysis - Participants With MZL
NCT01974440 (14) [back to overview]	Supplementary Analysis: Time to Worsening (TTW) in the Lymphoma (Lym) Subscale of the Functional Assessment of Cancer Therapy - Lymphoma Subscale (FACT-LymS) Questionnaire: Participants With MZL
NCT01974440 (14) [back to overview]	Supplementary Analysis: Complete Response Rate: Unstratified Analysis - Participants With MZL
NCT01980888 (1) [back to overview]	Progression-Free Survival
NCT02005471 (30) [back to overview]	Percentage of Participants With PD or Death as Assessed by the Investigator Using Standard iwCLL Guidelines in Participants With 17p Deletion as Identified by Fluorescence In-situ Hybridization (FISH) Test
NCT02005471 (30) [back to overview]	Percentage of Participants With PD or Death as Assessed by the Independent Review Committee (IRC) Using Standard iwCLL Guidelines
NCT02005471 (30) [back to overview]	Percentage of Participants With PD as Assessed by the Investigator Using Standard International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Guidelines or Death
NCT02005471 (30) [back to overview]	Percentage of Participants With Overall Response of CR, Cri, nPR, or PR at End of Combination Treatment Visit as Assessed by the IRC Using iwCLL Guidelines
NCT02005471 (30) [back to overview]	Percentage of Participants With Overall Response of CR, Cri, nPR, or PR at End of Combination Treatment Visit as Assessed by the Investigator Using iwCLL Guidelines
NCT02005471 (30) [back to overview]	Percentage of Participants With MRD Negativity in Bone Marrow
NCT02005471 (30) [back to overview]	Percentage of Participants With Minimal Residual Disease (MRD) Negativity in Peripheral Blood
NCT02005471 (30) [back to overview]	Percentage of Participants With Best Overall Response of CR, CRi, nPR, or PR as Assessed by the IRC Using iwCLL Guidelines
NCT02005471 (30) [back to overview]	Duration of Responses (DOR) as Assessed by the Investigator Using iwCLL Guidelines
NCT02005471 (30) [back to overview]	Percentage of Participants Who Died
NCT02005471 (30) [back to overview]	Overall Survival (OS)
NCT02005471 (30) [back to overview]	Event-Free Survival (EFS) as Assessed by the Investigator Using iwCLL Guidelines
NCT02005471 (30) [back to overview]	Percentage of Participants With PD or Death Among Participants With Best Overall Response of CR, CRi, nPR, or PR as Assessed by the Investigator Using iwCLL Guidelines
NCT02005471 (30) [back to overview]	Time to New Anti-CLL Treatment (TTNT) as Assessed by the Investigator
NCT02005471 (30) [back to overview]	Plasma Venetoclax Concentrations
NCT02005471 (30) [back to overview]	Percentage of Participants With Best Overall Response of Complete Response (CR), CR With Incomplete Bone Marrow Recovery (CRi), Nodular Partial Response (nPR), or Partial Response (PR) as Assessed by the Investigator Using iwCLL Guidelines
NCT02005471 (30) [back to overview]	Number of Participants With Grade 3 or Higher Tumor Lysis Syndrome (TLS) and Infusion-related Reactions (IRRs)
NCT02005471 (30) [back to overview]	Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT02005471 (30) [back to overview]	Change From Baseline in Monroe Dunaway (MD) Anderson Symptom Inventory (MDASI) Core Symptom Severity, Module Symptom Severity, and Interference Scores
NCT02005471 (30) [back to overview]	Change From Baseline in HRQoL as Measured by Quality of Life Questionnaire Associated CLL Module (QLQ-CLL16) Multi-Item Scales Score
NCT02005471 (30) [back to overview]	Change From Baseline in HRQoL as Measured by Quality of Life Questionnaire Associated CLL Module (QLQ-CLL16) Multi-Item Scales Score
NCT02005471 (30) [back to overview]	Change From Baseline in HRQoL as Measured by European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) Functional Scales Score and Global Health Status/Global Quality-of-Life (QoL) Scale Score
NCT02005471 (30) [back to overview]	Change From Baseline in HRQoL as Measured by European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) Functional Scales Score and Global Health Status/Global Quality-of-Life (QoL) Scale Score
NCT02005471 (30) [back to overview]	Progression-Free Survival (PFS) as Assessed by the Investigator Using Standard iwCLL Guidelines
NCT02005471 (30) [back to overview]	PFS as Assessed by the IRC Using Standard iwCLL Guidelines in Participants With 17p Deletion as Identified by FISH Test
NCT02005471 (30) [back to overview]	PFS as Assessed by the IRC Using Standard iwCLL Guidelines
NCT02005471 (30) [back to overview]	PFS as Assessed by the Investigator Using Standard iwCLL Guidelines in Participants With 17p Deletion as Identified by FISH Test
NCT02005471 (30) [back to overview]	Percentage of Participants With Start of New Anti-CLL Treatment or Death as Assessed by the Investigator
NCT02005471 (30) [back to overview]	Percentage of Participants With PD/Relapse, Start of a New Anti-Chronic Lymphocytic Leukemia (CLL) Therapy, or Death as Assessed by the Investigator Using iwCLL Guidelines
NCT02005471 (30) [back to overview]	Percentage of Participants With PD or Death as Assessed by the IRC Using Standard iwCLL Guidelines in Participants With 17p Deletion as Identified by FISH Test
NCT02059239 (8) [back to overview]	Number of Patients Achieving Neutrophil Engraftment
NCT02059239 (8) [back to overview]	Number of Patients Achieving Platelet Engraftment
NCT02059239 (8) [back to overview]	Progression-Free Survival After Stem Cell Transplant
NCT02059239 (8) [back to overview]	Transplant-Related Mortality
NCT02059239 (8) [back to overview]	Disease Response 30 Days Post-Transplant
NCT02059239 (8) [back to overview]	Overall Survival at Day 365 Post-Transplant
NCT02059239 (8) [back to overview]	Disease Response at 1 Year Post-Transplant
NCT02059239 (8) [back to overview]	Disease Response Following Salvage Chemotherapy
NCT02071225 (15) [back to overview]	Percentage of Participants With Infusion-related Reactions (IRRs)
NCT02071225 (15) [back to overview]	Percentage of Participants With Previous/Concomitant Diseases
NCT02071225 (15) [back to overview]	Progression Free Survival (PFS)
NCT02071225 (15) [back to overview]	Best Response Rate as Assessed by the Investigator Using the IWCLL 2008 Criteria
NCT02071225 (15) [back to overview]	Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT02071225 (15) [back to overview]	Percentage of Participants With Minimal Residual Disease (MRD) Negativity
NCT02071225 (15) [back to overview]	Time to Re-treatment/New Anti-leukemia Therapy
NCT02071225 (15) [back to overview]	Disease Free Survival (DFS)
NCT02071225 (15) [back to overview]	Overall Response Rate (ORR) as Assessed by the Investigator Using the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 Criteria
NCT02071225 (15) [back to overview]	Duration of Response (DR)
NCT02071225 (15) [back to overview]	Percentage of Participants With AEs of Special Interest (AESIs)
NCT02071225 (15) [back to overview]	Percentage of Participants With Concomitant Medication
NCT02071225 (15) [back to overview]	Overall Survival (OS)
NCT02071225 (15) [back to overview]	Percentage of Participants Who Discontinued Treatment Prematurely
NCT02071225 (15) [back to overview]	Event Free Survival (EFS)
NCT02187861 (22) [back to overview]	Percentage of Participants With CMR According to Investigator as Per Lugano Classification, Using PET Scan at Year 1
NCT02187861 (22) [back to overview]	Percentage of Participants With CMR According to IRC as Per Lugano Classification, Using PET Scan at Year 1
NCT02187861 (22) [back to overview]	Percentage of Participants With Complete Metabolic Response (CMR) According to Independent Review Committee (IRC) as Per Lugano Classification, Using Positron Emission Tomography (PET) Scan at Primary Response Assessment (PRA)
NCT02187861 (22) [back to overview]	Percentage of Participants With Disease Progression (According to Investigator as Per Lugano Classification, Using PET or CT Scan) or Death
NCT02187861 (22) [back to overview]	Percentage of Participants With Disease Progression (According to Investigator as Per Lugano Classification, Using PET or CT Scan), Death, or Start of a New Anti-lymphoma Therapy
NCT02187861 (22) [back to overview]	Percentage of Participants With OR According to Investigator as Per Lugano Classification, Using PET or CT Scan
NCT02187861 (22) [back to overview]	Progression-Free Survival (PFS) According to Investigator as Per Lugano Classification, Using PET or CT Scan
NCT02187861 (22) [back to overview]	Percentage of Participants With Complete Response (CR) According to IRC as Per Lugano Classification, Using Computed Tomography (CT) Scan
NCT02187861 (22) [back to overview]	Percentage of Participants With CR According to Investigator as Per Lugano Classification, Using CT Scan
NCT02187861 (22) [back to overview]	Percentage of Participants With Objective Response (OR) According to IRC as Per Lugano Classification, Using PET Scan
NCT02187861 (22) [back to overview]	Percentage of Participants With OR According to Investigator as Per Lugano Classification, Using CT Scan
NCT02187861 (22) [back to overview]	Percentage of Participants With OR According to Investigator as Per Lugano Classification, Using PET Scan
NCT02187861 (22) [back to overview]	Percentage of Participants With OR According to IRC as Per Lugano Classification, Using CT Scan
NCT02187861 (22) [back to overview]	Time to Maximum Plasma Concentration (Tmax) of Venetoclax
NCT02187861 (22) [back to overview]	Area Under the Plasma Concentration-Time Curve From Time 0 to 8 Hours Post Dose (AUC0-8h) of Venetoclax
NCT02187861 (22) [back to overview]	Area Under the Plasma Concentration-Time Curve From Time 0 to Last Observed Concentration (AUClast) of Venetoclax
NCT02187861 (22) [back to overview]	Duration of Response (DOR) According to Investigator as Per Lugano Classification, Using PET or CT Scan
NCT02187861 (22) [back to overview]	Event-Free Survival (EFS) According to Investigator as Per Lugano Classification, Using PET or CT Scan
NCT02187861 (22) [back to overview]	Maximum Plasma Concentration (Cmax) of Venetoclax
NCT02187861 (22) [back to overview]	Overall Survival (OS)
NCT02187861 (22) [back to overview]	Percentage of Participants Who Died Due to Any Cause
NCT02187861 (22) [back to overview]	Percentage of Participants With CMR According to Investigator as Per Lugano Classification, Using PET Scan at PRA
NCT02224729 (5) [back to overview]	Incidence of Grade 3-4 Adverse Events From the Combination of Bendamustine Hydrochloride, Bortezomib, and Dexamethasone Based on the Common Terminology Criteria Version 4.0
NCT02224729 (5) [back to overview]	Count of Participants That Experience Overall Response Following 4 Cycles of the Combination Regimen BBd
NCT02224729 (5) [back to overview]	Count of Participants That Experience Overall Survival (OS)
NCT02224729 (5) [back to overview]	Count of Participants That Experience Progression-free Survival (PFS)
NCT02224729 (5) [back to overview]	Count of Participants That Experience Very Good Partial Remission (VGPR)
NCT02257242 (3) [back to overview]	Number of Participants Who Completed Six Cycles of Study Treatment
NCT02257242 (3) [back to overview]	Maximum Tolerated Dose
NCT02257242 (3) [back to overview]	Complete Response Rate
NCT02257567 (96) [back to overview]	Phase Ib: Vss of Polatuzumab Vedotin, Bendamustine, and Obinutuzumab in Cohort 1b
NCT02257567 (96) [back to overview]	Phase II: Vss of Polatuzumab Vedotin, Bendamustine and Rituximab in Arms A and C
NCT02257567 (96) [back to overview]	Phase II: Vss of Polatuzumab Vedotin, Bendamustine and Obinutuzumab in Arms E and F
NCT02257567 (96) [back to overview]	Phase II: Vss of Bendamustine and Rituximab in Arms B and D
NCT02257567 (96) [back to overview]	Phase II: Cmax of Polatuzumab Vedotin, Obinutuzumab and Bendamustine in Arms E and F
NCT02257567 (96) [back to overview]	Phase II: Cmax of Polatuzumab Vedotin, Bendamustine, and Rituximab in Arms A and C
NCT02257567 (96) [back to overview]	Phase II: Cmax of Bendamustine and Rituximab in Arms B and D
NCT02257567 (96) [back to overview]	Phase II: CL of Polatuzumab Vedotin, Bendamustine and Rituximab in Arms A and C
NCT02257567 (96) [back to overview]	Phase II: CL of Polatuzumab Vedotin, Bendamustine and Obinutuzumab in Arms E and F
NCT02257567 (96) [back to overview]	Phase II: CL of Bendamustine and Rituximab in Arms B and D
NCT02257567 (96) [back to overview]	Phase II: AUCinf of Polatuzumab Vedotin, Bendamustine, and Rituximab in Arms A and C
NCT02257567 (96) [back to overview]	Phase II: AUCinf of Polatuzumab Vedotin, Bendamustine, and Obinutuzumab in Arms E and F
NCT02257567 (96) [back to overview]	Phase II: AUCinf of Bendamustine and Rituximab in Arms B and D
NCT02257567 (96) [back to overview]	Plasma Concentration of Bendamustine
NCT02257567 (96) [back to overview]	Plasma Concentration of of Polatuzumab Vedotin Analyte: acMMAE
NCT02257567 (96) [back to overview]	Plasma Concentration of of Polatuzumab Vedotin Analyte: acMMAE
NCT02257567 (96) [back to overview]	Plasma Concentration of of Polatuzumab Vedotin Analyte: acMMAE
NCT02257567 (96) [back to overview]	Plasma Concentration of of Polatuzumab Vedotin Analyte: acMMAE
NCT02257567 (96) [back to overview]	Plasma Concentration of of Polatuzumab Vedotin Analyte: acMMAE
NCT02257567 (96) [back to overview]	Phase II: Percentage of Participants With OR at PRA Based on CT Only as Determined by Investigator
NCT02257567 (96) [back to overview]	Arm H (Phase II NF Cohort): Percentage of Participants With CR at PRA Based on PET-CT as Determined by the IRC
NCT02257567 (96) [back to overview]	Arm G+H (Phase II NF Cohort): Percentage of Participants With AEs
NCT02257567 (96) [back to overview]	Arm G (Phase II NF Cohort): Percentage of Participants With OR at PRA Based on CT Only as Determined by IRC
NCT02257567 (96) [back to overview]	Arm G (Phase II NF Cohort): Percentage of Participants With OR at PRA Based on CT Only as Determined by Investigator
NCT02257567 (96) [back to overview]	Arm G (Phase II NF Cohort): Percentage of Participants With CR at PRA Based on PET-CT as Determined by the IRC
NCT02257567 (96) [back to overview]	Arm G (Phase II NF Cohort): Percentage of Participants With CR at PRA Based on CT Only as Determined by IRC
NCT02257567 (96) [back to overview]	Arm G (Phase II NF Cohort): Percentage of Participants With CR at PRA Based on CT Only as Determined by Investigator
NCT02257567 (96) [back to overview]	Plasma Concentration of of Polatuzumab Vedotin Analyte: acMMAE
NCT02257567 (96) [back to overview]	Plasma Concentration of Polatuzumab Vedotin Analyte: Unconjugated MMAE
NCT02257567 (96) [back to overview]	Plasma Concentration of Polatuzumab Vedotin Analyte: Unconjugated MMAE
NCT02257567 (96) [back to overview]	Plasma Concentration of Polatuzumab Vedotin Analyte: Unconjugated MMAE
NCT02257567 (96) [back to overview]	Serum Concentration of Obinutuzumab
NCT02257567 (96) [back to overview]	Plasma Concentration of Polatuzumab Vedotin Analyte: Unconjugated MMAE
NCT02257567 (96) [back to overview]	Plasma Concentration of Polatuzumab Vedotin Analyte: Unconjugated MMAE
NCT02257567 (96) [back to overview]	Plasma Concentration of Polatuzumab Vedotin Analyte: Unconjugated MMAE
NCT02257567 (96) [back to overview]	Serum Concentration of Obinutuzumab
NCT02257567 (96) [back to overview]	Serum Concentration of Obinutuzumab
NCT02257567 (96) [back to overview]	Serum Concentration of Obinutuzumab
NCT02257567 (96) [back to overview]	Phase Ib: Vss of Polatuzumab Vedotin, Bendamustine, and Obinutuzumab in Cohort 1a
NCT02257567 (96) [back to overview]	Phase Ib: Cmax of Polatuzumab Vedotin, Bendamustine, and Rituximab in Cohort 1a
NCT02257567 (96) [back to overview]	Phase Ib: Cmax of Polatuzumab Vedotin, Bendamustine, and Obinutuzumab in Cohort 1b
NCT02257567 (96) [back to overview]	Phase Ib: CL of Polatuzumab Vedotin, Bendamustine, and Rituximab in Cohort 1a
NCT02257567 (96) [back to overview]	Phase Ib: CL of Polatuzumab Vedotin, Bendamustine, and Obinutuzumab in Cohort 1b
NCT02257567 (96) [back to overview]	Serum Concentration of of Polatuzumab Vedotin Analyte: Total Ab
NCT02257567 (96) [back to overview]	Serum Concentration of of Polatuzumab Vedotin Analyte: Total Ab
NCT02257567 (96) [back to overview]	Serum Concentration of of Polatuzumab Vedotin Analyte: Total Ab
NCT02257567 (96) [back to overview]	Serum Concentration of of Polatuzumab Vedotin Analyte: Total Ab
NCT02257567 (96) [back to overview]	Serum Concentration of of Polatuzumab Vedotin Analyte: Total Ab
NCT02257567 (96) [back to overview]	Serum Concentration of of Polatuzumab Vedotin Analyte: Total Ab
NCT02257567 (96) [back to overview]	Serum Concentration of Rituximab
NCT02257567 (96) [back to overview]	Serum Concentration of Rituximab
NCT02257567 (96) [back to overview]	Serum Concentration of Rituximab
NCT02257567 (96) [back to overview]	Symptom Severity and Interference According to Therapy-Induced Neuropathy Assessment Score (TINAS) in Arms A-F
NCT02257567 (96) [back to overview]	Symptom Severity and Interference According to Therapy-Induced Neuropathy Assessment Score (TINAS) in Arms A-F
NCT02257567 (96) [back to overview]	Symptom Severity and Interference According to Therapy-Induced Neuropathy Assessment Score (TINAS) in Arms A-F
NCT02257567 (96) [back to overview]	Symptom Severity and Interference According to Therapy-Induced Neuropathy Assessment Score (TINAS) in Arms A-F
NCT02257567 (96) [back to overview]	Phase Ib: AUCinf of Polatuzumab Vedotin, Bendamustine, and Obinutuzumab in Cohort 1b
NCT02257567 (96) [back to overview]	Phase Ib: AUC From Time Zero to Infinity (AUCinf) of Polatuzumab Vedotin, Bendamustine, and Rituximab in Cohort 1a
NCT02257567 (96) [back to overview]	Cohort 1b (Phase Ib): Percentage of Participants With Treatment Emergent ADAs to Polatuzumab Vedotin and Obinutuzumab
NCT02257567 (96) [back to overview]	Cohort 1a (Phase Ib): Percentage of Participants With Treatment Emergent Anti-Drug Antibodies (ADAs) to Polatuzumab Vedotin
NCT02257567 (96) [back to overview]	Arms G+H: (Phase II NF Cohorts): Percentage of Participants With Treatment Emergent ADAs to Polatuzumab Vedotin (Lyophilized)
NCT02257567 (96) [back to overview]	Arms E and F (Phase II): Percentage of Participants With Treatment Emergent ADAs to Polatuzumab Vedotin and Obinutuzumab
NCT02257567 (96) [back to overview]	Arms A and C (Phase II): Percentage of Participants With Treatment Emergent ADAs to Polatuzumab Vedotin
NCT02257567 (96) [back to overview]	Arm G+H (Phase II NF Cohorts): Plasma Concentration of Polatuzumab Vedotin Analyte: Unconjugated MMAE
NCT02257567 (96) [back to overview]	Arm G+H (Phase II NF Cohorts): Plasma Concentration of Polatuzumab Vedotin Analyte: Total Ab
NCT02257567 (96) [back to overview]	Arm G+H (Phase II NF Cohorts): Plasma Concentration of of Polatuzumab Vedotin Analyte: acMMAE
NCT02257567 (96) [back to overview]	Arm G (Phase II NF Cohort): Maximum Concentration (Cmax) of Polatuzumab Vedotin (Lyophilized)
NCT02257567 (96) [back to overview]	Arm G (Phase II NF Cohort): Area Under Concentration-Time Curve (AUC) of Polatuzumab Vedotin (Lyophilized)
NCT02257567 (96) [back to overview]	Phase II: Percentage of Participants With OR at PRA Based on PET-CT as Determined by IRC
NCT02257567 (96) [back to overview]	Phase II: Percentage of Participants With OR at PRA Based on CT Only as Determined by IRC
NCT02257567 (96) [back to overview]	Symptom Severity and Interference According to Therapy-Induced Neuropathy Assessment Score (TINAS) in Arms A-F
NCT02257567 (96) [back to overview]	Phase II: Percentage of Participants With Objective Response (OR) at PRA Based on PET-CT as Determined by Investigator
NCT02257567 (96) [back to overview]	Phase II: Percentage of Participants With CR at PRA Based on PET-CT as Determined by the Investigator
NCT02257567 (96) [back to overview]	Phase II: Percentage of Participants With CR at PRA Based on CT Only as Determined by IRC
NCT02257567 (96) [back to overview]	Phase II: Percentage of Participants With CR at PRA Based on CT Only as Determined by Investigator
NCT02257567 (96) [back to overview]	Phase II: Percentage of Participants With Best Objective Response (BOR) Based on PET-CT or CT Only as Determined by the Investigator
NCT02257567 (96) [back to overview]	Phase II: Percentage of Participants With AEs
NCT02257567 (96) [back to overview]	Phase II Randomized and NF Cohorts: Percentage of Participants With Complete Response (CR) at Primary Response Assessment (PRA) Based on Positron Emission Tomography (PET)-Computed Tomography (CT) Scan as Determined by Independent Review Committee (IRC)
NCT02257567 (96) [back to overview]	Phase II NF Cohorts: Percentage of Participants With BOR Based on PET-CT or CT Only as Determined by the IRC
NCT02257567 (96) [back to overview]	Phase II NF Cohorts: Percentage of Participants With BOR Based on PET-CT or CT Only as Determined by the Investigator
NCT02257567 (96) [back to overview]	Phase II NF Cohorts: Overall Survival (OS)
NCT02257567 (96) [back to overview]	Phase II NF Cohort: PFS Based on PET-CT or CT Only as Determined by the IRC
NCT02257567 (96) [back to overview]	Phase II NF Cohort: PFS Based on PET-CT or CT Only as Determined by the Investigator
NCT02257567 (96) [back to overview]	Phase II NF Cohort: Percentage of Participants With OR at PRA Based on PET-CT as Determined by IRC
NCT02257567 (96) [back to overview]	Phase II NF Cohort: Percentage of Participants With OR at PRA Based on PET-CT as Determined by Investigator
NCT02257567 (96) [back to overview]	Phase II NF Cohort: Percentage of Participants With CR at PRA Based on PET-CT as Determined by the Investigator
NCT02257567 (96) [back to overview]	Phase II NF Cohort: Event-Free Survival (EFS) Based on PET-CT or CT Only, as Determined by the Investigator
NCT02257567 (96) [back to overview]	Phase II NF Cohort: DOR Based on PET-CT or CT Only as Determined by the IRC
NCT02257567 (96) [back to overview]	Phase II NF Cohort: DOR Based on PET-CT or CT Only as Determined by the Investigator
NCT02257567 (96) [back to overview]	Phase II Expansion Cohorts and Arm G (Phase II NF Cohort): Percentage of Participants With CR at PRA Based on PET-CT as Determined by the IRC
NCT02257567 (96) [back to overview]	Phase Ib: Percentage of Participants With Adverse Events (AEs)
NCT02257567 (96) [back to overview]	DLBCL Cohorts: Progression Free Survival (PFS) Based on PET-CT or CT Only as Determined by the Investigator
NCT02257567 (96) [back to overview]	DLBCL Cohorts: PFS Based on PET-CT or CT Only as Determined by the IRC
NCT02257567 (96) [back to overview]	DLBCL Cohorts: Percentage of Participants With BOR Based PET-CT or CT Only as Determined by IRC
NCT02257567 (96) [back to overview]	DLBCL Cohorts: Duration of Response (DOR) Based on PET-CT or CT Only as Determined by the Investigator
NCT02257567 (96) [back to overview]	DLBCL Cohorts: DOR Based on PET-CT or CT Only as Determined by the IRC
NCT02320487 (15) [back to overview]	Change From Baseline in the EORTC Quality of Life Questionnaire-Chronic Lymphocytic Leukemia 16 (QLQ-CLL16) Score
NCT02320487 (15) [back to overview]	Time to MRD-Negative Status in Peripheral Blood
NCT02320487 (15) [back to overview]	Progression-Free Survival (PFS), as Determined by the Investigator Using iwCLL NCI-WG Guidelines
NCT02320487 (15) [back to overview]	Percentage of Participants With Objective Response of CR or Partial Response (PR) at the End of Induction Therapy, as Determined by the Investigator Using iwCLL NCI-WG Guidelines
NCT02320487 (15) [back to overview]	Percentage of Participants With Complete Response (CR), as Determined by the Investigator Using International Workshop on Chronic Lymphocytic Leukemia National Cancer Institute-Working Group (iwCLL NCI-WG) Guidelines
NCT02320487 (15) [back to overview]	Percentage of Participants With Adverse Events (AEs)
NCT02320487 (15) [back to overview]	Overall Survival (OS)
NCT02320487 (15) [back to overview]	Percentage of Participants Who Achieved MRD-Negative Status in Peripheral Blood at Any Time During the Study
NCT02320487 (15) [back to overview]	Number of Hospitalizations Due to Adverse Events (AEs)
NCT02320487 (15) [back to overview]	Minimum Observed Concentration (Ctrough) of Obinutuzumab After Cycle 2
NCT02320487 (15) [back to overview]	Percentage of Participants Who Achieved Minimal Residual Disease (MRD)-Negative Status in Bone Marrow at Any Time During the Study
NCT02320487 (15) [back to overview]	Duration of Response Among Participants With Objective Response of CR or PR, as Determined by the Investigator Using iwCLL NCI-WG Guidelines
NCT02320487 (15) [back to overview]	Duration of MRD-Negativity in Peripheral Blood Among Participants Who Achieved MRD-Negative Status
NCT02320487 (15) [back to overview]	Ctrough of Obinutuzumab After Cycle 4
NCT02320487 (15) [back to overview]	Change From Baseline in the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score
NCT02420210 (1) [back to overview]	ORR (PR + CR) Using the Cheson et al Parameters
NCT02424851 (5) [back to overview]	Renal Response After Two Cycles of Trial Treatment
NCT02424851 (5) [back to overview]	Quality of Life Measured by the EQ-5D-3L Questionnaire at Baseline and 1 Month Follow up
NCT02424851 (5) [back to overview]	Haematological and Non-haematological Toxicity in Both Treatment Arms
NCT02424851 (5) [back to overview]	Overall Survival
NCT02424851 (5) [back to overview]	Number of Participants With >50% Reduction From Baseline in Serum Free Light Chain
NCT02477215 (7) [back to overview]	Objective Response Rate
NCT02477215 (7) [back to overview]	Number of Participants Experiencing Dose-Limiting Toxicity (DLT)
NCT02477215 (7) [back to overview]	Maximum Tolerated Dose of Bendamustine
NCT02477215 (7) [back to overview]	Duration of Response (DoR)
NCT02477215 (7) [back to overview]	Cumulative Response Rates in Patients After Eight Cycles.
NCT02477215 (7) [back to overview]	Overall Survival (OS)
NCT02477215 (7) [back to overview]	Progression Free Survival (PFS)
NCT02594163 (6) [back to overview]	Number and Severity of Adverse Events (AEs)
NCT02594163 (6) [back to overview]	Progression-free Survival (PFS)
NCT02594163 (6) [back to overview]	Overall Survival (OS)
NCT02594163 (6) [back to overview]	Objective Response Rate (ORR)
NCT02594163 (6) [back to overview]	Duration of Response (DOR)
NCT02594163 (6) [back to overview]	Complete Remission (CR) Rate
NCT02596971 (18) [back to overview]	Percentage of Participants With Complete Response (CR) at End of Induction (EOI), as Determined by the Independent Review Committee (IRC) Using Modified Lugano 2014 Criteria
NCT02596971 (18) [back to overview]	Percentage of Participants With Objective Response (CR or PR) at EOI, as Determined by the Investigator Using Modified Cheson 2007 Criteria
NCT02596971 (18) [back to overview]	Percentage of Participants With Objective Response (CR or PR) at EOI, as Determined by the Investigator Using Lugano 2014 Criteria
NCT02596971 (18) [back to overview]	Percentage of Participants With CR at EOI, as Determined by the IRC Using Modified Cheson 2007 Criteria
NCT02596971 (18) [back to overview]	Percentage of Participants With Objective Response (CR or PR) at EOI, as Determined by the IRC Using Modified Cheson 2007 Criteria
NCT02596971 (18) [back to overview]	Observed Serum Atezolizumab Concentration
NCT02596971 (18) [back to overview]	Percentage of Participants With CR at EOI, as Determined by the Investigator Using Modified Cheson 2007 Criteria
NCT02596971 (18) [back to overview]	Percentage of Participants With CR at EOI, as Determined by the Investigator Using Lugano 2014 Criteria
NCT02596971 (18) [back to overview]	Percentage of Participants With Objective Response (CR or PR) at EOI, as Determined by the IRC Using Lugano 2014 Criteria
NCT02596971 (18) [back to overview]	Percentage of Participants With Human Anti-Human Antibodies (HAHAs) to Obinutuzumab
NCT02596971 (18) [back to overview]	Observed Serum Atezolizumab Concentration
NCT02596971 (18) [back to overview]	Percentage of Participants With Adverse Events
NCT02596971 (18) [back to overview]	Percentage of Participants With Human Anti-Chimeric Antibodies (HACAs) to Rituximab
NCT02596971 (18) [back to overview]	Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) to Atezolizumab
NCT02596971 (18) [back to overview]	Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) to Atezolizumab
NCT02596971 (18) [back to overview]	Observed Serum Rituximab Concentration
NCT02596971 (18) [back to overview]	Observed Serum Obinutuzumab Concentration
NCT02596971 (18) [back to overview]	Percentage of Participants With Best Response of CR or PR During Study, as Determined by Investigator Using Modified Cheson 2007 Criteria
NCT02733042 (21) [back to overview]	Kaplan-Meier Estimate of Progression-free Survival (PFS)
NCT02733042 (21) [back to overview]	Maximum Observed Plasma Concentration (Cmax) of Durvalumab
NCT02733042 (21) [back to overview]	Overall Response Rate (ORR) During Durvalumab Treatment
NCT02733042 (21) [back to overview]	Overall Response Rate During the Entire Study
NCT02733042 (21) [back to overview]	Part 1: Number of Participants With Dose Limiting Toxicities (DLTs)
NCT02733042 (21) [back to overview]	Terminal Elimination Phase Half-Life (t½) of Durvalumab
NCT02733042 (21) [back to overview]	Time to First Response
NCT02733042 (21) [back to overview]	Time to Maximum Plasma Concentration (Tmax) of Durvalumab
NCT02733042 (21) [back to overview]	Volume of Distribution (Vz) of Durvalumab
NCT02733042 (21) [back to overview]	Maximum Observed Plasma Concentration (Cmax) of Lenalidomide
NCT02733042 (21) [back to overview]	Number of Participants With Treatment-emergent Adverse Events
NCT02733042 (21) [back to overview]	Number of Participants With Treatment-emergent Adverse Events (TEAEs) - Extended Collection
NCT02733042 (21) [back to overview]	Time to Maximum Observed Plasma Concentration (Tmax) of Ibrutinib
NCT02733042 (21) [back to overview]	Time to Maximum Observed Plasma Concentration (Tmax) of Lenalidomide
NCT02733042 (21) [back to overview]	Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUCinf) of Durvalumab
NCT02733042 (21) [back to overview]	Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUClast) of Durvalumab
NCT02733042 (21) [back to overview]	Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUClast) of Ibrutinib
NCT02733042 (21) [back to overview]	Maximum Observed Plasma Concentration (Cmax) of Ibrutinib
NCT02733042 (21) [back to overview]	Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUClast) of Lenalidomide
NCT02733042 (21) [back to overview]	Clearance (CL) of Durvalumab
NCT02733042 (21) [back to overview]	Kaplan-Meier Estimate of Duration of Response
NCT02853370 (8) [back to overview]	3-years Overall Survival Rate
NCT02853370 (8) [back to overview]	3-year Progression Free Survival (PFS)
NCT02853370 (8) [back to overview]	3-years Duration of Response (DOR)
NCT02853370 (8) [back to overview]	3-years Event Free Survival (EFS)
NCT02853370 (8) [back to overview]	5 Years Overall Survival (OS)
NCT02853370 (8) [back to overview]	Complete Response Rate (CRR)
NCT02853370 (8) [back to overview]	Overall Response Rate (ORR)
NCT02853370 (8) [back to overview]	5 Years Progression Free Survival (PFS) -
NCT02951156 (18) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Greater Than or Equal to (>=) Grade 3, As Per National Cancer Institute Common Terminology Criteria For Adverse Events (NCI-CTCAE), Version 4.03
NCT02951156 (18) [back to overview]	Number of Participants With Minimal Residual Disease Burden (MRD) Positive, Negative and Not Evaluable (NE) Status
NCT02951156 (18) [back to overview]	Number of Participants With Electrocardiogram (ECG) Abnormalities
NCT02951156 (18) [back to overview]	Overall Survival
NCT02951156 (18) [back to overview]	Progression-Free Survival (PFS) as Assessed by the Investigator Per Lugano Response Classification Criteria
NCT02951156 (18) [back to overview]	Time to Tumor Response (TTR) as Assessed by Investigator Per Lugano Response Classification Criteria
NCT02951156 (18) [back to overview]	Concentration Verses Time Summary of Avelumab
NCT02951156 (18) [back to overview]	Concentration Verses Time Summary of Avelumab
NCT02951156 (18) [back to overview]	Number of Participants With Anti-Drug Antibodies (ADA) Against Avelumab by Never and Ever Positive Status
NCT02951156 (18) [back to overview]	Number of Participants With Anti-Drug Antibodies (ADA) Against Rituximab by Never and Ever Positive Status
NCT02951156 (18) [back to overview]	Objective Response Rate (ORR) as Assessed by Investigator Per Lugano Response Classification Criteria
NCT02951156 (18) [back to overview]	Number of Participants With Anti-Drug Antibodies (ADA) Against Utomilumab by Never and Ever Positive Status
NCT02951156 (18) [back to overview]	Number of Participants With Dose Limiting Toxicities (DLT)
NCT02951156 (18) [back to overview]	Duration of Response (DOR) as Assessed by Investigator Per Lugano Response Classification Criteria
NCT02951156 (18) [back to overview]	Disease Control Rate as Assessed by the Investigator Per Lugano Response Classification Criteria
NCT02951156 (18) [back to overview]	Number of Participants With Laboratory Abnormalities As Per National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI-CTCAE), Version 4.03
NCT02951156 (18) [back to overview]	Programmed Death Receptor-1 Ligand-1 (PD-L1) Biomarker Expression in Tumor and Immune Cells as Assessed by Immunohistochemistry (IHC) at Baseline
NCT02951156 (18) [back to overview]	Number of Participants With Neutralizing Antibodies (nAb) Against Utomilumab by Never and Ever Positive Status
NCT02954406 (8) [back to overview]	Cmax: Maximum Observed Plasma Concentration for TAK-659
NCT02954406 (8) [back to overview]	AUCtau: Area Under the Plasma Concentration-time Curve During Dosing Interval
NCT02954406 (8) [back to overview]	Time to Progression (TTP)
NCT02954406 (8) [back to overview]	Duration of Response (DOR)
NCT02954406 (8) [back to overview]	Dose Escalation Phase: Recommended Phase 2 Dose (RP2D) of TAK-659
NCT02954406 (8) [back to overview]	Tmax: Time to Reach the Maximum Plasma Concentration for TAK-659
NCT02954406 (8) [back to overview]	Dose Escalation Phase: Maximum Tolerated Dose (MTD) of TAK-659
NCT02954406 (8) [back to overview]	Overall Response Rate (ORR)
NCT02970318 (8) [back to overview]	Duration of Response (DOR) Per Investigator Assessment Based on 03 September 2021 Data Cutoff
NCT02970318 (8) [back to overview]	Time to Next Treatment (TTNT) Based on 03 September 2021 Data Cutoff
NCT02970318 (8) [back to overview]	Duration of Response (DOR) Per Independent Review Committee (IRC) Assessment Based on 15 January 2019 Data Cutoff From Interim Analysis.
NCT02970318 (8) [back to overview]	Progression-free Survival (PFS) Per Investigator Assessment
NCT02970318 (8) [back to overview]	Progression-free Survival (PFS) Per Independent Review Committee (IRC) Assessment
NCT02970318 (8) [back to overview]	Overall Survival (OS)
NCT02970318 (8) [back to overview]	IRC-assessed Overall Response Rate (ORR) Per IWCLL 2008 Criteria Based on Data Cutoff 15 January 2019 From Interim Analysis
NCT02970318 (8) [back to overview]	Investigator Assessed Overall Response Rate (ORR) Per IWCLL 2008 Criteria Based on Data Cutoff 03 September 2021
NCT03336333 (1) [back to overview]	Cohort 1: Progression-free Survival (PFS) as Determined by Independent Central Review (ICR)
NCT03406156 (8) [back to overview]	Time to Progression (TTP)
NCT03406156 (8) [back to overview]	Duration of Response (DoR)
NCT03406156 (8) [back to overview]	Overall Response Rate (ORR)
NCT03406156 (8) [back to overview]	Overall Survival (OS)
NCT03406156 (8) [back to overview]	Progression-Free Survival (PFS)
NCT03406156 (8) [back to overview]	Percentage of Participants Achieving Low Tumor Burden Status With Induction of Obinutuzumab or Obinutuzumab Plus Bendamustine (Debulking Period)
NCT03406156 (8) [back to overview]	Undetectable Minimal Residual Disease (UMRD) Rate
NCT03406156 (8) [back to overview]	Complete Response Rate
NCT03623373 (4) [back to overview]	Overall Response Rate (ORR = Complete Response (CR) + Partial Response (PR)) of Subjects
NCT03623373 (4) [back to overview]	Pre-transplant Complete Response Rate
NCT03623373 (4) [back to overview]	Stem Cell Mobilization Success Rate With Cytarabine and Rituximab
NCT03623373 (4) [back to overview]	Safety and Tolerability of Regimen in Subjects With MCL as Measured by Treatment Related Non-hematologic Toxicity of Grade 3 or Higher
NCT03817853 (8) [back to overview]	Objective Response Rate (ORR) at the End of Induction (EOI) Therapy
NCT03817853 (8) [back to overview]	Percentage of IRRs Regardless of Grade by Cycle
NCT03817853 (8) [back to overview]	Type of Grade >=3 IRRs Associated With the Obinutuzumab Administered as an SDI by Cycle
NCT03817853 (8) [back to overview]	Duration (In Minutes) of Obinutuzumab Administration by Cycle
NCT03817853 (8) [back to overview]	Duration of Grade >=3 IRRs Associated With the Obinutuzumab Administered as an SDI by Cycle
NCT03817853 (8) [back to overview]	Percentage of Grade >=3 Infusion-Related Reactions (IRRs) During Cycle 2 in Patients Who Had Previously Received Obinutuzumab at the Standard Infusion Rate During Cycle 1 Without Experiencing a Grade 3 or 4 IRR
NCT03817853 (8) [back to overview]	Percentage of Participants With Adverse Events (AEs)
NCT03817853 (8) [back to overview]	Time to IRR From Infusion to Onset of the IRR During Cycle 2
NCT04236141 (21) [back to overview]	Number of Participants With Positive Treatment Emergent Anti-Drug Antibodies (ADA) to Polatuzumab Vedotin
NCT04236141 (21) [back to overview]	Overall Survival (OS)
NCT04236141 (21) [back to overview]	Percentage of Participants With Adverse Events (AEs)
NCT04236141 (21) [back to overview]	Percentage of Participants With Best Overall Response (BOR) Based on PET-CT or CT Only as Assessed by Investigator
NCT04236141 (21) [back to overview]	Percentage of Participants With Complete Response (CR) at the End of Treatment (EOT) Assessment Based on Positron Emission Tomography-Computed Tomography (PET-CT) Assessed by Independent Review Committee (IRC)
NCT04236141 (21) [back to overview]	Plasma Concentration of Antibody-Conjugated Monomethyl Auristatin E (acMMAE) at Specified Timepoints
NCT04236141 (21) [back to overview]	Percentage of Participants With Best Overall Response (BOR) Based on PET-CT or CT Only as Assessed by IRC
NCT04236141 (21) [back to overview]	DOR Based on PET-CT/CT Only as Assessed by IRC
NCT04236141 (21) [back to overview]	Duration Of Response (DOR) Based on PET-CT/CT Only as Assessed by Investigator
NCT04236141 (21) [back to overview]	Event-Free Survival (EFS) Based on PET-CT or CT Assessed by Investigator
NCT04236141 (21) [back to overview]	Percentage of Participants With CR at EOT Based on Computed Tomography (CT) as Assessed by Investigator
NCT04236141 (21) [back to overview]	Percentage of Participants With CR at EOT Based on CT as Assessed by IRC
NCT04236141 (21) [back to overview]	Progression-Free Survival (PFS) Based on PET-CT/CT Only as Assessed by Investigator
NCT04236141 (21) [back to overview]	Percentage of Participants With CR at the EOT Assessment Based on PET-CT as Assessed by Investigator
NCT04236141 (21) [back to overview]	Percentage of Participants With Objective Response (OR) at EOT Based on PET-CT as Assessed by Investigator
NCT04236141 (21) [back to overview]	Percentage of Participants With OR at EOT Assessment Based on CT as Assessed by Investigator
NCT04236141 (21) [back to overview]	Percentage of Participants With OR at EOT Assessment Based on CT as Assessed by IRC
NCT04236141 (21) [back to overview]	Percentage of Participants With OR at EOT Based on PET-CT as Assessed by IRC
NCT04236141 (21) [back to overview]	PFS Based on PET-CT/CT Only as Assessed by IRC
NCT04236141 (21) [back to overview]	Serum Concentration of Total Antibody at Specified Timepoints
NCT04236141 (21) [back to overview]	Plasma Concentration of Unconjugated Monomethyl Auristatin E (MMAE) at Specified Timepoints
NCT04745832 (2) [back to overview]	Number of SAEs (Zandelisib When Combined With Rituximab)
NCT04745832 (2) [back to overview]	Number of Treatment Emergent AEs (Zandelisib When Combined With Rituximab)

Optimal Bendamustine Dosage for Further Studies

(NCT00426855)
Timeframe: Three weeks after treatment termination

Intervention	mg/m^2 (Number)
Group 1	60

Intervention	participants (Number)
	Complete Response	Partial Response	Marrow Complete Response
Bendamustine (75 mg/m^2)	0	0	1

Intervention	months (Median)
Treatment (Bendamustine Hydrochloride) for Glioblastoma	18.3
Treatment (Bendamustine Hydrochloride) for Anaplastic Glioma	45.6

Intervention	patients (Number)
	Dose level I, n=5	Dose level II, n=6
Bendamustine and Erlotinib	0	1

Intervention	participants (Number)
	Phase I - Cohort I	Phase I - Cohort II	Phase I - Cohort III
Novel Drug Combination	0	1	1

Intervention	participants (Number)
	Psycholeptics	Sex Hormones and Modulators of the Genital System	Stomatological Preparations	Throat Preparations	Thyroid Therapy	Topical Products for Join and Muscular Pain	Unspecified Herbal	Urologicals	Vaccines	Vasoprotectives	Vitamins
Bendamustine and Rituximab (BR)	57	11	0	0	16	1	10	20	2	0	70
R-CHOP/R-CVP	59	12	0	0	17	0	10	11	7	0	61

Intervention	participants (Number)
	Absolute Neutrophil Count: Grade 1	Absolute Neutrophil Count: Grade 2	Absolute Neutrophil Count: Grade 3	Absolute Neutrophil Count: Grade 4	Absolute Neutrophil Count: Grades 1-4	Hemoglobin: Grade 1	Hemoglobin: Grade 2	Hemoglobin: Grade 3	Hemoglobin: Grade 4	Hemoglobin: Grades 1-4	Lymphocytes Absolute: Grade 1	Lymphocytes Absolute: Grade 2	Lymphocytes Absolute: Grade 3	Lymphocytes Absolute: Grade 4	Lymphocytes Absolute: Grades 1-4	Platelets: Grade 1	Platelets: Grade 2	Platelets: Grade 3	Platelets: Grade 4	Platelets: Grades 1-4	White Blood Cells: Grade 1	White Blood Cells: Grade 2	White Blood Cells: Grade 3	White Blood Cells: Grade 4	White Blood Cells: Grades 1-4
Bendamustine and Rituximab (BR)	22	51	48	50	171	129	42	5	1	177	1	5	54	83	143	106	14	9	7	136	41	79	65	19	204
R-CHOP/R-CVP	14	20	47	104	185	129	51	7	2	189	6	55	55	9	125	72	14	7	8	101	22	49	89	27	187

Intervention	participants (Number)
	Improved	Stayed the Same	Worsened
Bendamustine/Rituximab	32	153	34
R-CHOP/R-CVP	28	141	42

Intervention	participants (Number)
	Albumin: Grade 1	Albumin: Grade 2	Albumin: Grade 3	Albumin: Grade 4	Albumin: Grades 1-4	Alkaline Phosphatase: Grade 1	Alkaline Phosphatase: Grade 2	Alkaline Phosphatase: Grade 3	Alkaline Phosphatase: Grade 4	Alkaline Phosphatase: Grades 1-4	Creatinine: Grade 1	Creatinine: Grade 2	Creatinine: Grade 3	Creatinine: Grade 4	Creatinine: Grades 1-4	Gamma-glutamyl transferase: Grade 1	Gamma-glutamyl transferase: Grade 2	Gamma-glutamyl transferase: Grade 3	Gamma-glutamyl transferase: Grade 4	Gamma-glutamyl transferase: Grades 1-4	Hypercalcemia: Grade 1	Hypercalcemia: Grade 2	Hypercalcemia: Grade 3	Hypercalcemia: Grade 4	Hypercalcemia: Grades 1-4	Hyperglycemia: Grade 1	Hyperglycemia: Grade 2	Hyperglycemia: Grade 3	Hyperglycemia: Grade 4	Hyperglycemia: Grades 1-4	Hyperkalemia: Grade 1	Hyperkalemia: Grade 2	Hyperkalemia: Grade 3	Hyperkalemia: Grade 4	Hyperkalemia: Grades 1-4	Hypernatremia: Grade 1	Hypernatremia: Grade 2	Hypernatremia: Grade 3	Hypernatremia: Grade 4	Hypernatremia: Grades 1-4	Hypocalcemia: Grade 1	Hypocalcemia: Grade 2	Hypocalcemia: Grade 3	Hypocalcemia: Grade 4	Hypocalcemia: Grades 1-4	Hypoglycemia: Grade 1	Hypoglycemia: Grade 2	Hypoglycemia: Grade 3	Hypoglycemia: Grade 4	Hypoglycemia: Grades 1-4	Hypokalemia: Grade 1	Hypokalemia: Grade 2	Hypokalemia: Grade 3	Hypokalemia: Grade 4	Hypokalemia: Grades 1-4	Hyponatremia: Grade 1	Hyponatremia: Grade 2	Hyponatremia: Grade 3	Hyponatremia: Grade 4	Hyponatremia: Grades 1-4	Magnesium: Grade 1	Magnesium: Grade 2	Magnesium: Grade 3	Magnesium: Grade 4	Magnesium: Grades 1-4	Phosphorus: Grade 1	Phosphorus: Grade 2	Phosphorus: Grade 3	Phosphorus: Grade 4	Phosphorus: Grades 1-4	Aspartate Aminotransferase: Grade 1	Aspartate Aminotransferase: Grade 2	Aspartate Aminotransferase: Grade 3	Aspartate Aminotransferase: Grade 4	Aspartate Aminotransferase: Grades 1-4	Alanine Aminotransferase: Grade 1	Alanine Aminotransferase: Grade 2	Alanine Aminotransferase: Grade 3	Alanine Aminotransferase: Grade 4	Alanine Aminotransferase: Grades 1-4	Total Bilirubin: Grade 1	Total Bilirubin: Grade 2	Total Bilirubin: Grade 3	Total Bilirubin: Grade 4	Total Bilirubin: Grades 1-4	Uric Acid: Grade 1	Uric Acid: Grade 2	Uric Acid: Grade 3	Uric Acid: Grade 4	Uric Acid: Grades 1-4
Bendamustine and Rituximab (BR)	33	14	3	0	50	41	1	0	0	42	19	3	1	0	23	31	18	3	0	52	6	0	1	0	7	94	20	15	0	129	7	3	1	0	11	8	0	0	0	8	36	8	1	3	48	15	1	0	0	16	18	0	0	0	18	40	0	0	0	40	46	0	0	0	46	7	25	3	0	35	42	2	1	0	45	46	6	2	0	54	14	1	0	0	15	41	0	0	1	42
R-CHOP/R-CVP	44	13	0	0	57	25	3	0	0	28	25	1	0	0	26	37	10	6	0	53	6	0	0	0	6	74	34	15	1	124	8	1	0	0	9	10	0	0	0	10	28	6	0	0	34	10	0	0	0	10	16	0	1	0	17	28	0	5	0	33	44	1	1	0	46	5	22	3	1	31	32	2	1	0	35	38	3	1	0	42	7	0	0	0	7	42	0	0	0	42

Intervention	participants (Number)
	Increase >=10%	Decrease >=10%
Bendamustine and Rituximab (BR)	8	18
R-CHOP/R-CVP	5	8

Intervention	Participants (Count of Participants)
	All Deaths	Deaths within 30 days of study treatment	Deaths greater than 30 days of study treatment
Bendamustine and Rituximab (BR)	40	2	38
R-CHOP/R-CVP	32	1	31

Intervention	participants (Number)
	Any AE	Severe AEs (grades 3, 4, 5)	Treatment-related AEs	Deaths	SAEs	Withdrawn due to AEs
Bendamustine and Rituximab (BR)	221	130	209	12	60	10
R-CHOP/R-CVP	213	127	NA	9	49	3

Intervention	participants (Number)
	Heart Rate >=120 and ↑ >=15 bpm	Heart Rate <=50 and ↓ >=15 bpm	Systolic Blood Pressure(BP) >=180 and ↑ >=20 mm Hg	Systolic BP <=90 and ↓ >=20 mm Hg	Diastolic BP >=105 and ↑ from Baseline >=15 mm Hg	Diastolic BP <=50 and ↓ from Baseline >=15 mm Hg
Bendamustine and Rituximab (BR)	0	2	2	6	1	2
R-CHOP/R-CVP	1	2	2	2	2	2

Intervention	participants (Number)
	Improved	Stayed the same	Deteriorated
Bendamustine+Rituximab	8	32	4

Intervention	participants (Number)
	Baseline Negative - Study Negative	Baseline Positive - Study Negative	Baseline Negative - Study Positive	Baseline Positive - Study Positive
Bendamustine+Rituximab	0	0	23	15

Intervention	Participants (Count of Participants)
Dose Level 1	0
Dose Level 2	1
Dose Level 3	0
Dose Level 4	0
Dose Level 5	0
Dose Level 6	0

Intervention	participants (Number)
Bendamustine 50 mg/m^2 Cohort	0
Bendamustine 70 mg/m^2 Cohort	0
Bendamustine 90 mg/m^2 Cohort	0

Intervention	percentage of participants (Number)
Bendamustine 50 mg/m^2 Cohort	40.0
Bendamustine 70 mg/m^2 Cohort	25.0
Bendamustine 90 mg/m^2 Cohort	51.6

Intervention	participants (Number)
	Complete response (CR)	Very good partial response (VGPR)	Partial response (PR)	Minimal response (MR)	Stable disease (SD)	Progressive disease (PD)
Bendamustine 50 mg/m^2 Cohort	0	0	1	1	2	1
Bendamustine 70 mg/m^2 Cohort	0	0	0	1	2	1
Bendamustine 90 mg/m^2 Cohort	1	2	8	5	13	2

Intervention	participants (Number)
	Any adverse event	Any non-haematologic adverse event	Severe adverse event (grade 3 or 4)	Treatment-related adverse events	Deaths	Serious adverse events	Withdrawn from study due to AE
Bendamustine 50 mg/m^2 Cohort	5	5	3	4	1	0	2
Bendamustine 70 mg/m^2 Cohort	4	4	3	4	0	1	2
Bendamustine 90 mg/m^2 Cohort	31	31	22	31	5	7	5

Intervention	Proportion of participants (Median)
	1-year progression-free survival	2-year progression-free survival	3-year progression-free survival
Induction/Maintenance Chemotherapy	0.62	0.35	0.23

bendamustine hydrochloride

Cross-References

Synonyms (111)

Research Excerpts

Overview

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Protein Targets (1)

Potency Measurements

Bioassays (8)

Research

Studies (1,041)

Market Indicators

Research Demand Index: 42.68

Study Types

Clinical Trials (340)

Trial Overview

Trial Outcomes

Optimal Bendamustine Dosage for Further Studies

Number of Participants With Progression Free Survival at 2 Years

Toxicity of Drug Combination in the Subjects

Overall Response Rate (ORR)

Number of Participants With Overall Response (Complete and Partial Response)

Number of Participants With Complete Response

Determine the Overall Response Rate (RR) to Bendamustine HCL in Patients With Relapsed and Primary Refractory HL.

Number of Participants With a Response

Maximum Tolerated Dose (MTD)

Overall Survival

PFS

PFS-6

Toxic Death

Objective Response Rate (ORR)

Progression-free Survival at 6 Months and 12 Months (Phase II)

Overall Survival (OS)

Maximum-tolerated Dose of Erlotinib Hydrochloride (Phase I)

Maximum-tolerated Dose of Bendamustine Hydrochloride (Phase I)

Duration of Response (DR)

Dose-limiting Toxicity (Phase I)

Number of Patients With Adverse Events - Phase II

Number of Participants Experiencing Dose Limiting Toxicity Regimen A - Phase I

Progression Free Survival

Toxicities of Patients Treated With Bendamustine.

Overall Survival in Patients With Platinum and Taxane Refractory Ovarian Cancer, Fallopian Tube Cancer and Primary Peritoneal Cancer With Bendamustine Treatment.

Progression Free Survival in Patients With Platinum and Taxane Refractory Ovarian Cancer, Fallopian Tube Cancer and Primary Peritoneal Cancer With Bendamustine Treatment.

Participants With Disease Progression, Relapse or Death At the End of the Treatment Period or the Long-Term Follow-up Period

Overall Survival (OS)

Kaplan-Meier Estimate for Progression-free Survival (PFS)

Kaplan-Meier Estimate for Event-free Survival (EFS)

Change From Baseline to End of Treatment in the Global Health Status Score of the European Organization for Research and Treatment of Cancer (EORTC) 30-item Core Quality of Life Questionnaire (QLQ-C30)

Kaplan-Meier Estimate for Duration of Response (DOR)

Therapeutic Classification of Prior Medications

Worst Overall CTCAE Grade for Hematology Laboratory Test Results

Eastern Cooperative Oncology Group (ECOG) Performance Status at the End of Treatment Period

Worst Overall Common Terminology Criteria for Adverse Events (CTCAE) Grades for Serum Chemistry Laboratory Test Results

Therapeutic Classification of Concomitant Medications

Potentially Clinically Significant Abnormal Weight

Participants Who Died At the End of the Treatment Period or the Long-Term Follow-up Period

Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths and Discontinuations Due to AEs at End of Treatment Period

Clinically Significant Abnormal Vital Signs

Percentage of Participants With Overall Response at End of Treatment Period

Percentage of Participants With Complete Response (CR) at End of Treatment Period

Kaplan-Meier Estimate for Duration of Response

Kaplan-Meier Estimate for Overall Survival

Kaplan-Meier Estimate for Progression-Free Survival

Overall Response Rate (Complete Response + Partial Response) at the End of Cycles 3 and 6 Using the 2007 International Working Group Criteria

Shifts in Baseline Eastern Cooperative Oncology Group (ECOG) Performance Status

Shifts in Baseline to Post-Treatment in Positron Emission Tomography (PET)

Percentage of Participants With GVHD (Graft Versus Host Disease)

Complete Response Rate of the Combination of BMR (Bendamustine + Mitoxantrone + Rituximab)

Participants With Adverse Events

Time to Progression (TTP) for Participants Treated With BMR (Bendamustine, Mitoxantrone, and Rituximab)

Maximum Tolerated Dose (Phase 1)

Progression-Free Survival (Phase 2)

Progression-Free Survival (Phase 1)

Overall Response Rate (Phase 2) - Number of Participants Achieving at Least a Partial Response or Better in Disease Status at Day 100 Post-transplant

Overall Survival at 2 Years (Phase 1)

Overall Survival at 3 Years (Phase 2)

Intervention	participants (Number)
	Grade 3 leukopenia	Grade 4 leukopenia	Grade 3 neutropenia	Grade 4 neutropenia	Grade 3 anemia	Grade 3 thrombocytopenia	Grade 4 thrombocytopenia	Grade 3 febrile neutropenia	Grade 3 infection	Grade 4 infection	Grade 5 infection	Grade 3 fatigue	Grade 4 fatigue	Grade 3 nausea/emesis	Grade 3 serum transaminase levels (Gr 3/Gr 4)
Induction Chemoimmunotherapy	5	5	6	14	1	5	2	4	10	1	1	2	0	3	4
Maintenance	6	1	7	2	0	1	0	1	4	1	0	0	1	0	0

Intervention	participants (Number)
Complete Response (CR)	7
Partial Response (PR)	12
Stable Disease	9
Overall Response Rate	19

Intervention	participants (Number)
	Number of patients with worst-grade toxicity of 1	Number of patients with worst-grade toxicity of 2	Number of patients with worst-grade toxicity of 3	Number of patients with worst-grade toxicity of 4	Number of patients with worst-grade toxicity of 5
Bendamustine	1	14	21	5	9

Intervention	participants (Number)
	Complete Response	Partial Response	Progressive Disease	Stable Disease
Bendamustine	1	10	14	17

Intervention	participants (Number)
	Leukopenia	Neutropenia	Lymphopenia	Thrombocytopenia	Anemia	Peripheral Neuropathy	Diarrhea	Fatigue	Nausea/Vomiting	Cough	Rash	Syncope	Hypocalcemia/Hyponatremia
Bendamustine/Bortezomib/Rituximab	16	16	9	4	3	5	4	4	3	2	2	2	2

Intervention	Dose Limiting Toxic Events (Number)
Phase I, Dose Level 1	0
Phase I, Dose Level 2	1
Phase I, Dose Level 3	0
Phase I, Dose Level 4	0
Phase I, Dose Level 5	2

Intervention	percentage of participants (Number)
	CR with biopsy (C6), CR (confirmed)	CR with biopsy (C6), CRi (confirmed)	CR with biopsy (C6), nPR (confirmed)	CR with biopsy (C6), PR (confirmed)	CR with biopsy (C6), SD (confirmed)	CR with biopsy (C6), PD (confirmed)	CR with biopsy (C6), Missing (confirmed)	CR without biopsy (C6), CR (confirmed)	CR without biopsy (C6), CRi (confirmed)	CR without biopsy (C6), nPR (confirmed)	CR without biopsy (C6), PR (confirmed)	CR without biopsy (C6), SD (confirmed)	CR without biopsy (C6), PD (confirmed)	CR without biopsy (C6), Missing (confirmed)	PR (C6), CR (confirmed)	PR (C6), CRi (confirmed)	PR (C6), nPR (confirmed)	PR (C6), PR (confirmed)	PR (C6), SD (confirmed)	PR (C6), PD (confirmed)	PR (C6), Missing (confirmed)	SD (C6), CR (confirmed)	SD (C6), CRi (confirmed)	SD (C6), nPR (confirmed)	SD (C6), PR (confirmed)	SD (C6), SD (confirmed)	SD (C6), PD (confirmed)	SD (C6), Missing (confirmed)	Missing (C6), CR (confirmed)	Missing (C6), CRi (confirmed)	Missing (C6), nPR (confirmed)	Missing (C6), PR (confirmed)	Missing (C6), SD (confirmed)	Missing (C6), PD (confirmed)	Missing (C6), Missing (confirmed)
Rituximab + Bendamustine	21.5	2.5	1.7	19.0	0	0	0	2.5	0	0	16.5	0	0	0.8	1.7	0	0	8.3	0	0.8	0	0	0	0	0	0	0	0	0.8	0	0	0	0	0	24.0
Rituximab + Chlorambucil	9.2	0	6.7	17.5	1.7	0	0	5.8	0	0	10.0	0	0	0	4.2	0	0	21.7	0	2.5	0	0	0	0	0	0.8	0.8	0	0	0	0	0	0	0	19.2

Intervention	percentage of participants (Number)
	Molecular response	No molecular response
Rituximab + Bendamustine	57.1	42.9
Rituximab + Chlorambucil	16.0	84.0

Intervention	percentage of participants (Number)
	Confirmed CR with biopsy	CR without biopsy	No confirmed CR
Rituximab + Bendamustine	15.8	3.5	80.7
Rituximab + Chlorambucil	1.7	1.7	96.6

Intervention	percentage of participants (Number)
	After 3 cycles	After 6 cycles	At the EOT visit
Rituximab + Bendamustine	78.5	75.2	90.9
Rituximab + Chlorambucil	80.0	79.2	85.8